Institutes
Refine
Year of publication
- 2021 (667) (remove)
Document Type
- Article (618)
- Preprint (32)
- Conference Proceeding (11)
- Doctoral Thesis (6)
Language
- English (667) (remove)
Has Fulltext
- yes (667) (remove)
Is part of the Bibliography
- no (667)
Keywords
- SARS-CoV-2 (23)
- COVID-19 (20)
- inflammation (12)
- prostate cancer (9)
- autophagy (8)
- Epilepsy (7)
- survival (7)
- ADHD (6)
- breast cancer (6)
- radical prostatectomy (6)
- tumor microenvironment (6)
- Genetics (5)
- aging (5)
- apoptosis (5)
- children (5)
- endothelial cells (5)
- mortality (5)
- outcome (5)
- risk factors (5)
- Cancer (4)
- Heart failure (4)
- Immunotherapy (4)
- Neurology (4)
- ROS (4)
- Risk factors (4)
- acute myeloid leukemia (4)
- angiogenesis (4)
- chemotherapy (4)
- cirrhosis (4)
- epilepsy (4)
- extracellular matrix (4)
- gene therapy (4)
- hypoxia (4)
- iron (4)
- iron deficiency (4)
- oxidative stress (4)
- prevalence (4)
- stroke (4)
- targeted therapy (4)
- vaccination (4)
- 177Lu-PSMA-617 (3)
- Acute myeloid leukemia (3)
- Alcohol (3)
- Angiogenesis (3)
- Apoptosis (3)
- Biochemistry (3)
- Bipolar disorder (3)
- Cell biology (3)
- Diagnostic markers (3)
- EEG (3)
- Edema (3)
- Immunology (3)
- IntelliCage (3)
- Medical research (3)
- Melanoma (3)
- Microbiology (3)
- Molecular biology (3)
- Mortality (3)
- NK cells (3)
- Outcome (3)
- PSMA (3)
- Proteomics (3)
- Quality of life (3)
- Radiotherapy (3)
- Seizure (3)
- Surgery (3)
- Survival (3)
- VEGF (3)
- adverse events (3)
- biomarker (3)
- bladder cancer (3)
- cancer (3)
- data science (3)
- dentate gyrus (3)
- epidemiology (3)
- exosomes (3)
- external beam radiotherapy (3)
- fMRI (3)
- glioblastoma (3)
- haemophilia care (3)
- haemophilia treatment (3)
- immune cells (3)
- immunotherapy (3)
- influenza (3)
- liver (3)
- liver cirrhosis (3)
- lung cancer (3)
- macrophage polarization (3)
- macrophages (3)
- metastasis (3)
- metastatic prostate cancer (3)
- pediatric (3)
- proliferation (3)
- toll-like receptor (3)
- treatment (3)
- treatment centres (3)
- 3D printing (2)
- ALK (2)
- Acuris (2)
- Acute lymphoblastic leukemia (2)
- Adenocarcinoma (2)
- Age estimation (2)
- Anemia (2)
- Angiography (2)
- Ataxia-telangiectasia (2)
- Attitude (2)
- Autopsy (2)
- BAG3 (2)
- BCOR (2)
- BPH (2)
- Bacterial infection (2)
- Behavior (2)
- Blood (2)
- Blood loss estimation (2)
- Blow flies (2)
- Bone density (2)
- Bone marrow (2)
- Brain (2)
- Breast cancer (2)
- Burden of illness (2)
- CD14 (2)
- COVID 19 (2)
- CRM (2)
- CSM (2)
- Cancer-specific mortality (2)
- Cardiovascular diseases (2)
- Cell culture (2)
- Cesarean section (2)
- Chronic kidney disease (2)
- Cirrhosis (2)
- Collagen (2)
- Corona (2)
- DMEK (2)
- Dental implant (2)
- Depression (2)
- Dravet syndrome (2)
- ER stress (2)
- EWSR1 (2)
- Endocannabinoid (2)
- Endocrinology (2)
- Entscheidungsassistenz (2)
- Environmental support (2)
- Epidemiology and End Results (2)
- Fasting (2)
- Forensic medicine (2)
- Gene fusion (2)
- Gene regulation (2)
- Gleason score (2)
- Glioblastoma (2)
- Glucose (2)
- Health care (2)
- Healthcare costs (2)
- Human behaviour (2)
- Hypertension (2)
- Induction chemotherapy (2)
- Infection (2)
- Inflammation (2)
- Intensive care treatment (2)
- Intensive care units (2)
- Interleukin-6 (2)
- Ketogenic diet (2)
- Labor and delivery (2)
- Leptin (2)
- MRI (2)
- Machine learning (2)
- Medical consultation (2)
- Medical risk factors (2)
- Model (2)
- Multidetector computed tomography (2)
- NADH dehydrogenase (2)
- NADPH oxidase (2)
- NCCN (2)
- NF-κB (2)
- Neuroscience (2)
- Osteoporosis (2)
- PCR (2)
- Pandemic (2)
- Pathogenesis (2)
- Patient blood management (2)
- Patient needs (2)
- Patientenbedürfnisse (2)
- Pediatric (2)
- Penile cancer (2)
- Periodontal treatment (2)
- Person-Umwelt-Passung (2)
- Person-environment fit (2)
- Physical activity (2)
- Physiology (2)
- Platelet-rich fibrin (2)
- Point-of-care testing (2)
- Portal hypertension (2)
- Post-mortem interval (2)
- Pregnancy (2)
- Preterm birth (2)
- Prevalence (2)
- Prognostic tool (2)
- Prophylaxis (2)
- Prostate cancer (2)
- Pulmonary embolism (2)
- Radiation (2)
- Rare diseases (2)
- Research Article (2)
- SCC (2)
- SV2A (2)
- Sensitivity (2)
- Specificity (2)
- Spine (2)
- Squamous cell carcinoma (2)
- Status epilepticus (2)
- Suicide (2)
- Supported decision making (2)
- Surveillance (2)
- Systemic inflammation (2)
- Systemic therapy (2)
- TSC (2)
- Tomography (x-ray computed) (2)
- Tooth loss (2)
- Trauma (2)
- Treatment (2)
- Treatment outcome (2)
- Ultrasound (2)
- Undergraduate medical education (2)
- Unterstützung der Umwelt (2)
- Usability (2)
- Variant histology (2)
- Visual estimation (2)
- alcohol use disorder (2)
- anemia (2)
- animal experiments (2)
- antibiotic resistance (2)
- antiviral therapy (2)
- bibliometrics (2)
- biomarkers (2)
- biopsy cores (2)
- bleeding (2)
- bortezomib (2)
- brain cancer (2)
- cancer-specific mortality (2)
- cell cycle (2)
- cell migration (2)
- cerebrospinal fluid (2)
- cesarean section (2)
- child (2)
- childhood acute myeloid leukemia (2)
- chronic kidney disease (2)
- clinical trial (2)
- clinical trials (2)
- colon cancer (2)
- complexome profiling (2)
- computed tomography (2)
- contemporary (2)
- coronavirus (2)
- critical care (2)
- dexamethasone (2)
- diabetes (2)
- diabetes mellitus (2)
- diagnostic algorithm (2)
- drug resistance (2)
- efficacy (2)
- elderly (2)
- electrophysiology (2)
- epigenetics (2)
- epithelial to mesenchymal transition (2)
- ergonomics (2)
- executive function (2)
- extracellular vesicles (2)
- fibroblasts (2)
- follow-up (2)
- furcation involvement class III (2)
- fusion biopsy (2)
- heart (2)
- heart failure (2)
- hematopoietic stem cell transplantation (2)
- hepatitis C virus (2)
- homeostatic plasticity (2)
- innate immunity (2)
- intermediate risk (2)
- iron metabolism (2)
- kidney (2)
- kidney cancer (2)
- levetiracetam (2)
- lipocalin-2 (2)
- liver transplantation (2)
- lncRNA (2)
- localized prostate cancer (2)
- long-term tooth survival (2)
- lymph node dissection (2)
- machine learning (2)
- macrophage (2)
- magnetic resonance imaging (2)
- mast cells (2)
- metastatic castration-resistant prostate cancer (2)
- miRNA (2)
- microRNA (2)
- microglia (2)
- multiple sclerosis (2)
- ncRNA (2)
- neurocognitive (2)
- neuropathic pain (2)
- neutralizing antibodies (2)
- niche (2)
- oligomerisation (2)
- osteoarthritis (2)
- other-cause mortality (2)
- out-patient paediatrics (2)
- overall survival (2)
- oxidative phosphorylation (2)
- p53 (2)
- pain (2)
- patients (2)
- pediatric patients (2)
- pentose phosphate pathway (2)
- perception (2)
- periodontitis stage III and IV (2)
- pharmacokinetics (2)
- phosphorylation (2)
- platelets (2)
- pneumonia (2)
- portal hypertension (2)
- primary care (2)
- primary cilium (2)
- primary prostate cancer (2)
- questionnaire (2)
- radical prostatecomy (2)
- radiotherapy (2)
- receptor (2)
- refractory (2)
- regenerative medicine (2)
- relapse (2)
- residual myometrial thickness (2)
- respiratory chain (2)
- respiratory tract infection (2)
- salvage therapy (2)
- second-line (2)
- seizure (2)
- spine head (2)
- status epilepticus (2)
- strength training (2)
- stress (2)
- stress granules (2)
- supportive periodontal therapy (2)
- surgery (2)
- synaptic plasticity (2)
- synaptopodin (2)
- systematic biopsy (2)
- systemic antibiotics (2)
- thrombolysis (2)
- thrombosis (2)
- tissue engineering (2)
- tooth loss (2)
- triple-negative breast cancer (2)
- tumor necrosis factor (2)
- tumor-associated macrophages (2)
- tyrosine kinase inhibitors (2)
- ubiquitination (2)
- urological cancer (2)
- very high risk (2)
- working memory (2)
- Ärztliche Aufklärung (2)
- (sub-) luxation (1)
- 1-propanol (1)
- 2-AG (1)
- 2-Arachidonoyl glycerol (1)
- 2-deoxy-d-glucose (1)
- 26 LncRNA (1)
- 2′,3′-cGAMP (1)
- 3-year survival (1)
- 3D gait analysis (1)
- 3D printing using composite resin (1)
- 3D printing using zirconia (1)
- 3D rapid prototyping (1)
- 3T3-L1 mouse fibroblasts (1)
- 5-lipoxygenase (1)
- 8 weeks (1)
- ABCB5 (1)
- ACE inhibitor (1)
- ACLF (1)
- ADAM15 (1)
- ADCC (1)
- AGMO (1)
- AIDS (1)
- AKT (1)
- AKT signaling (1)
- ALD (1)
- ALDH2 (1)
- AML (1)
- AO-PCCF (1)
- APT-CEST (1)
- ARDS (1)
- AT1 receptor antagonist (1)
- ATG3 (1)
- AU-rich element (1)
- Accidents (1)
- Acinetobacter baumannii (1)
- Acquired resistance (1)
- Acute Myeloid Leukemia (AML) (1)
- Acute inflammation (1)
- Acute kidney failure (1)
- Acute kidney injury (1)
- Acute respiratory distress syndrom (1)
- Adiposity (1)
- Adults (1)
- Advanced stage (1)
- Adverse effects (1)
- Aedes aegypti (1)
- Aedes albopictus (1)
- Affective Misattribution Procedure (1)
- Ag-RDT (1)
- Aganglionosis (1)
- Aging (1)
- Albumin (1)
- Algorithms (1)
- Alpha power (1)
- Alpha-fetoprotein (AFP) (1)
- Alzheimer's disease (1)
- Amblyopia (1)
- Amino acids (1)
- Amniotic fluid (1)
- Amphetamine (1)
- Analysis tool (1)
- Anandamide (1)
- Anemia management (1)
- Angiomyolipoma (1)
- Angststörungen (1)
- Animal disease models (1)
- Animal experiment (1)
- Animal models (1)
- Anti-seizure medication (1)
- Antibiotic steward-ship (1)
- Antibiotics (1)
- Antibody avidity (1)
- Anticonvulsant (1)
- Antimicrobial treatment (1)
- Antiretroviral therapy (1)
- Anwendbarkeit (1)
- Anxiety (1)
- Apoptotic cell death (1)
- Ara h2-specific IgE (1)
- Artificial intelligence (1)
- Asparaginase (1)
- Aspergillus (1)
- Astrocytoma (1)
- Ataxia telangiectasia (1)
- Atomoxetine (1)
- Attention (1)
- Attention Deficit Hyperactivity Disorder (ADHD) (1)
- Attention-Deficit/Hyperactivity Disorder (ADHD) (1)
- Autism (1)
- Autism Spectrum disorder (1)
- Autism spectrum disorder (1)
- Autologous biomaterial (1)
- Ayurveda (1)
- B cells (1)
- B-cell transcription factors (1)
- B.1.1.7 (1)
- B.1.617.1 (1)
- B.1.617.2 (1)
- BCORL1 (1)
- BCX7353 (1)
- BEACOPP (1)
- BMI (1)
- BMNC (1)
- BNT162b2 (1)
- BNT2b2 (1)
- BPO (1)
- BPTF (1)
- BRD4 (1)
- Back scan (1)
- Bacterial leakage (1)
- Barrier (1)
- Bartonella grahamii (1)
- Bartonella henselae (1)
- Bartonella schoenbuchensis (1)
- Basal ganglia (1)
- Beckwith–Wiedemann syndrome (1)
- Behandlungspfad (1)
- Behavioural ecology (1)
- Berotralstat (1)
- Bevacizumab (1)
- Big Five (1)
- Bio safety (1)
- Biofilm (1)
- Biological profile (1)
- Biomarker (1)
- Biomarkers (1)
- Biophysical models (1)
- Biophysics (1)
- Biopsy (1)
- Birth (1)
- Birth weight (1)
- Bleeding (1)
- Blood coagulation disorder (1)
- Blood loss calculator (1)
- Blood loss formula (1)
- Blood management (1)
- Blood plasma (1)
- Blood sampling (1)
- Blutungskontrolle (1)
- Body sway (1)
- Bone cement implantation syndrome (1)
- Bone diseases, Metabolic (1)
- Bone metastases (1)
- Bowel obstruction (1)
- Bradycardia (1)
- Brain metastasis (1)
- Brain tumor (1)
- Browsertool (1)
- Burkitt’s lymphoma (1)
- C-reactive protein (1)
- C1 inhibitor (1)
- CAD-CAM (1)
- CAD/ CAM crown (1)
- CAD/CAM crown (1)
- CAM (1)
- CAPON (1)
- CCC-2 (1)
- CD16 (1)
- CD34+ cell enumeration (1)
- CD36 (1)
- CD45RA Depletion (1)
- CD47 (1)
- CD62L (1)
- CD8+ T cells (1)
- CDH13 (1)
- CDK2 (1)
- CDK4/6 inhibitors (1)
- CDK9 (1)
- CEST EPI (1)
- CNDAC (1)
- COMP (1)
- COPD (1)
- COVID-19 pandemic (1)
- COVID-19 vaccination (1)
- COVID-19, Primary care (1)
- COVID‐19 (1)
- CRISPR/Cas (1)
- CRPC (1)
- CT (1)
- CT dual-energy computed tomography (1)
- CTLA-4 (1)
- Cabozantinib (1)
- Calcium (1)
- Calcium calmodulin kinase (1)
- Calliphoridae (1)
- Cancer genomics (1)
- Cancer survivors (1)
- Cancer therapy (1)
- Cancer-specific survival (1)
- Cannabis (1)
- Cardiac biomarkers (1)
- Cardiac implantable electronic devices (1)
- Cardiac rehabilitation (1)
- Cardiac resynchronization therapy (1)
- Cardio-oncology (1)
- Cardiotoxicity (1)
- Cardiovascular biology (1)
- Cardiovascular disease risk (1)
- Cardiovascular magnetic resonance (1)
- Carotid injury (1)
- Case report (1)
- Catumaxomab (1)
- Cell death (1)
- Cell division (1)
- Cell-based Assays (1)
- Cement gap (1)
- Ceramides (1)
- Checkpoint Inhibitor (1)
- Chikungunya (1)
- Chimeric Antigen Receptor (CAR) (1)
- Cholinergic (1)
- Chrna7 knockout (1)
- Circadian (1)
- Clinical Global Impression of Change (1)
- Clinical Trials and Observations (1)
- Clinical decision support systems (1)
- Clinical pathway (1)
- Clinical pharmacology (1)
- ClpB (1)
- Cochlear implantation (1)
- Cognitive dysfunction (1)
- Cohort studies (1)
- Colorectal cancer (1)
- Colorimetric blood loss estimation (1)
- Combined surgical therapy (1)
- Combustion (1)
- Complex decongestive therapy (1)
- Complicated stage (1)
- Complications (1)
- Computational models (1)
- Computational neuroscience (1)
- Computational science (1)
- Computed tomography, X-ray (1)
- Computer hardware (1)
- Computer science (1)
- Computer software (1)
- Computer-assisted diagnosis (1)
- Cone-beam computed tomography (1)
- Conometric connection (1)
- Consensus document (1)
- Constipation (1)
- Contingent Negative Variation, CNV (1)
- Continuous Performance Test, CPT (1)
- Continuous renal replacement therapy (1)
- Contrast agent (1)
- Corneal tomography (1)
- Corona virus (1)
- Coronary heart disease (1)
- Costs (1)
- Course (1)
- Covid-19 (1)
- Cre-recombinase (1)
- Crisis (1)
- Critical care (1)
- Cue-P3 (1)
- Culicidae (1)
- Custom-made mouthguard (1)
- Cyclin T1 (1)
- Cystatin C (1)
- DC-NK cell interaction (1)
- DCK (1)
- DNA integrity (1)
- DPPIV (1)
- Data Analysis (1)
- Data processing (1)
- Data reduction (1)
- Daubert criteria (1)
- Dead space (1)
- Decision support (1)
- Deep brain stimulation (1)
- Degradation (1)
- Dengue (1)
- Dentists (1)
- Developmental Biology (1)
- Dexamethasone (1)
- Diagnosis (1)
- Diagnostic algorithm (1)
- Diffusion magnetic resonance imaging (1)
- Diphtheria (1)
- Diptera (1)
- Direct measurement (1)
- Direct oral anticoagulation (1)
- Disease progression (1)
- Diseases (1)
- Dislocations of the knee (1)
- Dizygotic ectopic (1)
- Dopamine (1)
- Dose response (1)
- Droplets (1)
- Drospirenon (1)
- Drug addiction (1)
- Drug resistance (1)
- Drug targets (1)
- Drug therapy (1)
- Dual-energy computed tomography (1)
- Dynamic MRI (1)
- Dysfunctional social assumptions (1)
- D’Amico classification (1)
- EBRT (1)
- ECMO (1)
- EET (1)
- EHL concentrates (1)
- ENIGMA (1)
- EP300 (1)
- EQ5D5L (1)
- EQA scheme (1)
- ER-phagy (1)
- ERAL1 (1)
- ERK inhibitor (1)
- ERK1/2 signaling (1)
- ESBL (1)
- Early setting (1)
- Eccentric fixation (1)
- Ectopic pregnancy (1)
- Effective half-life (1)
- Efficacy (1)
- Efficiency (1)
- Electric stimulation (1)
- Elternurteil (1)
- Emergency room (1)
- Ena/VASP proteins (1)
- Encephalopathy (1)
- Endocrine system and metabolic diseases (1)
- Endocrine therapy (1)
- Endothelial cells (1)
- Endothelial progenitor cells (1)
- Energy (1)
- Engraftment (1)
- Enterobacterales (1)
- Environmental biotechnology (1)
- Environmental sciences (1)
- EpCAM positive tumor (1)
- Ephrin-B2–EphB4 (1)
- Epigenetics (1)
- Epileptische Anfälle (1)
- Epileptischer Anfall (1)
- Epithelialization (1)
- Epsilon (1)
- Estimated glomerular filtration rate (1)
- Event related potentials (1)
- Everolimus (1)
- Evidence-based (1)
- Evidenzbasiert (1)
- Ewing sarcoma (1)
- Ewing-like (1)
- Exercise (1)
- Exercise training (1)
- Exoscope (1)
- Exosomes (1)
- Expansion (1)
- Expectation violation (1)
- External beam radiotherapy (1)
- Extracellular matrix (1)
- Extracellular vesicles (1)
- Exudates and transudates (1)
- FABP (1)
- FAM134 (1)
- FFP3 respirator (1)
- FGFR (1)
- FOXO1 (1)
- FOXO3 (1)
- FXR (1)
- Facial nerve (1)
- Falls (1)
- Feasibility studies (1)
- Fendrr (1)
- Fertility counseling (1)
- Filariasis (1)
- Fluid overload (1)
- Fluorescence (1)
- Forensic entomology (1)
- Forensic experts (1)
- Forensic pathology (1)
- Frontobasal (1)
- Fuchs endothelial dystrophy (1)
- G2A (1)
- GD2 (1)
- GEMs (1)
- GFR (1)
- GIIb/IIIa-receptor (1)
- GMP (1)
- GPCR (1)
- GPR4 (1)
- GTP cyclohydrolase (1)
- Ganglionic (1)
- Gan–Dou–Fu–Mu decoction (GDFMD) (1)
- Gastric motility (1)
- Gastroenterology (1)
- Gender (1)
- Gene expression (1)
- General Practitioner (1)
- Genetic techniques (1)
- Genetics research (1)
- Genome editing (1)
- Gestagen-Monopräparate (1)
- Gezielte Therapie (1)
- Glaucoma (1)
- Gleason Grade Group (1)
- Gleason grade group (1)
- Glioblastoma survival (1)
- Glomerulosclerosis (1)
- Glycolysis (1)
- Grading (1)
- Graft (1)
- Graft quality (1)
- Granulocytes (1)
- Graves’ disease (1)
- Gravimetric method (1)
- Guidance (1)
- Guide profession (1)
- Gut (1)
- H1N1 (1)
- HAE (1)
- HARS2 (1)
- HBV (1)
- HCC (1)
- HCC marker (1)
- HDR-brachytherapy (1)
- HER2 (1)
- HIV (1)
- HIV protease inhibitors (1)
- HL7 FHIR (1)
- HLA antibodies (1)
- HNSCC (1)
- HOLEP (1)
- HOTAIR (1)
- HPO (1)
- HPV-positive OPSCC (1)
- HRCT (1)
- HSC (1)
- HSP (hereditary spastic paraplegia) (1)
- HVPG (1)
- Haematologic diseases (1)
- Haemophilia (1)
- HeLa cells (1)
- Head and neck cancer (1)
- Health care workers (1)
- Health services (1)
- Health surveys (1)
- Healthcare resource utilisation (1)
- Healthcare resource utilization (1)
- Healthy adults (1)
- Healthy men (1)
- Heart (1)
- Heart transplantation (1)
- Heartrate (1)
- Hematologic adverse events (1)
- Hematopoietic stem cell (1)
- Hematotoxicity (1)
- Hepatic stellate cell (1)
- Hepatocellular carcinoma (1)
- Hepatocellular carcinoma (HCC) (1)
- Hereditary angioedema (1)
- Herniated disk (1)
- Heterotopic pregnancy (1)
- Hierarchical drift-diffusion modeling (1)
- High altitude (1)
- High-risk prostate cancer (1)
- Himalayas (1)
- Hip hemiarthroplasty (1)
- Hirschsprung disease (1)
- Hispanic–Latino race/ethnicity (1)
- Histology (1)
- HoLEP (1)
- Hormone receptor positive breast cancer (1)
- Hydromineral (1)
- Hymenoptera venom allergy (1)
- IAP (1)
- ICG (1)
- IFN-β (1)
- IL-17A (1)
- IL-1b (1)
- IL-33 (1)
- INR (1)
- IPSS (1)
- ISR (1)
- IgA deficiency (1)
- Ileostomy (1)
- Ileus (1)
- Image processing (1)
- Immune cells (1)
- Immune checkpoint inhibitors (1)
- Immune complex vasculitis (1)
- Immune paralysis (1)
- Immune status (1)
- Immunodeficiency (1)
- Immunogenetics (1)
- Immunoglobulins (1)
- Immunohistochemistry (1)
- Immunophenotyping (1)
- Immuno‑histochemistry (1)
- Implantable cardioverter-defibrillator (1)
- Implicit Processing (1)
- Implicit Association Test (1)
- In vivo electrophysiology (1)
- Inactivation (1)
- IncX (1)
- Incidence rate (1)
- Incontinence (1)
- Indication for fertility preservation (1)
- Indirect treatment comparison (ITC) (1)
- Indocyanine green (1)
- Indonesia (1)
- Injuries (1)
- Injury (1)
- Intention attribution (1)
- Interleukin-10 (1)
- International normalized ratio (1)
- Internet-based therapy (1)
- Interpretation Bias (1)
- Intervention (1)
- Intervertebral disc displacement (1)
- Interviews (1)
- Intimal-medial thickness (1)
- Intraoperative blood salvage (1)
- Intrinsic resistance (1)
- Intubation (1)
- Isoflurane (1)
- Isothermal amplification (1)
- Ixodes ricinus (1)
- JAK2V617F (1)
- KCCQ (1)
- KCNQ1 (1)
- KLHL11 (1)
- KPS (1)
- Kallikrein inhibitor (1)
- Kappa (1)
- Keap1-Nrf2 (1)
- Ki-67 (1)
- Kindes- und Jugendalter (1)
- Knee surgery (1)
- Kontrazeption (1)
- LARS2 (1)
- LDHB (1)
- LEOSS (1)
- LPS (1)
- LQTS (1)
- LSCC (1)
- LSEC (1)
- LanCL2 (1)
- Lasers (1)
- Lateral flow antigen testing (1)
- Lateral flow immunoassay (1)
- Learning and memory (1)
- Lee type, functional outcome (1)
- Legal medicine (1)
- Leigh syndrome (1)
- Leishmaniasis (1)
- Lemperle (1)
- Leukemia (1)
- Leukocyte depletion filter (1)
- Lipedema (1)
- Liposuction (1)
- Liver Transplantation (1)
- Liver cancer (1)
- Liver fibrosis (1)
- Local therapy (1)
- Long non-coding RNA (1)
- Long non-coding RNAs (1)
- Low grade glioma (1)
- Low-molecular-weight heparin (1)
- Low-virulent infection (1)
- Lung neoplasms (1)
- Lymphocyte subpopulations (1)
- Lymphopenia Mortality (1)
- MDD (1)
- MEIS (1)
- MEK inhibitor (1)
- MLKL (1)
- MN1 (1)
- MRI-negative epilepsy (1)
- MTOR inhibitor (1)
- MTRasym (1)
- MVPA (1)
- MYC (1)
- MYCN amplification (1)
- Macrophage polarization (1)
- Magnetic resonance imaging (1)
- Major depressive disorder (1)
- Malaria (1)
- Malignant meningioma (1)
- Manchester scar scale (1)
- Marginal integrity (1)
- Masking effect (1)
- Mastoiditis (1)
- Matching-adjusted indirect comparison (MAIC) (1)
- Materials science (1)
- Mathematical functions (1)
- Maxillofacial reconstruction (1)
- Maxillofacial trauma (1)
- Medical history (1)
- Meersseman test (1)
- Meningioma (1)
- Mental health and psychiatry (1)
- Mental health therapies (1)
- Metabolic diseases (1)
- Metabolic dysfunction (1)
- Metabolic models (1)
- Metabolic vulnerabilities (1)
- Metalloproteinases (1)
- Metastasis-directed therapy (1)
- Metastatic castration-resistant prostate cancer (1)
- Methanol (1)
- Methicillin-resistant Staphylococcus aureus (1)
- Method validation (1)
- Methylphenidate (1)
- MiSpEx-network (1)
- Micro computed tomography (1)
- MicroRNAs (1)
- Microbiology and Infectious Disease (1)
- Microgap (1)
- Microwave ablation (1)
- Minimal invasive dentistry (1)
- Mitochondrial ROS (1)
- Mitochondrial dysfunction (1)
- Mitosis (1)
- Molecular Biology (1)
- Molecular diagnostics (1)
- Molecular neuroscience (1)
- Monoclonal antibody (mAb) (1)
- Monocytes (1)
- Mosquito (1)
- Motivation (1)
- Mountain (1)
- Multianalyte detection (1)
- Multidrug-resistant organisms (1)
- Multiligament instability (1)
- Multivariate analysis (1)
- Musculoskeletal abnormalities (1)
- Musculoskeletal problems (1)
- Musculoskeletal system (1)
- Mycobacteria (1)
- Mycobacterium avium complex (1)
- Myeloid Neoplasia (1)
- Myiasis (1)
- Myocardial infarction (1)
- Myocardial remodeling (1)
- N471D strumpellin knock-in mice (1)
- N501Y (1)
- NAFLD (1)
- NASH (1)
- NET (1)
- NFkB (1)
- NK cell subsets (1)
- NK-92 (1)
- NO (1)
- NOS-I (1)
- NOS1AP (1)
- NSBB (1)
- NURF (1)
- Natural killer cells (1)
- Necroptosis (1)
- Necrotizing enterocolitis (1)
- Negligence (1)
- Nephrectomy (1)
- Neural stem cells (1)
- Neurodegeneration (1)
- Neuroepithelial (1)
- Neuroepithelial tumor (1)
- Neurofeedback (1)
- Neurofilament light chain (1)
- Neuroligins (1)
- Neurooncology (1)
- Neuropilin (1)
- Neurotoxicity (1)
- Neurovascular damage (1)
- Next-generation sequencing (1)
- NfL (1)
- Niche (1)
- Nicotine (1)
- Nitric oxide (1)
- Nonaerosolizing treatment (1)
- Nontuberculous mycobacteria (1)
- Noradrenergic (1)
- Norepinephrine (1)
- Nox4 (1)
- Nrf-2 (1)
- Nrf2 (1)
- Nutrition (1)
- OA (1)
- OGR1 (1)
- OHIP-G14 (1)
- OHRQoL (1)
- ORP (1)
- OSCE (1)
- OXA-48 (1)
- OXA-484 (1)
- OXPHOS (1)
- Obstetrics and gynecology (1)
- Occlusion treatment (1)
- Occupational health (1)
- Older patient (1)
- Olfactory groove meningioma (1)
- Olfactory system (1)
- Oligodendroglioma (1)
- Oligometastatic (1)
- Omega lipids (1)
- Oncogenes (1)
- Oncology (1)
- Online Survey (1)
- Opinion (1)
- Opioids (1)
- Opportunistic infections (1)
- Oral food challenge (1)
- Oral immunotherapy (OIT) (1)
- Oral therapy (1)
- Orbital fracture (1)
- Organ failure (1)
- Organ injury (1)
- Orthodontic tooth movement (1)
- Osteoporotic fractures (1)
- Otorhinolaryngological (1)
- Outcomes (1)
- Outcomes research (1)
- Outpatients (1)
- Overweight (1)
- Oxidative phosphorylation (1)
- P2X7 receptor (1)
- PAC-1 (1)
- PAD-test (1)
- PAPR (1)
- PATZ1 (1)
- PBSC (1)
- PBX (1)
- PD-1 (1)
- PD-L1 (1)
- PLAGL1 (1)
- PMA (1)
- PML (1)
- PMMA (1)
- POCT (1)
- POR (1)
- PPAR-γ (1)
- PRF (1)
- PRNT (1)
- PRRT (1)
- PSA (1)
- PTEN inducible kinase 1 (1)
- PTM (1)
- Pacemaker (1)
- Pain (1)
- Pain management (1)
- Palacos reaction (1)
- Pandemie (1)
- Parenteral nutrition (1)
- Parkinson's disease (1)
- Parkinson’s disease (1)
- Particulates (1)
- Pathogens (1)
- Pathology (1)
- Pathophysiology (1)
- Patient manikins (1)
- Patient perspective (1)
- Patient preference (1)
- Patterns of care (1)
- Pediatric oncology (1)
- Pediatric stem cell transplantation (1)
- Pediatric surgery (1)
- Per1−/−-mice (1)
- Peri-implant disease (1)
- Peritoneal macrophages (1)
- Peritumoural oedema (1)
- Peri‑implantitis (1)
- Persistence SARS-CoV-2 antibodies (1)
- Personal protective equipment (1)
- Personalisierte translationale Therapie (1)
- Personalized medicine (1)
- Phagocytosis (1)
- Phantoms (imaging) (1)
- Pharmacokinetics (1)
- Pharmacology (1)
- Pharmacotherapy (1)
- Phase 3 (1)
- Phase 3 trial (1)
- Phenylketonuria (PKU) (1)
- Physical self-perception (1)
- Play (1)
- Pleasure (1)
- Pneumocystis jirovecii (1)
- Pneumonia (1)
- Podospora anserina (1)
- Point of care (1)
- Point-of-care wound diagnostics (1)
- Poly-Pore (1)
- Polypharmacy (1)
- Population dynamics (1)
- Portal veins (1)
- Post mortem examination (1)
- Post-cesarean (1)
- Post-offence drinking (1)
- Post-thaw recovery (1)
- Post-traumatic stress disorder (1)
- Postmortem (1)
- Postmortem interval (1)
- Posture analysis (1)
- Potassium iodide (1)
- Powered air-purifying respirator (1)
- Pre-analytics (1)
- Preclinical research (1)
- Prediction of locoregional recurrence (1)
- Predictive coding (1)
- Predictive markers (1)
- Predictive model (1)
- Prevention (1)
- Preventive medicine (1)
- Primary care (1)
- Primary health care (1)
- Primary molars (1)
- Primärversorgung (1)
- Principal component analysis (1)
- Prisoners (1)
- Prisons (1)
- Probability density (1)
- Probability distribution (1)
- Proficiency testing (1)
- Prognostic markers (1)
- Prognostic models (1)
- Protease inhibitor therapy (1)
- Proximal (1)
- Pseudomonas aeruginosa (1)
- Pseudophakia (1)
- Psoriasis (1)
- Psoriatic arthritis (1)
- Psychiatric disorders (1)
- Psychiatry (1)
- Psychology (1)
- Pyogenic spondylodiscitis (1)
- Python (1)
- Qualitative study (1)
- Quality control (1)
- RARP (1)
- RAS pathway (1)
- RCT (1)
- RET (1)
- RGAG1 (1)
- RMS (1)
- RNA (1)
- RNA sequencing (1)
- RNA therapeutics (1)
- RNA therapy (1)
- RNA-binding protein (1)
- RNA-sequencing (1)
- RNAP II (1)
- RND (1)
- RNF4 (1)
- ROC analyses (1)
- ROC-Analysen (1)
- ROS1 (1)
- RT-PCR-detection (1)
- Race (1)
- Radiation Oncology (1)
- Radiation necrosis (1)
- Radical prostatectomy (1)
- Radiochemotherapy (1)
- Radioiodine therapy (1)
- Radioiodine uptake test (1)
- Radiology (1)
- Radiomics (1)
- Radiosurgery (1)
- Ramucirumab (1)
- Randomisation (1)
- Randomized Controlled Trial (1)
- Randomized controlled trial (1)
- Reactive oxygen species (1)
- Ready-made mouthguard (1)
- Real-time MRI (1)
- Real-time polymerase chain reaction (PCR) tests (1)
- Rectal cancer (1)
- Redoxin (1)
- Refractive changes (1)
- Region (1)
- Registry (1)
- Renal cell carcinoma (1)
- Rescue medication (1)
- Resection (1)
- Residual myometrial thickness (1)
- Respiratory distress syndrome (1)
- Respiratory infections (1)
- Response control (1)
- Restenosis (1)
- Resting-state (1)
- Retrospective study (1)
- Reward (1)
- Rhabdomyoma (1)
- Rho-kinase (1)
- Ridge preservation (1)
- Riftia pachyptila (1)
- Risk factor (1)
- Risk stratification (1)
- Roussel Uclaf Causality Assess- ment Method (RUCAM) (1)
- S1P lyase (1)
- S63845 (1)
- SAH (1)
- SAMHD1 (1)
- SARS CoV 2 (1)
- SARS-CoV-2 testing (1)
- SARS-CoV‑2 (1)
- SCCHN (1)
- SCD14 (1)
- SEC-ICP-DRC-MS (1)
- SEER (1)
- SELEX (1)
- SF-36 (1)
- SGPL1 (1)
- SGPL1 knockout cell line (1)
- SH-SY5Y neuroblastoma cells (1)
- SIRPalpha (1)
- SIRT1 (1)
- SKALE score (1)
- SLC6a3 (1)
- SLC7A11 (1)
- SPG8 (1)
- SUMO (1)
- Safety (1)
- Salivary gland cancer (1)
- Salivary gland carcinoma (1)
- Sandfly (1)
- Sapacitabine (1)
- Sarcoma (1)
- Satisfaction (1)
- Scheimpflug imaging (1)
- Schizophrenia (1)
- Sclerotic glomeruli (1)
- Screeningfragebogen (1)
- Seasonal variation (1)
- Sedation (1)
- Sedatives (1)
- Seizures (1)
- Self-esteem (1)
- Sequencing (1)
- Short bowel syndrome (1)
- Side effect (1)
- Silver diamine fluoride (1)
- Simulated patients (1)
- Simulation training (1)
- Single-cell RNA sequencing (1)
- Skeletal health (1)
- Skull base (1)
- Slow Cortical Potentials, SCP (1)
- Smac mimetics (1)
- Smoking habits (1)
- Social Phobia (1)
- Social cognition (1)
- Social decision-making (1)
- Social neuroscience (1)
- Sociodemographic characteristics (1)
- Socket healing (1)
- Socket preservation (1)
- Soft tissue healing (1)
- Software (1)
- Solar insolation (1)
- Sonication (1)
- Sonography (1)
- Spinal fractures (1)
- Spinal surgery (1)
- Sport (1)
- Stability (1)
- Standard value (1)
- Standardization (1)
- Static MRI (1)
- Stem cell dose (1)
- Stem cell enumeration (1)
- Stereotactic ablative body radiotherapy (1)
- Stimulant (1)
- Sting challenge (1)
- Structured written feedback (1)
- Subependymal giant cell astrocytoma (1)
- Sudden Cardiac Death (SCD) (1)
- Suicidality (1)
- Sunlight (1)
- Superficial vein thrombosis (1)
- Supratentorial (1)
- Surgical blood loss (1)
- Surgical site infection (1)
- Sustained attention (1)
- Symmetrical blocked occlusion (1)
- Synaptic organizer (1)
- Synaptic transmission (1)
- Synaptosomal preparation (1)
- Syndecan-1 (1)
- Synthetic biology (1)
- Syrian hamster (1)
- Systematic review (1)
- T-cell development (1)
- T-cell receptor (TCR) (1)
- T-cells (1)
- TACE (1)
- TAM (1)
- TAVI (1)
- TDAG8 (1)
- TGF-β1 (1)
- TGFB-induced factor homeobox 1 (1)
- TGIF (1)
- TIPS (1)
- TLR4 (1)
- TME (1)
- TMT (1)
- TRAIL (1)
- TRP2 (1)
- TRPM8 (1)
- TRPV4 (1)
- TSP-4 (1)
- TTFields (1)
- TURP (1)
- TWNK (1)
- Taekwondoka (1)
- Tailored therapy (1)
- Tar (1)
- Targeted therapy (1)
- Telemedicine (1)
- Temozolomide (1)
- Tempo-parietal junction (1)
- Temporomandibular joint (1)
- Temporomandibular joint dysfunction (1)
- Tetanus (1)
- Tetrahydrobiopterin (1)
- Theft (1)
- Therapeutic anticoagulation (1)
- Thermogenesis (1)
- Thorax (1)
- Thyroid (1)
- Time of death (1)
- Time trend (1)
- Tobacco (1)
- Tomography (1)
- Tooth segmentation (1)
- Traditional Chinese Medicine (TCM) (1)
- Traditional Indian Medicine (1)
- Trajectories (1)
- Transcranial direct current stimulation (1)
- Transcription (1)
- Transcriptomics (1)
- Transdifferentiation (1)
- Transfusion (1)
- Translation (1)
- Translational research (1)
- Transplant logistics (1)
- Transplantation Centers (1)
- Travel times (1)
- Trisomy 21 (1)
- Troponin (1)
- Tuberous sclerosis complex (1)
- Tumor cell (1)
- Type three hypersensitivity (1)
- Tyrosine kinase inhibitor (TKI) (1)
- Tyrosinemia (1)
- UTUC (1)
- Ulixertinib (1)
- Understanding (1)
- Undiagnosed patients (1)
- Upper airway infection (1)
- Upper body posture (1)
- Urethral cancer (1)
- Uterus (1)
- VEGF receptor 2 internalization and signaling (1)
- VEGF receptors (1)
- VRE (1)
- Vaccine (1)
- Vagus nerve (1)
- Vagus nerve stimulation (1)
- Vascular endothelial growth factor (VEGF) (1)
- Ventilators (1)
- Video rasterstereography (1)
- Virtual noncalcium reconstructions (1)
- Virus trapping (1)
- Visual quality (1)
- WASH complex subunit 5 (1)
- WIPI2 (1)
- WIPI2b (1)
- Weight distribution (1)
- White blood cells (1)
- White matter hyperintensity (1)
- Wilson disease (WD) (1)
- Wnt (1)
- Working memory capacity (1)
- Wound healing (1)
- Wounds and injuries (1)
- X-ray computed (1)
- Yoga (1)
- Zika Virus (1)
- Zika fever (1)
- Zymosan-induced peritonitis (1)
- ablation (1)
- abscisic acid (1)
- abscopal effect (1)
- acetaminophen (1)
- acne inversa (1)
- acoustic radiation force impulse (1)
- action (1)
- activated factor XIII (1)
- acute decompensation (1)
- acute pain (1)
- acute stroke care (1)
- adaptation (1)
- adenosine (1)
- adhesion (1)
- adipocytes (1)
- adipose-derived stromal/stem cells (1)
- adjuvant chemotherapy (1)
- adolescence (1)
- adolescent (1)
- adult (1)
- advanced melanoma (1)
- adversity (1)
- age (1)
- aged (1)
- agent-based models (1)
- agility (1)
- agreeableness (1)
- air abrasive (1)
- allogeneic hematological stem cell transplantation (1)
- allogeneic stem cell transplant (1)
- allostasis (1)
- alpha power (1)
- alpha-synuclein (1)
- alpha7 nicotinic acetylcholine receptor (1)
- amide proton transfer (1)
- amyotrophic lateral sclerosis (1)
- aneurysm (1)
- animal model (1)
- anorectal malformation (1)
- anti-neural autoantibodies (1)
- antiadhesive composites (1)
- antibacterial composites (1)
- antibiotic prophylactic therapy (1)
- antibiotic prophylaxis (1)
- antibiotics (1)
- anticipation (1)
- anticoagulation (1)
- antiepileptic drug (1)
- antihelix shaping (1)
- antimicrobial stewardship (1)
- antiviral signaling (1)
- anxiety (1)
- anxiety disorders (1)
- aortic root replacement (1)
- aortic valve repair (1)
- aortic valve stenosis (1)
- aortic valve-sparing (1)
- aphrodisin (1)
- apical constriction (1)
- apical polarity (1)
- aptamer (1)
- aptamer modeling (1)
- arterial stiffness (1)
- articular cartilage (1)
- artifacts (1)
- artificial feeding (1)
- artificial intelligence (1)
- artificial intelligence (AI) (1)
- assembly (1)
- assembly factor (1)
- asthma (1)
- asymptomatic temporal encephaloceles (1)
- at-risk mental state (1)
- ataxia (1)
- atopic dermatitis (1)
- atrial fibrillation (1)
- attachment (1)
- attention (1)
- attention-deficit/hyperactivity disorder (ADHD) (1)
- auditory (1)
- auditory cortex (1)
- augmentation (1)
- autism (1)
- autoantibodies (1)
- autobiographical memories (1)
- autogenous tooth roots (1)
- autoimmune encephalitis (1)
- autoimmune-mediated psychosis (1)
- automatic scene classification (1)
- autophagy inhibition (1)
- azacitidine (1)
- bacteremia (1)
- bacteria (1)
- bacterial leakage (1)
- bacterial viability (1)
- bacteriophages (1)
- ball (1)
- basilar artery occlusion (BAO) (1)
- bats (1)
- behavioral inhibition (1)
- behavioural rhythms (1)
- benfooxythiamine (1)
- best medical treatment (1)
- beta-band activity (1)
- beta-lactamases (1)
- bibliometric analysis (1)
- bilateral (1)
- bile (1)
- bile acids (1)
- binocular vision (1)
- biochemical relapse free survival (1)
- biologization (1)
- bladder neck stenosis (1)
- blood cell mutations (1)
- blood coagulation (1)
- blood concentrates (1)
- blood culture (1)
- blood transfusion (1)
- blood-brain barrier (1)
- bloodstream infections (1)
- body plethysmography (1)
- bone (1)
- bone augmentation (1)
- bone barrow (1)
- bone regeneration (1)
- bone-regeneration (1)
- bowel dysfunction (1)
- brachytherapy (1)
- brain disorders (1)
- brain imaging (1)
- brain infection (1)
- brain metastases (1)
- cAMP (1)
- cGMP (1)
- callous-unemotional traits (1)
- calretinin (1)
- cancer cell metabolism (1)
- cancer immunotherapy (1)
- cancer metastases (1)
- cancer specific survival (1)
- cancer surveillance (1)
- cancer therapy (1)
- cancer treatment (1)
- cancer-associated fibroblasts (1)
- cancer-specific survival (1)
- cannabinoid receptors (1)
- carbapenem resistance (1)
- carbapenemases (1)
- cardiac differentiation (1)
- cardiac magnetic resonance (1)
- cardiac regeneration (1)
- cardiac reprogramming (1)
- cardiocerebral resuscitation (1)
- cardiomyocyte apoptosis (1)
- cardiomyocyte proliferation (1)
- cardiomyocytes (1)
- cardiopulmonary resuscitation (1)
- cardiovascular disease (1)
- caregivers (1)
- cartilage (1)
- castration resistance (1)
- cell barrier integrity (1)
- cell culture (1)
- cell differentiation (1)
- cell heterogeneity (1)
- cell lines (1)
- cell proliferation regulating inhibitor of protein phosphatase 2A (1)
- cellular therapies (1)
- central nervous system (1)
- central spasticity (1)
- ceramides (1)
- cerebral imaging (1)
- cerebral ischemia (1)
- cerebral metastasis (1)
- cerebral palsy (1)
- cerebral sinus and vein thrombosis (CVT) (1)
- cervical cancer (1)
- cetuximab (1)
- chaperone-mediated autophagy (1)
- chemokines (1)
- chemoradiotherapy (1)
- childhood cancer (1)
- children and adolescents (1)
- cholesterol (1)
- cholinergic system (1)
- chronic (1)
- chronic granulomatous disease (1)
- chronic hepatitis C (1)
- chronic inflammation (1)
- classical Hodgkin lymphoma (1)
- classification (1)
- clindamycin (1)
- clinical decision-making (1)
- clinical high at-risk mental state (1)
- clinical isolates (1)
- clinical research (1)
- clinical stage (1)
- clinical teaching (1)
- clinically important restrictions and symptoms (1)
- clonal haematopoiesis (1)
- cluster analysis (1)
- cluttering (1)
- co-infection (1)
- cochlear implant (1)
- cochlear implants (1)
- collagen (1)
- collagen membranes (1)
- collective cell migration (1)
- colorectal cancer (1)
- combined modality therapy (1)
- comorbidities (1)
- complementary medicine (1)
- complete response (1)
- complex systems (1)
- compound screen (1)
- computational knowledge-discovery (1)
- computer-assisted (1)
- concordance (1)
- conduct disorder (1)
- confinement (1)
- congenital diaphragmatic hernia (1)
- congenital disorders of autophagy (1)
- conical coupling (1)
- conometric connection (1)
- consensus (1)
- conservative dentistry (1)
- constipation (1)
- contraception (1)
- control of menstrual bleeding (1)
- convulsive seizures (1)
- coping (1)
- core expression (1)
- corona virus (1)
- coronally advanced flap (1)
- corticosteroids (1)
- cost-effective (1)
- criteria (1)
- critical-size defect (1)
- critically ill patients (1)
- cross-linking (1)
- curcumin (1)
- cyclic nucleotide analogues (1)
- cyclic nucleotide binding proteins (1)
- cycling (1)
- cyclooxygenase-2 (1)
- cytochrome P450 enzymes (1)
- cytochrome P450 reductase (1)
- cytokines (1)
- cytotoxic T lymphocyte (1)
- dance teacher (1)
- data quality (1)
- data repositories (1)
- data sharing (1)
- death rates (1)
- decompressive craniectomy (1)
- default mode network (1)
- degradation (1)
- delayed diagnosis (1)
- delivery mode (1)
- delta (1)
- dendrite morphogenesis (1)
- dendritic cells (1)
- dengue vector (1)
- dental assistant (1)
- dental education (1)
- dental implant (1)
- dental school (1)
- dental treatment concept (1)
- dentist (1)
- dentist’s chair design (1)
- depth perception (1)
- desensitization (1)
- development (1)
- diabetes complication (1)
- diabetic nephropathy (1)
- diagnosis (1)
- diet (1)
- diffuse marrow involvement (1)
- digital medicine (1)
- digital one-piece casting (1)
- digital pressing technology (1)
- digital workflow (1)
- dihydrocannabidiol (1)
- diphtheria toxin (1)
- direct-acting antiviral (DAA) treatment (1)
- discontinuation (1)
- disease progression (1)
- dislocation (1)
- disordered iron metabolism (1)
- dobutamine stress (1)
- docetaxel (DX) resistance (1)
- dopamine transporter (1)
- dorsal attention network (1)
- double immune checkpoint inhibition (1)
- downgrading (1)
- doxycycline (1)
- drinking (1)
- drospirenone (1)
- drug (1)
- drug–drug interactions (1)
- drug–gene interactions (1)
- drug–g–gene interactions (1)
- dual-energy (1)
- dynamic causal modeling (1)
- dynamic system (1)
- early onset (1)
- early-onset prostate cancer (1)
- echo planar imaging (1)
- edentulous (1)
- efferocytosis (1)
- efflux pump (1)
- egg sampling (1)
- elastin (1)
- electrical coupling (1)
- electroanatomical mapping (1)
- electrode design (1)
- electroencephalography (1)
- electroencephalography (EEG) (1)
- electrolytic cleaning (1)
- electron transfer (1)
- element speciation (1)
- emergency care (1)
- emicizumab (1)
- endodontic curriculum (1)
- endodontic education (1)
- endodontics (1)
- endothelial dysfunction (1)
- endourology (1)
- endovascular treatment (1)
- enterobacter infections; pseudomonas aeruginosa; epidemiology (1)
- enzyme activity assay (1)
- epidermal growth factor receptor (1)
- epilepsy surgery (1)
- erastin (1)
- erythropoiesis (1)
- essential thrombocythemia (ET) (1)
- ethanol (1)
- everolimus (1)
- executive functions (1)
- exercise (1)
- expert witness statement (1)
- extraskeletal (1)
- eye movements (1)
- fMLP (1)
- factor XIII (1)
- faecal microbiota transfer (1)
- fall (1)
- famotidine (1)
- fasting insulin (1)
- fat grafting (1)
- fatty acid synthesis (1)
- fecal incontinence (1)
- fecal microbiota transfer (1)
- females (1)
- fenfluramine (1)
- ferric carboxymaltose (1)
- ferric derisomaltose (1)
- ferroportin (1)
- ferroptosis (1)
- ferumoxytol (1)
- fibrinolysis (1)
- fibrosis (1)
- first-time shoulder dislocation (1)
- flow cytometry (1)
- fondaparinux (1)
- fracture strength (1)
- fracture strength equation (1)
- frontotemporal dementia (1)
- full-arch restoration (1)
- function (1)
- functional connectome acute (1)
- functional magnetic resonance imaging (1)
- functional outcome (1)
- fungal sugar (1)
- fusion (1)
- fusion kinase (1)
- gait symmetry (1)
- gargle lavage (1)
- gastrointestinal stromal tumours (1)
- gender (1)
- genetic diversity (1)
- genetic variants (1)
- genetically caused iron imbalance (1)
- genotype G (1)
- geriatrics (1)
- gingival recession therapy (1)
- glecaprevir (1)
- glioma (1)
- glioma microenvironment (1)
- global health (1)
- glucose-6-phosphate dehydrogenase (1)
- glucosylceramides (1)
- glycoproteins (1)
- gp100 (1)
- graft-vs-host disease (1)
- granule polarization (1)
- graphic 3D models (1)
- great height (1)
- grisel syndrome (1)
- growth (1)
- growth inhibition (1)
- guided bone regeneration (1)
- guideline (1)
- haNK (1)
- haemophilia (1)
- harmonization (1)
- hatching (1)
- head and neck neoplasms (1)
- health database (1)
- health information interoperability (1)
- health-relatedquality of life (1)
- healthy control (1)
- hematotoxicity (1)
- hemorrhage (1)
- herb-induced liver injury (HILI) (1)
- heterogeneity (1)
- high risk (1)
- high-altitude adaptation (1)
- high-altitude pulmonary hypertension (1)
- high-fat-diet (1)
- high-risk (1)
- high-risk neuroblastoma (1)
- hip osteoarthritis (hip OA) (1)
- hippocampus (1)
- histamine (1)
- histopathological growth pattern (1)
- homeodomain protein (1)
- homeostasis (1)
- hospital admission (1)
- host-microbe interaction (1)
- human allogeneic hematopoietic cell transplantation (1)
- human behaviour (1)
- human factors (1)
- human intestinal microbiota (1)
- human olfaction (1)
- human subjects (1)
- humans (1)
- hybrid materials (1)
- hybrid production (1)
- hydrogen peroxide (1)
- hypersensitivity (1)
- hypobaric hypoxia (1)
- hypophosphatemia (1)
- hypoxia inducible factor 1 alpha (1)
- iCBT (1)
- idiosyncratic drug-induced liver injury (DILI) (1)
- image-guided tissue acquisition (1)
- imaging genetics (1)
- imaging protocol (1)
- immobilization in external rotation and abduction (1)
- immune checkpoint blockade (1)
- immune checkpoint inhibitor (ICI) (1)
- immune escape (1)
- immune host defense (1)
- immune infiltration (1)
- immunohistochemistry (1)
- immunological risk (1)
- impulsivity (1)
- incidence (1)
- incontinence (1)
- induction chemotherapy (1)
- induction regimen (1)
- induction therapy (1)
- inertial motion units (1)
- infection (1)
- infection control (1)
- infection precaution (1)
- infections (1)
- infectivity (1)
- inflammasome (1)
- inflammatory bowel disease (1)
- inflammatory reaction (1)
- informal care (1)
- inherited (1)
- inhibitor (1)
- inhibitory control (1)
- injury pattern (1)
- injury prevention (1)
- inosine (1)
- insurance data (1)
- integrate-and-fire (1)
- integrative medicine (1)
- integrative neuromotor training (1)
- intellectual disability (1)
- intensive care admission and mortality (1)
- interim positron emissiontomography (1)
- interleukin-22 (1)
- international transport (1)
- interstitial multicatheter brachytherapy (1)
- intestinal iron loss (1)
- intestinal manipulation (1)
- intracellular (1)
- intracerebral hemorrhage (ICH) (1)
- intracranial hemorrhage (1)
- intranasal administration (1)
- intraoperatively molded (1)
- intravenous iron (1)
- intravenous iron therapy (1)
- intrinsic and innate immune response (1)
- invasive fungal disease (1)
- inverse spacer (1)
- inverse stage migration (1)
- iron deficiency anemia (1)
- iron isomaltoside (1)
- iron-trafficking (1)
- irritable bowel syndrome (1)
- jejunoileal atresia (1)
- joint innervation (1)
- joint load (1)
- juvenile myelomonocytic leukemia (1)
- kidney transplantation (1)
- kinematic analysis (1)
- landrace pigs (1)
- language impairment (1)
- lasso regression (1)
- layer-specificity (1)
- learning and memory (1)
- left atrial appendage occlusion (1)
- legislation (1)
- leisure-time activity (1)
- lenalidomide (1)
- leptin receptor-deficient mouse (1)
- leucocytes (1)
- leukemia (1)
- leukocytes (1)
- leukodystrophy (1)
- life table (1)
- life-expectancy (1)
- lifestyle intervention (1)
- light irradiation (1)
- limitations (1)
- lipids (1)
- lipofilling (1)
- lipofuscin (1)
- live-cell imaging (1)
- live/dead staining (1)
- liver X receptor (1)
- liver damage (1)
- liver metastasis (1)
- liver steatosis (1)
- liver stiffness (1)
- liver volume (1)
- local drug delivery (1)
- local preemptive analgesia (1)
- local recurrence (1)
- local treatment (1)
- location (1)
- locator (1)
- logistic models (1)
- long non-coding RNA (1)
- long term (1)
- long-term outcome (1)
- long-term success (1)
- loss of B-cell phenotype (1)
- loss-of-function (1)
- low molecular weight heparin (1)
- low risk (1)
- low-back-pain (1)
- low-carbohydrate (1)
- low-dose irradiation (1)
- low-glycaemic meal replacement (1)
- lower leg fracture (1)
- lung development (1)
- lung function (1)
- lungs (1)
- lymph node metastases (1)
- mRNA stability (1)
- mRNA1273 (1)
- mTOR (1)
- mTOR inhibitor (1)
- machine-learning (1)
- magnetoencephalography (1)
- male (1)
- malignancy (1)
- mammary carcinoma (1)
- manganese (1)
- marginal fit (1)
- marked lymph node (1)
- mass spectrometry (1)
- mathematical analysis (1)
- mathematical modeling (1)
- mechanotransduction (1)
- medical risk factors (1)
- medulloblastoma (1)
- melanoma (1)
- membrane-less organelles (1)
- membranous urethral stricture (1)
- meningioma (1)
- mental health (1)
- mesenchymal stromal cell (1)
- mesenchymal stromal/stem cells (1)
- mesial temporal lobe epilepsy (1)
- meta-analysis (1)
- metabolic liver disease (1)
- metabolic rewiring (1)
- metabolism (1)
- metabolomics (1)
- metastatic renal cell carcinoma (1)
- mice (1)
- michael acceptor (1)
- microbiome (1)
- microdissection (1)
- microsurgery (1)
- microvesicles (1)
- mild cognitive impairment (1)
- minimally invasive therapy (1)
- minocycline (1)
- mitochondrial disease (1)
- mitochondrial respiration (1)
- mitral regurgitation (1)
- mitral valve surgery (1)
- mold (1)
- molecular marker (1)
- molecular neuroscience (1)
- molecular surveillance (1)
- monitoring (1)
- monoacylglycerol lipase (1)
- monoclonal antibodies (1)
- monoclonal antibody (1)
- monocytes (1)
- monotherapy (1)
- mood (1)
- morbidity (1)
- motor functions (1)
- motor-control-exercise (1)
- mouse (1)
- mouse models (1)
- mouse tumor model (1)
- mucormycetes (1)
- multi-material 3D printing (1)
- multi-scale models (1)
- multicenter study (1)
- multicentre study (1)
- multidisciplinary-therapy (1)
- multimorbidity (1)
- multiple myeloma (1)
- multisensory integration (1)
- multislice imaging (1)
- multivoxel pattern analysis (1)
- musculoskeletal disorders (1)
- musculoskeletal repair (1)
- musculoskeletal system (1)
- mutation (1)
- mutism (1)
- myeloproliferative neoplasms (MPN) (1)
- myocardial efficiency (1)
- myocardial fibrosis (1)
- myocardial ischaemia (1)
- myocardial power (1)
- nNOS (1)
- nasal swab (1)
- natural selection (1)
- natural sounds (1)
- necroptosis (1)
- neoadjuvant therapy (1)
- neonate (1)
- neovascularization (1)
- nephroureterectomy (1)
- neural correlates (1)
- neural oscillations (1)
- neurodegeneration (1)
- neurodevelopment (1)
- neurodevelopmental disorde (1)
- neuroendocrine tumor (1)
- neuroethology (1)
- neurogenic bowel (1)
- neuroimaging (1)
- neurological manifestations (1)
- neurology (1)
- neuropeptide (1)
- neuropeptides (1)
- neuroprotection (1)
- neurotransmitter (1)
- neutralization (1)
- neutralizing antibody (1)
- next-generation sequencing (1)
- nitric oxide (1)
- nitroalkene (1)
- nitroglycerin (1)
- nociception (1)
- nodular lymphocyte-predominant Hodgkin lymphoma (1)
- nomogram (1)
- non-aneurysmal (1)
- non-aneurysmal SAH (1)
- non-coding RNA (1)
- non-contact injuries (1)
- non-perimesencephalic (1)
- non-small cell lung cancer (1)
- nontraumatic atlantoaxial rotatory subluxation (1)
- nucleic acid amplification test (1)
- nucleic acid docking (1)
- nucleic acid lateral flow immunoassay (1)
- nucleolus (1)
- nucleoredoxin (1)
- nutrition - clinical (1)
- nymphs (1)
- obesity (1)
- observational study (1)
- olfaction (1)
- oluble epoxide hydrolase (1)
- oncogenesis (1)
- oncogenic RAS (1)
- oncological exercise therapy (1)
- online intervention (1)
- online research (1)
- online survey (1)
- open field behavior (1)
- open science (1)
- open skill exercise (1)
- operating microscope (1)
- oral health (1)
- oral health burden (1)
- oral progestins (1)
- orale Gestagene (1)
- ordinary differential equations (ODE) (1)
- organ preservation (1)
- organic nitrates (1)
- organotypic culture (1)
- other cause mortality (1)
- otoplasty (1)
- outcomes (1)
- ovarian cancer (1)
- overdenture (1)
- overtreatment (1)
- overweight (1)
- oviposition (1)
- oviposition substrate (1)
- ovitrap (1)
- oxaliplatin (1)
- oxythiamine (1)
- p-eIF2α (1)
- p21Cip1/CDKN1A (1)
- p53 pathway (1)
- pH (1)
- pad-test (1)
- pain intensity (1)
- paired samples (1)
- palliative care (1)
- palliative care services (1)
- pancreatic ductal adenocarcinoma (1)
- pannexin-1 (1)
- paper-based detection (1)
- paracrine signaling (1)
- parent rating (1)
- pathogen (1)
- patient preferences (1)
- patient safety (1)
- patient–doctor relationship (1)
- pediatric solid tumors (1)
- pelvic trauma (1)
- penile cancer (1)
- pentaerythritol tetranitrate (1)
- peptide receptor radionuclide therapy (1)
- perforant path transection (1)
- peri-implant disease (1)
- peri-implant diseases (1)
- peri-implantitis (1)
- peri-implantitis treatment (1)
- periimplantitis (1)
- perimesencephalic (1)
- periodontal diseases (1)
- periodontal treatment (1)
- peripheral blood stem cell collection (1)
- peritoneal macrophages (1)
- peritumoral edema (1)
- peritumoral edema zone (1)
- peroxisome proliferator-activated receptor (1)
- persistent periodontal pockets (1)
- personalized (1)
- phagocytes (1)
- phagocytosis (1)
- pharmacodynamics (1)
- pharmacoepigenetics (1)
- pharmacogenetics (1)
- pharmacological data science (1)
- pharmacological plasticity (1)
- phase IV (1)
- phase separation (1)
- phenoconversion (1)
- pheromone (1)
- phosphoproteomics (1)
- photodynamic therapy (1)
- physical activity (1)
- physiotherapy (1)
- pibrentasvir (1)
- pitch (1)
- plasmid (1)
- platelet hyperactivity (1)
- platelet substitution (1)
- platelet-rich-fibrin (1)
- point-of-care diagnostics (1)
- polo-like kinases (1)
- polyQ (1)
- polycythemia vera (PV) (1)
- polymer infiltrated ceramic network (1)
- polymeric micelle (1)
- polypept(o)ide (1)
- polypharmacy (1)
- polytrauma (1)
- polyunsaturated fatty acid (1)
- portal pressure (1)
- positron-emissions-tomography (1)
- post-transcriptional regulation (1)
- posterior circulation (1)
- postinfectious bronchiolitis obliterans (1)
- postoperative pain (1)
- potassium channel (1)
- preclinical (1)
- prediabetes and type 2 diabetes (1)
- prediction (1)
- predictive (1)
- predictive coding (1)
- predictor (1)
- preeclampsia (1)
- prehabilitation (1)
- prepontine (1)
- preventive strategies (1)
- primary biliary cholangitis (1)
- primary immunodeficiency (1)
- primary myelofibrosis (PMF) (1)
- prion-like (1)
- production (1)
- progestin mono-preparation (1)
- prognostic (1)
- prognostic scores (1)
- progranulin (1)
- promyelocytic leukemia nuclear bodies (1)
- prostate cancer (PCa) (1)
- prostate neoplasm (1)
- proteasome (1)
- protein aggregation (1)
- protein complexes (1)
- protein evolution (1)
- protein folding (1)
- protein phosphorylation (1)
- protein-rich (1)
- protein–protein interaction (1)
- proteoglycan (1)
- proteomics (1)
- proton pumping (1)
- proton-sensing GPCR (1)
- protruding ear (1)
- pseudomonas aeruginosa (1)
- psoriasis (1)
- psychiatric comorbidity (1)
- psychiatric disorders (1)
- psychogenic non-epileptic seizures (1)
- psychosocial factors (1)
- public health (1)
- publication output (1)
- pulsed SILAC (1)
- quantitative MRI (1)
- quantitative RUCAM (1)
- quantitative magnetic resonance imaging (1)
- quiescence (1)
- radiation (1)
- radiation-induced (1)
- radio sensitivity (1)
- radioimmunotherapy (1)
- radiomics (1)
- randomized (1)
- randomized controlled trial (1)
- rare disease (1)
- rare mendelian disorders (1)
- rat calvaria defect (1)
- re-irradiation (1)
- reactive coordination (1)
- reactive oxygen species (1)
- real-world (1)
- recall (1)
- recombinase polymerase amplification (1)
- recovery (1)
- recurrent urinary tract infections (1)
- red cells (1)
- reduced kidney function (1)
- reduction potential (1)
- regenerative therapy (1)
- relapsing–remitting multiple sclerosis (1)
- remodeling (1)
- renal cell carcinoma (1)
- renal dysfunction (1)
- renal failure (1)
- renal tubular epithelial cells (1)
- research database (1)
- research funding (1)
- resectability (1)
- resin nano ceramics (1)
- resistance (1)
- resistance mutation (1)
- resolution (1)
- response (1)
- response inhibition (1)
- resting-state (1)
- reticulocyte hemoglobin equivalent (1)
- retrospective studies (1)
- reverberation (1)
- revision knee arthroplasty (1)
- reward (1)
- reward probabilities (1)
- rheumatoid arthritis (1)
- rifampicin (1)
- risk group (1)
- risk stratification (1)
- room simulation (1)
- safety attitudes questionnaire (1)
- salience network (1)
- saliva (1)
- salvage mastectomy (1)
- salvage radical prostatectomy (1)
- sampling (1)
- sarcoma (1)
- scar (1)
- schizophrenia (1)
- screening questionnaire (1)
- searchlight analysis (1)
- second line therapy (1)
- second-line immunotherapy (1)
- second-line treatment / 2L treatment (1)
- secondary data analysis (1)
- secondary progressive multiple sclerosis (1)
- secreted Ly-6/uPAR-related protein 1 (1)
- seed and soil (1)
- segmental ureteral resection (1)
- self-collected samples (1)
- semiquinone (1)
- sensory loss (1)
- sensory organ development (1)
- serine protease (NS3-4A) (1)
- serum (1)
- severely injured patient (1)
- sex (1)
- sex differences (1)
- sexual arousal (1)
- sexual dysfunction (1)
- sexual rehabilitation (1)
- shared decision-making (1)
- shear stress (1)
- shikonin (SHI) (1)
- short bowel (1)
- short linear motif (1)
- short-term (1)
- shoulder instability (1)
- shoulder stabilization (1)
- simulation (1)
- simulation training (1)
- sleep deprivation (1)
- sleep disordered breathing (1)
- small bowel (1)
- small ubiquitin-related modifier (1)
- social anxiety (1)
- social communication (1)
- socio-economic influences (1)
- socioeconomic factors (1)
- soft tissue (1)
- soft tissue sarcoma (1)
- solid tumor (1)
- sonoSens (1)
- sorafenib (1)
- sound-induced flash illusion (1)
- spared nerve injury (1)
- speech perception (1)
- sphingolipids (1)
- sphingosine-1-phosphate (1)
- spike mutation (1)
- spike protein (1)
- spina bifida (1)
- spinal bone metastasis (1)
- spinal infection (1)
- spine injury (1)
- spinocerebellar ataxia (1)
- splicing (1)
- split-mouth (1)
- sprouting (1)
- sprouting angiogenesis (1)
- stage (1)
- stage migration (1)
- statin (1)
- statin treatment (1)
- statins (1)
- stoma (1)
- structure-function (1)
- strumpellin (1)
- stuttering (1)
- subarachnoid hemorrhage (1)
- subchondral bone (1)
- subgrouping (1)
- subpopulation (1)
- sulforaphane (1)
- sulfur-oxidizing symbiont (1)
- superparamagnetic iron oxide nanoparticles (1)
- support (1)
- suprachiasmatic nucleus (1)
- surgical complications (1)
- surrogate ELISA (1)
- symbiosis (1)
- symptoms (1)
- synoviocytes (1)
- synovitis (1)
- systematic review (1)
- tDCS (1)
- tVNS (1)
- tachycardia (1)
- target (1)
- targeted axillary dissection (1)
- targeted sequencing (1)
- taste buds (1)
- temporal encephaloceles (1)
- temporal lobe epilepsy (1)
- testosterone (1)
- tetracycline (1)
- tetrahydrobiopterin (1)
- tetrahydrocannabinol (1)
- therapy (1)
- therapy response (1)
- thermal ablation (1)
- thrombectomy (1)
- thromboembolism (1)
- thymic selection (1)
- tibial fracture (1)
- tip cell filopodia formation (1)
- tissue reconstruction (1)
- toddler’s fracture (1)
- tolerability (1)
- topical administration (1)
- topographical pattern (1)
- torticollis (1)
- total hip replacement (1)
- toxic milk mice (TX mice) (1)
- toxicity (1)
- traditional Chinese medicine (TCM) (1)
- trafficking (1)
- training (1)
- transduction (1)
- transfer entropy (1)
- transglutaminase (1)
- transient elastography (1)
- transjugular intrahepatic portosystemic shunt (1)
- translational investigation (1)
- translational study (1)
- transmission (1)
- transovarial transmission (1)
- transplant-free survival (1)
- transstadial transmission (1)
- trauma (1)
- traumatic brain injury (1)
- traumatic injury (1)
- treatment outcome (1)
- treatment resistance (1)
- treatment response (1)
- trials registry (1)
- triplex (1)
- trophoblast organoids (1)
- trophoblasts (1)
- trough levels (1)
- tumor immunity (1)
- tumor immunology (1)
- tumor stroma (1)
- tumor-associated macrophages (TAM) (1)
- tunnel technique (1)
- type 2 diabetes (1)
- tyrosine hydroxylase (1)
- tyrosine kinase inhibitor (TKI) (1)
- ubiquitin ligase (1)
- ultra-high risk for psychosis (1)
- unacceptable antigen mismatches (1)
- undifferentiated pleomorphic sarcoma (1)
- unilateral (1)
- unilateral hip osteoarthritis (1)
- upgrading (1)
- upper tract urothelial carcinoma (1)
- ureteroscopy (1)
- urethal stricture (1)
- urethroplasty (1)
- urinary incontinence (1)
- ursodeoxycholic acid (1)
- uveal melanoma (1)
- vaccine-induced immune thrombotic thrombocytopenia (VITT) (1)
- vaginal breech (1)
- vaginal hysterectomy (1)
- variants of concern (1)
- vascular biology (1)
- vasodilation (1)
- vector (1)
- venous thrombosis (1)
- ventral otoplasty (1)
- ventral striatum (1)
- ventricular tachycardia (1)
- vergence (1)
- vertigo (1)
- very high-risk (1)
- vestibular function (1)
- viral fitness (1)
- virus (1)
- viruses (1)
- volumetric measurement technology (1)
- von Willebrand disease (1)
- waiting time (1)
- walking (1)
- wearable sensors (1)
- weight reduction (1)
- white matter hyperintensity (1)
- whole-genome sequencing (1)
- work place evaluation (1)
- wound exudate (1)
- wound healing (1)
- wound infection (1)
- wound repair (1)
- yellow flags (1)
- younger (1)
- zinc protoporphyrin (1)
- Übergewicht (1)
- ß-amyloid (1)
- β-HCG (1)
Institute
- Medizin (667)
- Biochemie, Chemie und Pharmazie (8)
- Biowissenschaften (7)
- Psychologie und Sportwissenschaften (6)
- Buchmann Institut für Molekulare Lebenswissenschaften (BMLS) (5)
- Georg-Speyer-Haus (4)
- Physik (3)
- Biodiversität und Klima Forschungszentrum (BiK-F) (2)
- Ernst Strüngmann Institut (2)
- Erziehungswissenschaften (2)
Large-scale molecular profiling studies in recent years have shown that central nervous system (CNS) tumors display a much greater heterogeneity in terms of molecularly distinct entities, cellular origins and genetic drivers than anticipated from histological assessment. DNA methylation profiling has emerged as a useful tool for robust tumor classification, providing new insights into these heterogeneous molecular classes. This is particularly true for rare CNS tumors with a broad morphological spectrum, which are not possible to assign as separate entities based on histological similarity alone. Here, we describe a molecularly distinct subset of predominantly pediatric CNS neoplasms (n = 60) that harbor PATZ1 fusions. The original histological diagnoses of these tumors covered a wide spectrum of tumor types and malignancy grades. While the single most common diagnosis was glioblastoma (GBM), clinical data of the PATZ1-fused tumors showed a better prognosis than typical GBM, despite frequent relapses. RNA sequencing revealed recurrent MN1:PATZ1 or EWSR1:PATZ1 fusions related to (often extensive) copy number variations on chromosome 22, where PATZ1 and the two fusion partners are located. These fusions have individually been reported in a number of glial/glioneuronal tumors, as well as extracranial sarcomas. We show here that they are more common than previously acknowledged, and together define a biologically distinct CNS tumor type with high expression of neural development markers such as PAX2, GATA2 and IGF2. Drug screening performed on the MN1:PATZ1 fusion-bearing KS-1 brain tumor cell line revealed preliminary candidates for further study. In summary, PATZ1 fusions define a molecular class of histologically polyphenotypic neuroepithelial tumors, which show an intermediate prognosis under current treatment regimens.
Background: Deep surgical site infections (dSSIs) after instrumented spinal surgery pose major therapeutic challenges. Standard treatment involves surgical debridement, wound drainage, and long-term antibiotic administration. Autologous platelet-rich fibrin (PRF) constitutes a biomaterial obtained from patients’ own blood that contains leukocytes, chemokines and growth factors boosting cicatrization. Due to favorable results reported from other surgical disciplines such as dentistry, orthopedics, maxillofacial and plastic surgery using PRF, the authors hypothesized that PRF augmentation will promote wound healing in dSSIs. Objective: To report our preliminary results on the safety and efficacy of autologous-PRF as an add-on therapy on a pilot case series of persistent dSSI after instrumented spinal surgery. Methods: Among the 293 patients who underwent dorsal decompression and stabilization of the cervical, thoracic, and lumbar spine due to degenerative diseases in our department, 12 patients (4%) presented persisting dSSI after standard wound debridement and antibiotic treatment. PRF augmentation was used during a second surgical revision as an add-on therapy to standard debridement. In all cases, the wound was primarily closed without drains. Results: Wound healing was completed between 14 and 21 days after the second surgical revision in all patients. At a median follow-up of 8 months (range: 6 to 18 months), no recurrence of dSSI nor complications were encountered in any case. Conclusions: Our preliminary results suggest that PRF augmentation in persistent dSSI after instrumented spinal surgery appears to be a safe and effective strategy to promote wound healing. Prospective controlled studies are required to define the efficiency of PRF more clearly in both treating and preventing dSSI.
Objectives: The aim of this study was to develop a prognostic tool to estimate long-term tooth retention in periodontitis patients at the beginning of active periodontal therapy (APT). Material and methods: Tooth-related factors (type, location, bone loss (BL), infrabony defects, furcation involvement (FI), abutment status), and patient-related factors (age, gender, smoking, diabetes, plaque control record) were investigated in patients who had completed APT 10 years before. Descriptive analysis was performed, and a generalized linear-mixed model-tree was used to identify predictors for the main outcome variable tooth loss. To evaluate goodness-of-fit, the area under the curve (AUC) was calculated using cross-validation. A bootstrap approach was used to robustly identify risk factors while avoiding overfitting. Results: Only a small percentage of teeth was lost during 10 years of supportive periodontal therapy (SPT; 0.15/year/patient). The risk factors abutment function, diabetes, and the risk indicator BL, FI, and age (≤ 61 vs. > 61) were identified to predict tooth loss. The prediction model reached an AUC of 0.77. Conclusion: This quantitative prognostic model supports data-driven decision-making while establishing a treatment plan in periodontitis patients. In light of this, the presented prognostic tool may be of supporting value. Clinical relevance: In daily clinical practice, a quantitative prognostic tool may support dentists with data-based decision-making. However, it should be stressed that treatment planning is strongly associated with the patient’s wishes and adherence. The tool described here may support establishment of an individual treatment plan for periodontally compromised patients.
Background: No simple classification system has emerged for ‘advanced basal cell carcinomas’, and more generally for all difficult-to-treat BCCs (DTT-BCCs), due to the heterogeneity of situations, TNM inappropriateness to BCCs, and different approaches of different specialists. Objective: To generate an operational classification, using the unconscious ability of experts to simplify the great heterogeneity of the clinical situations into a few relevant groups, which drive their treatment decisions. Method: Non-supervised independent and blinded clustering of real clinical cases of DTT-BCCs was used. Fourteen international experts from different specialties independently partitioned 199 patient cases considered ‘difficult to treat’ into as many clusters they want (≤10), choosing their own criteria for partitioning. Convergences and divergences between the individual partitions were analyzed using the similarity matrix, K-mean approach, and average silhouette method. Results: There was a rather consensual clustering of cases, regardless of the specialty and nationality of the experts. Mathematical analysis showed that consensus between experts was best represented by a partition of DTT-BCCs into five clusters, easily recognized a posteriori as five clear-cut patterns of clinical situations. The concept of ‘locally advanced’ did not appear consistent between experts. Conclusion: Although convergence between experts was not granted, this experiment shows that clinicians dealing with BCCs all tend to work by a similar pattern recognition based on the overall analysis of the situation. This study thus provides the first consensual classification of DTT-BCCs. This experimental approach using mathematical analysis of independent and blinded clustering of cases by experts can probably be applied to many other situations in dermatology and oncology.
Resilience has been defined as the maintenance or quick recovery of mental health during and after times of adversity. How to operationalize resilience and to determine the factors and processes that lead to good long-term mental health outcomes in stressor-exposed individuals is a matter of ongoing debate and of critical importance for the advancement of the field. One of the biggest challenges for implementing an outcome-based definition of resilience in longitudinal observational study designs lies in the fact that real-life adversity is usually unpredictable and that its substantial qualitative as well as temporal variability between subjects often precludes defining circumscribed time windows of inter-individually comparable stressor exposure relative to which the maintenance or recovery of mental health can be determined. To address this pertinent issue, we propose to frequently and regularly monitor stressor exposure (E) and mental health problems (P) throughout a study's observation period [Frequent Stressor and Mental Health Monitoring (FRESHMO)-paradigm]. On this basis, a subject's deviation at any single monitoring time point from the study sample's normative E–P relationship (the regression residual) can be used to calculate that subject's current mental health reactivity to stressor exposure (“stressor reactivity,” SR). The SR score takes into account the individual extent of experienced adversity and is comparable between and within subjects. Individual SR time courses across monitoring time points reflect intra-individual temporal variability in SR, where periods of under-reactivity (negative SR score) are associated with accumulation of fewer mental health problems than is normal for the sample. If FRESHMO is accompanied by regular measurement of potential resilience factors, temporal changes in resilience factors can be used to predict SR time courses. An increase in a resilience factor measurement explaining a lagged decrease in SR can then be considered to index a process of adaptation to stressor exposure that promotes a resilient outcome (an allostatic resilience process). This design principle allows resilience research to move beyond merely determining baseline predictors of resilience outcomes, which cannot inform about how individuals successfully adjust and adapt when confronted with adversity. Hence, FRESHMO plus regular resilience factor monitoring incorporates a dynamic-systems perspective into resilience research.
Hirschsprung’s disease (HD) is a congenital disorder, characterized by aganglionosis in the distal part of the gastrointestinal tract. Despite complete surgical resection of the aganglionic segment, both constipation and fecal incontinence persist in a considerable number of patients with limited treatment options. There is growing evidence for structural abnormalities in the ganglionic bowel proximal to the aganglionosis in both humans and animals with HD, which may play a role in persistent bowel dysfunction. These abnormalities include: (1) Histopathological abnormalities of enteric neural cells; (2) Imbalanced expression of neurotransmitters and neuroproteins; (3) Abnormal expression of enteric pacemaker cells; (4) Abnormalities of smooth muscle cells; and (5) Abnormalities within the extracellular matrix. Hence, a better understanding of these previously unrecognized neuropathological abnormalities may improve follow-up and treatment in patients with HD suffering from persistent bowel dysfunction following surgical correction. In the long term, further combination of clinical and neuropathological data will hopefully enable a translational step towards more individual treatment for HD.
Background: Intensive Care Resources are heavily utilized during the COVID-19 pandemic. However, risk stratification and prediction of SARS-CoV-2 patient clinical outcomes upon ICU admission remain inadequate. This study aimed to develop a machine learning model, based on retrospective & prospective clinical data, to stratify patient risk and predict ICU survival and outcomes. Methods: A Germany-wide electronic registry was established to pseudonymously collect admission, therapeutic and discharge information of SARS-CoV-2 ICU patients retrospectively and prospectively. Machine learning approaches were evaluated for the accuracy and interpretability of predictions. The Explainable Boosting Machine approach was selected as the most suitable method. Individual, non-linear shape functions for predictive parameters and parameter interactions are reported. Results: 1039 patients were included in the Explainable Boosting Machine model, 596 patients retrospectively collected, and 443 patients prospectively collected. The model for prediction of general ICU outcome was shown to be more reliable to predict “survival”. Age, inflammatory and thrombotic activity, and severity of ARDS at ICU admission were shown to be predictive of ICU survival. Patients’ age, pulmonary dysfunction and transfer from an external institution were predictors for ECMO therapy. The interaction of patient age with D-dimer levels on admission and creatinine levels with SOFA score without GCS were predictors for renal replacement therapy. Conclusions: Using Explainable Boosting Machine analysis, we confirmed and weighed previously reported and identified novel predictors for outcome in critically ill COVID-19 patients. Using this strategy, predictive modeling of COVID-19 ICU patient outcomes can be performed overcoming the limitations of linear regression models. Trial registration “ClinicalTrials” (clinicaltrials.gov) under NCT04455451.
The development of binocular vision is an active learning process comprising the development of disparity tuned neurons in visual cortex and the establishment of precise vergence control of the eyes. We present a computational model for the learning and self-calibration of active binocular vision based on the Active Efficient Coding framework, an extension of classic efficient coding ideas to active perception. Under normal rearing conditions with naturalistic input, the model develops disparity tuned neurons and precise vergence control, allowing it to correctly interpret random dot stereograms. Under altered rearing conditions modeled after neurophysiological experiments, the model qualitatively reproduces key experimental findings on changes in binocularity and disparity tuning. Furthermore, the model makes testable predictions regarding how altered rearing conditions impede the learning of precise vergence control. Finally, the model predicts a surprising new effect that impaired vergence control affects the statistics of orientation tuning in visual cortical neurons.
Importance Surgery is a mainstay in the management of hidradenitis suppurativa (HS). Adalimumab is the first drug approved for HS. Objective To investigate the efficacy and safety of adalimumab in combination with wide-excision surgery followed by secondary intention healing. Design, Setting, and Participants The Safety and Efficacy of Adalimumab for Hidradenitis Suppurativa Peri-Surgically (SHARPS) trial was a phase 4, randomized, double-blind, placebo-controlled study of adalimumab in conjunction with surgery. Patients were enrolled in 45 sites across 20 countries from July 18, 2016, to February 2, 2019, with the last patient visit on October 16, 2019. Eligible patients (aged 18-65 years) had moderate to severe HS that required radical surgery in an axillary or inguinal region and had 2 other anatomical regions affected, with 1 or more regions at Hurley stage II or III. Analysis was conducted in November 2019. Interventions Patients were randomized 1:1 to receive continuous adalimumab, 40 mg, or placebo during presurgery (12 weeks), perioperative (2 weeks), and postoperative (10 weeks) periods. Main Outcomes and Measures The primary end point was the proportion of patients achieving HS clinical response across all body regions at week 12. Results Overall, 103 patients were randomized to adalimumab and 103 to matching placebo. Among all patients, 51% (n = 106) were women, 94% (n = 193) were White, and the mean (SD) age was 37.6 (11.3) years. At week 12, significantly more patients receiving adalimumab (49 of 103 [48%]) vs placebo (35 of 103 [34%]; P = .049) achieved HS clinical response across all body regions (treatment difference, 14% [95% CI, 0%-27%]). Treatment-emergent adverse events were reported in 74 of 103 patients (72%) and 69 of 103 patients (67%) in the adalimumab and placebo groups, respectively. No increased risk of postoperative wound infection, complication, or hemorrhage was observed with adalimumab vs placebo. Two deaths occurred in the adalimumab group; neither was considered as having a reasonable possibility of relationship to study drug. Conclusions and Relevance Adalimumab was efficacious in conjunction with wide-excision surgery followed by secondary intention healing, with no need to interrupt treatment prior to surgery. These data support further investigation of adalimumab as an adjuvant therapy to surgery in patients with moderate to severe HS. Trial Registration ClinicalTrials.gov Identifier: NCT02808975
Objectives: To compare dual-energy CT (DECT) and MRI for assessing presence and extent of traumatic bone marrow edema (BME) and fracture line depiction in acute vertebral fractures. Methods: Eighty-eight consecutive patients who underwent dual-source DECT and 3-T MRI of the spine were retrospectively analyzed. Five radiologists assessed all vertebrae for presence and extent of BME and for identification of acute fracture lines on MRI and, after 12 weeks, on DECT series. Additionally, image quality, image noise, and diagnostic confidence for overall diagnosis of acute vertebral fracture were assessed. Quantitative analysis of CT numbers was performed by a sixth radiologist. Two radiologists analyzed MRI and grayscale DECT series to define the reference standard. Results: For assessing BME presence and extent, DECT showed high sensitivity (89% and 84%, respectively) and specificity (98% in both), and similarly high diagnostic confidence compared to MRI (2.30 vs. 2.32; range 0–3) for the detection of BME (p = .72). For evaluating acute fracture lines, MRI achieved high specificity (95%), moderate sensitivity (76%), and a significantly lower diagnostic confidence compared to DECT (2.42 vs. 2.62, range 0–3) (p < .001). A cutoff value of − 0.43 HU provided a sensitivity of 89% and a specificity of 90% for diagnosing BME, with an overall AUC of 0.96. Conclusions: DECT and MRI provide high diagnostic confidence and image quality for assessing acute vertebral fractures. While DECT achieved high overall diagnostic accuracy in the analysis of BME presence and extent, MRI provided moderate sensitivity and lower confidence for evaluating fracture lines.
Evaluation of stability and inactivation methods of SARS-CoV-2 in context of laboratory settings
(2021)
The novel coronavirus SARS-CoV-2 is the causative agent of the acute respiratory disease COVID-19, which has become a global concern due to its rapid spread. Laboratory work with SARS-CoV-2 in a laboratory setting was rated to biosafety level 3 (BSL-3) biocontainment level. However, certain research applications in particular in molecular biology require incomplete denaturation of the proteins, which might cause safety issues handling contaminated samples. In this study, we evaluated lysis buffers that are commonly used in molecular biological laboratories for their ability to inactivate SARS-CoV-2. In addition, viral stability in cell culture media at 4 °C and on display glass and plastic surfaces used in laboratory environment was analyzed. Furthermore, we evaluated chemical and non-chemical inactivation methods including heat inactivation, UV-C light, addition of ethanol, acetone-methanol, and PFA, which might be used as a subsequent inactivation step in the case of insufficient inactivation. We infected susceptible Caco-2 and Vero cells with pre-treated SARS-CoV-2 and determined the tissue culture infection dose 50 (TCID50) using crystal violet staining and microscopy. In addition, lysates of infected cells and virus containing supernatant were subjected to RT-qPCR analysis. We have found that guanidine thiocyanate and most of the tested detergent containing lysis buffers were effective in inactivation of SARS-CoV-2, however, the M-PER lysis buffer containing a proprietary detergent failed to inactivate the virus. In conclusion, careful evaluation of the used inactivation methods is required especially for non-denaturing buffers. Additional inactivation steps might be necessary before removal of lysed viral samples from BSL-3.
Background: Myelosuppression is a potential dose-limiting factor in radioligand therapy (RLT). This study aims to investigate occurrence, severity and reversibility of hematotoxic adverse events in patients undergoing RLT with 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC). The contribution of pretreatment risk factors and cumulative treatment activity is taken into account specifically. Methods: RLT was performed in 140 patients receiving a total of 497 cycles. A mean activity of 6.9 ± 1.3 GBq 177Lu-PSMA-617 per cycle was administered, and mean cumulative activity was 24.6 ± 15.9 GBq. Hematological parameters were measured at baseline, prior to each treatment course, 2 to 4 weeks thereafter and throughout follow-up. Toxicity was graded based on Common Terminology Criteria for Adverse Events v5.0. Results: Significant (grade ≥ 3) hematologic adverse events occurred in 13 (9.3%) patients, with anemia in 10 (7.1%), leukopenia in 5 (3.6%) and thrombocytopenia in 6 (4.3%). Hematotoxicity was reversible to grade ≤ 2 through a median follow-up of 8 (IQR 9) months in all but two patients who died from disease progression within less than 3 months after RLT. Myelosuppression was significantly more frequent in patients with pre-existing grade 2 cytopenia (OR: 3.50, 95%CI 1.08–11.32, p = 0.04) or high bone tumor burden (disseminated or diffuse based on PROMISE miTNM, OR: 5.08, 95%CI 1.08–23.86, p = 0.04). Previous taxane-based chemotherapy was associated with an increased incidence of significant hematotoxicity (OR: 4.62, 95%CI 1.23–17.28, p = 0.02), while treatment with 223Ra-dichloride, cumulative RLT treatment activity and activity per cycle were not significantly correlated (p = 0.93, 0.33, 0.29). Conclusion: Hematologic adverse events after RLT have an acceptable overall incidence and are frequently reversible. High bone tumor burden, previous taxane-based chemotherapy and pretreatment grade 2 cytopenia may be considered as risk factors for developing clinically relevant myelosuppression, whereas cumulative RLT activity and previous 223Ra-dichloride treatment show no significant contribution to incidence rates.
Purpose: To analyze refractive and topographic changes secondary to Descemet membrane endothelial keratoplasty (DMEK) in pseudophakic eyes with Fuchs’ endothelial dystrophy (FED). Methods: Eighty-seven pseudophakic eyes of 74 patients who underwent subsequent DMEK surgery for corneal endothelial decompensation and associated visual impairment were included. Median post-operative follow-up time was 12 months (range: 3–26 months). Main outcome measures were pre- and post-operative manifest refraction, anterior and posterior corneal astigmatism, simulated keratometry (CASimK) and Q value obtained by Scheimpflug imaging. Secondary outcome measures included corrected distance visual acuity (CDVA), central corneal densitometry, central corneal thickness, corneal volume (CV), anterior chamber volume (ACV) and anterior chamber depth (ACD). Results: After DMEK surgery, mean pre-operative spherical equivalent (± SD) changed from + 0.04 ± 1.73 D to + 0.37 ± 1.30 D post-operatively (p = 0.06). CDVA, proportion of emmetropic eyes, ACV and ACD increased significantly during follow-up. There was also a significant decrease in posterior corneal astigmatism, central corneal densitometry, central corneal thickness and corneal volume over time (p = 0.001). Only anterior corneal astigmatism and simulated keratometry (CASimK) remained fairly stable after DMEK. Conclusion: Despite tendencies toward a hyperopic shift, changes in SE were not significant and refraction remained overall stable in pseudophakic patients undergoing DMEK for FED. Analysis of corneal parameters by Scheimpflug imaging mainly revealed changes in posterior corneal astigmatism pointing out the relevance of posterior corneal profile changes during edema resolution after DMEK.
The integrated stress response (ISR) is a central cellular adaptive program that is activated by diverse stressors including ER stress, hypoxia and nutrient deprivation to orchestrate responses via activating transcription factor 4 (ATF4). We hypothesized that ATF4 is essential for the adaptation of human glioblastoma (GB) cells to the conditions of the tumor microenvironment and is contributing to therapy resistance against chemotherapy. ATF4 induction in GB cells was modulated pharmacologically and genetically and investigated in the context of temozolomide treatment as well as glucose and oxygen deprivation. The relevance of the ISR was analyzed by cell death and metabolic measurements under conditions to approximate aspects of the GB microenvironment. ATF4 protein levels were induced by temozolomide treatment. In line, ATF4 gene suppressed GB cells (ATF4sh) displayed increased cell death and decreased survival after temozolomide treatment. Similar results were observed after treatment with the ISR inhibitor ISRIB. ATF4sh and ISRIB treated GB cells were sensitized to hypoxia-induced cell death. Our experimental study provides evidence for an important role of ATF4 for the adaptation of human GB cells to conditions of the tumor microenvironment characterized by low oxygen and nutrient availability and for the development of temozolomide resistance. Inhibiting the ISR in GB cells could therefore be a promising therapeutic approach.
The aim of this study was to quantify and to compare the wear rates of premolar (PM) and molar (M) restorations of lithium disilicate ceramic (LS2) and an experimental CAD/CAM polymer (COMP) in cases of complex rehabilitations with changes in vertical dimension of occlusion (VDO). Twelve patients with severe tooth wear underwent prosthetic rehabilitation, restoring the VDO with antagonistic occlusal coverage restorations either out of LS2 (n = 6 patients, n = 16 posterior restorations/patient; N = 96 restorations/year) or COMP (n = 6 patients; n = 16 posterior restorations/patient; N = 96 restorations/year). Data was obtained by digitalization of plaster casts with a laboratory scanner at annual recalls (350 ± 86 days; 755 ± 92 days; 1102 ± 97 days). Each annual recall dataset of premolar and molar restorations (N = 192) was overlaid individually with the corresponding baseline dataset using an iterative best-fit method. Mean vertical loss of the occlusal contact areas (OCAs) was calculated for each restoration and recall time. For LS2 restorations, the mean wear rate per month over 1 year was 7.5 ± 3.4 μm (PM), 7.8 ± 2.0 μm (M), over 2 years 3.8 ± 1.6 µm (PM), 4.4 ± 1.5 µm (M), over 3 years 2.8 ± 1.3 µm (PM), 3.4 ± 1.7 µm (M). For COMP restorations, the mean wear rate per month over 1 year was 15.5 ± 8.9 μm (PM), 28.5 ± 20.2 μm (M), over 2 years 9.2 ± 5.9 µm (PM), 16.7 ± 14.9 µm (M), over 3 years 8.6 ± 5.3 µm (PM), 9.5 ± 8.0 µm (M). Three COMP restorations fractured after two years and therefore were not considered in the 3-year results. The wear rates in the LS2 group showed significant differences between premolars and molars restorations (p = 0.041; p = 0.023; p = 0.045). The wear rates in COMP group differed significantly between premolars and molars only in the first two years (p < 0.0001; p = 0.007). COMP restorations show much higher wear rates compared to LS2. The presented results suggest that with increasing time in situ, the monthly wear rates for both materials decreased over time. On the basis of this limited dataset, both LS2 and COMP restorations show reasonable clinical wear rates after 3 years follow-up. Wear of COMP restorations was higher, however prosthodontic treatment was less invasive. LS2 showed less wear, yet tooth preparation was necessary. Clinicians should balance well between necessary preparation invasiveness and long-term occlusal stability in patients with worn dentitions.
The cell—cell signaling gene CDH13 is associated with a wide spectrum of neuropsychiatric disorders, including attention-deficit/hyperactivity disorder (ADHD), autism, and major depression. CDH13 regulates axonal outgrowth and synapse formation, substantiating its relevance for neurodevelopmental processes. Several studies support the influence of CDH13 on personality traits, behavior, and executive functions. However, evidence for functional effects of common gene variation in the CDH13 gene in humans is sparse. Therefore, we tested for association of a functional intronic CDH13 SNP rs2199430 with ADHD in a sample of 998 adult patients and 884 healthy controls. The Big Five personality traits were assessed by the NEO-PI-R questionnaire. Assuming that altered neural correlates of working memory and cognitive response inhibition show genotype-dependent alterations, task performance and electroencephalographic event-related potentials were measured by n-back and continuous performance (Go/NoGo) tasks. The rs2199430 genotype was not associated with adult ADHD on the categorical diagnosis level. However, rs2199430 was significantly associated with agreeableness, with minor G allele homozygotes scoring lower than A allele carriers. Whereas task performance was not affected by genotype, a significant heterosis effect limited to the ADHD group was identified for the n-back task. Heterozygotes (AG) exhibited significantly higher N200 amplitudes during both the 1-back and 2-back condition in the central electrode position Cz. Consequently, the common genetic variation of CDH13 is associated with personality traits and impacts neural processing during working memory tasks. Thus, CDH13 might contribute to symptomatic core dysfunctions of social and cognitive impairment in ADHD.
Nucleoredoxin is a thioredoxin-like redoxin that has been recognized as redox modulator of WNT signaling. Using a Yeast-2-Hybrid screen, we identified calcium calmodulin kinase 2a, Camk2a, as a prominent prey in a brain library. Camk2a is crucial for nitric oxide dependent processes of neuronal plasticity of learning and memory. Therefore, the present study assessed functions of NXN in neuronal Nestin-NXN-/- deficient mice. The NXN-Camk2a interaction was confirmed by coimmunoprecipitation, and by colocalization in neuropil and dendritic spines. Functionally, Camk2a activity was reduced in NXN deficient neurons and restored with recombinant NXN. Proteomics revealed reduced oxidation in the hippocampus of Nestin-NXN-/- deficient mice, including Camk2a, further synaptic and mitochondrial proteins, and was associated with a reduction of mitochondrial respiration. Nestin-NXN-/- mice were healthy and behaved normally in behavioral tests of anxiety, activity and sociability. They had no cognitive deficits in touchscreen based learning & memory tasks, but omitted more trials showing a lower interest in the reward. They also engaged less in rewarding voluntary wheel running, and in exploratory behavior in IntelliCages. Accuracy was enhanced owing to the loss of exploration. The data suggested that NXN maintained the oxidative state of Camk2a and thereby its activity. In addition, it supported oxidation of other synaptic and mitochondrial proteins, and mitochondrial respiration. The loss of NXN-dependent pro-oxidative functions manifested in a loss of exploratory drive and reduced interest in reward in behaving mice.
Objectives: The aim of this study was to develop a prognostic tool to estimate long-term tooth retention in periodontitis patients at the beginning of active periodontal therapy (APT). Material and methods: Tooth-related factors (type, location, bone loss (BL), infrabony defects, furcation involvement (FI), abutment status), and patient-related factors (age, gender, smoking, diabetes, plaque control record) were investigated in patients who had completed APT 10 years before. Descriptive analysis was performed, and a generalized linear-mixed model-tree was used to identify predictors for the main outcome variable tooth loss. To evaluate goodness-of-fit, the area under the curve (AUC) was calculated using cross-validation. A bootstrap approach was used to robustly identify risk factors while avoiding overfitting. Results: Only a small percentage of teeth was lost during 10 years of supportive periodontal therapy (SPT; 0.15/year/patient). The risk factors abutment function, diabetes, and the risk indicator BL, FI, and age (≤ 61 vs. > 61) were identified to predict tooth loss. The prediction model reached an AUC of 0.77. Conclusion: This quantitative prognostic model supports data-driven decision-making while establishing a treatment plan in periodontitis patients. In light of this, the presented prognostic tool may be of supporting value. Clinical relevance: In daily clinical practice, a quantitative prognostic tool may support dentists with data-based decision-making. However, it should be stressed that treatment planning is strongly associated with the patient’s wishes and adherence. The tool described here may support establishment of an individual treatment plan for periodontally compromised patients.
Introduction: Deep brain stimulation (DBS) has become a well-established treatment modality for a variety of conditions over the last decades. Multiple surgeries are an essential part in the postoperative course of DBS patients if nonrechargeable implanted pulse generators (IPGs) are applied. So far, the rate of subclinical infections in this field is unknown. In this prospective cohort study, we used sonication to evaluate possible microbial colonization of IPGs from replacement surgery. Methods: All consecutive patients undergoing IPG replacement between May 1, 2019 and November 15, 2020 were evaluated. The removed hardware was investigated using sonication to detect biofilm-associated bacteria. Demographic and clinical data were analyzed. Results: A total of 71 patients with a mean (±SD) of 64.5 ± 15.3 years were evaluated. In 23 of these (i.e., 32.4%) patients, a positive sonication culture was found. In total, 25 microorganisms were detected. The most common isolated microorganisms were Cutibacterium acnes (formerly known as Propionibacterium acnes) (68%) and coagulase-negative Staphylococci (28%). Within the follow-up period (5.2 ± 4.3 months), none of the patients developed a clinical manifest infection. Discussions/Conclusions: Bacterial colonization of IPGs without clinical signs of infection is common but does not lead to manifest infection. Further larger studies are warranted to clarify the impact of low-virulent pathogens in clinically asymptomatic patients.
Purpose: The prospective, randomized ERGO2 trial investigated the effect of calorie-restricted ketogenic diet and intermittent fasting (KD-IF) on re-irradiation for recurrent brain tumors. The study did not meet its primary endpoint of improved progression-free survival in comparison to standard diet (SD). We here report the results of the quality of life/neurocognition and a detailed analysis of the diet diaries. Methods: 50 patients were randomized 1:1 to re-irradiation combined with either SD or KD-IF. The KD-IF schedule included 3 days of ketogenic diet (KD: 21–23 kcal/kg/d, carbohydrate intake limited to 50 g/d), followed by 3 days of fasting and again 3 days of KD. Follow-up included examination of cognition, quality of life and serum samples. Results: The 20 patients who completed KD-IF met the prespecified goals for calorie and carbohydrate restriction. Substantial decreases in leptin and insulin and an increase in uric acid were observed. The SD group, of note, had a lower calorie intake than expected (21 kcal/kg/d instead of 30 kcal/kg/d). Neither quality of life nor cognition were affected by the diet. Low glucose emerged as a significant prognostic parameter in a best responder analysis. Conclusion: The strict caloric goals of the ERGO2 trial were tolerated well by patients with recurrent brain cancer. The short diet schedule led to significant metabolic changes with low glucose emerging as a candidate marker of better prognosis. The unexpected lower calorie intake of the control group complicates the interpretation of the results. Clinicaltrials.gov number: NCT01754350; Registration: 21.12.2012.
As some cognitive functions decline in old age, the ability to decide about important life events such as medical treatment is endangered. Environmental support to improve the comprehension of health-related information is therefore necessary. With a small-scale explorative approach, the present survey study aimed at investigating person-environment fit (PE-fit) of support provided during medical consultations. This fit was calculated by assessing the match between aids provided by five medical practitioners during medical consultations and aids most appreciated by the geriatric patients (N = 88). The results showed that the largest discrepancies of used and appreciated aids could be found concerning the opportunity to discuss decisions with relatives, the possibility to take notes, the use of objects, pictures and a keyword list. Female patients indicated a lower PE-fit. These findings highlight discrepancies between the use of specific aids and the wishes of patients and call for thoughtful use of aids during consultations with geriatric patients.
Purpose: Amblyopia with eccentric fixation, especially when not diagnosed early, is a therapeutic challenge, as visual outcome is known to be poorer than in amblyopia with central fixation. Consequently, treatment after late diagnosis is often denied. Electronic monitoring of occlusion provides us the chance to gain first focussed insight into age-dependent dose response and treatment efficiency, as well as the shift of fixation in this rare group of paediatric patients. Methods: In our prospective pilot study, we examined amblyopes with eccentric fixation during 12 months of occlusion treatment. We evaluated their visual acuity, recorded patching duration using a TheraMon®-microsensor, and determined their fixation with a direct ophthalmoscope. Dose-response relationship and treatment efficiency were calculated. Results: The study included 12 participants with strabismic and combined amblyopia aged 2.9–12.4 years (mean 6.5). Median prescription of occlusion was 7.7 h/day (range 6.6–9.9) and median daily received occlusion was 5.2 h/day (range 0.7–9.7). At study end, median acuity gain was 0.6 log units (range 0–1.6) and residual interocular visual acuity difference (IOVAD) 0.3 log units (range 0–1.8). There was neither significant acuity gain nor reduction in IOVAD after the 6th month of treatment. Children younger than 4 years showed best response with lowest residual IOVAD at study end. Efficiency calculation showed an acuity gain of approximately one line from 100 h of patching in the first 2 months and half a line after 6 months. There was a significant decline of treatment efficiency with age (p = 0.01). Foveolar fixation was achieved after median 3 months (range 1–6). Three patients (> 6 years) did not gain central fixation. Conclusion: Eccentric fixation is a challenge to therapy success. Based on electronic monitoring, our study quantified for the first time the reduction of treatment efficiency with increasing age in amblyopes with eccentric fixation. Despite some improvement in patients up to 8 years, older patients showed significantly lower treatment efficiency. In younger patients with good adherence, despite poor initial acuity, central fixation and low residual IOVAD could be attained after median 3 months. Hence, the necessity of early diagnosis and intensive occlusion should be emphasized.
Background: Transcutaneous auricular vagus nerve stimulation (taVNS) has been investigated regarding its therapeutic properties in several several conditions such as epilepsy, migraine and major depressive disorder and was shown to access similar neural pathways as invasive vagus nerve stimulation. While the vagus nerve's role in gut motility is physiologically established, the effect of taVNS has scarcely been investigated in humans and yielded conflicting results. Real-time gastric magnetic resonance imaging (rtMRI) is an established reproducible method to investigate gastric motility non-invasively. Objective: To investigate the influence of taVNS on gastric motility of healthy participants using rtMRI. Methods: We conducted a randomized, double-blind study using high-frequency (HF) stimulation at 25Hz or low-frequency (LF) taVNS at 1Hz after ingestions of a standardized meal in 57 healthy participants. The gastric motility index (GMI) was determined by measuring the amplitude and velocity of the peristaltic waves using rtMRI. Results: After HF taVNS, GMI was significantly higher than after LF stimulation (p = 0.005), which was mainly attributable to a higher amplitude of the peristaltic waves (p = 0.003). Conclusion: We provide evidence that 4-h of taVNS influences gastric motility in healthy human participants for the first time using rtMRI. HF stimulation is associated with higher amplitudes of peristaltic waves in the gastric antrum compared to LF stimulation. Further studies are needed to investigate the effect of different frequencies of taVNS and its therapeutic properties in conditions with impaired gastric motility.
Transjugular intrahepatic portosystemic shunt (TIPS) is the most effective measure to treat complications of portal hypertension. However, liver function may deteriorate after TIPS. Predictors of liver function and outcome after TIPS are therefore important for management of TIPS patients. The study aimed to evaluate the impact of liver volume on transplant-free survival (TFS) after TIPS, as well as the evolution of liver volume and its relationship with liver function after TIPS. A retrospective analysis of all consecutive patients who underwent TIPS in a tertiary care university liver center between 2012 and 2017 (n = 216) was performed; n = 72 patients with complete prior and follow-up (FU) computed tomography (CT) imaging studies were included in the study. Volumetry of the liver was performed by a semi-automatic 9-lobe image segmentation algorithm at baseline and FU (FU 1: 90–180 d; FU 2: 180–365 d; FU 3: 365–545 d; FU 4: 545–730 d; FU 5: >730 d). Output variables were total liver volume (TLV, cm3), left liver volume (LLV, cm3), right liver volume (RLV, cm3) and TLV/body weight ratio. CT derived liver volumes were correlated with liver function tests, portosystemic pressure gradient (PPG) measurements and survival. To assess predictors of liver volume change over time we fitted linear mixed models. Kaplan–Meier analysis was performed and validated by matched pair analysis followed by Cox regression to determine independent prognostic factors for survival. The median TLV at baseline was 1507.5 cm3 (773.7–3686.0 cm3). Livers with higher baseline liver volumes and larger TLV/weight ratios retained their volume after an initial loss while smaller livers continuously lost volume after TIPS. At the first follow-up period (90–180 d post-TIPS) lower liver volumes and TLV/weight ratios were associated with higher bilirubin levels. Within the final multivariable model containing time (days since TIPS), baseline INR and baseline TLV, the average loss of liver volume was 0.74 mL per day after TIPS. Twelve-month overall transplant-free survival was 89% and median overall TFS was 33 months. The median TFS for a baseline TLV/body weight ratio > 20 was significantly higher compared with ≤20 (40.0 vs. 27.0 months, p = 0.010) while there were no differences regarding the indication for TIPS or etiology of liver disease in the matched pair analysis. Lower TLV/weight ratios before TIPS were associated with shorter TFS and should therefore be critically considered when selecting patients for TIPS. In addition, this study provides first evidence of an effect of TIPS on subsequent liver volume change and associated liver function.
Hormonal contraceptives are an effective and safe method for preventing pregnancy. Progestins used in contraception are either components of combined hormonal contraceptives (tablets, patches or vaginal rings) or are used as a single active ingredient in progestin mono-preparations (the progestin-only pill (POP), implants, intrauterine systems or depot preparations). Progestins are highly effective in long-term contraception when used properly, and have a very good safety profile with very few contraindications. A new oestrogen-free ovulation inhibitor (POP) has recently been authorised in the USA and the EU. This progestin mono-preparation contains 4 mg of drospirenone (DRSP), which has anti-gonadotropic, anti-mineralocorticoidic and anti-androgenic properties. The hormone administration regimen of 24 days followed by a 4-day hormone-free period was chosen to improve bleeding control and to maintain oestradiol concentrations at early follicular-phase levels, preventing oestrogen deficiency. Clinical trials have demonstrated a high contraceptive effectiveness, a very low risk of cardiovascular side effects and a favourable menstrual bleeding pattern. Due to the long half-life of DRSP (30 – 34 hours), the effectiveness of the preparation is maintained even if a woman forgets to take a pill on a single occasion. Studies involving deliberate 24-hour delays in taking a pill have demonstrated that ovulation inhibition is maintained if a single pill is missed. Following a summary of the current status of oestrogen-free contraception, this review article will describe the clinical development programme of the 4 mg DRSP mono-preparation and the resulting data on the effectiveness and safety of this new oestrogen-free oral hormonal contraceptive.
As some cognitive functions decline in old age, the ability to decide about important life events such as medical treatment is endangered. Environmental support to improve the comprehension of health-related information is therefore necessary. With a small-scale explorative approach, the present survey study aimed at investigating person-environment fit (PE-fit) of support provided during medical consultations. This fit was calculated by assessing the match between aids provided by five medical practitioners during medical consultations and aids most appreciated by the geriatric patients (N = 88). The results showed that the largest discrepancies of used and appreciated aids could be found concerning the opportunity to discuss decisions with relatives, the possibility to take notes, the use of objects, pictures and a keyword list. Female patients indicated a lower PE-fit. These findings highlight discrepancies between the use of specific aids and the wishes of patients and call for thoughtful use of aids during consultations with geriatric patients.
Objective: To assess the effect of cesarean section (CS) timing, elective versus unplanned, on the residual myometrial thickness (RMT) and CS scars. Methods: This is a prospective single-blinded observational cohort study with 186 observations. Patients indicated to undergo first singleton CS were preoperatively recruited. Exclusion criteria were history of repeated CS, vertical hysterotomy, diabetes, and additional uterine surgeries. Sonographic examination was performed for assessing the RMT ratio, the presence of a niche, fibrosis, and the distance from the scar to the internal os (SO) 1 year after CS. Power analysis was performed with 0.05 α, 0.1 β, and all statistical analyses were conducted with Stata®. Results: Wilcoxon rank-sum test for the association between CS timing, RMT ratio and SO showed Z values of −0.59 and −4.94 (P = 0.553 and P < 0.001), respectively. There was no association between CS timing and niches and fibrosis (P > 0.99 and P = 0.268, respectively). Linear regression between SO and the extent of cervical dilatation showed a −0.45 β (95% confidence interval −0.68 to −0.21) and a 10.22-mm intercept (P < 0.001). Conclusion: RMT is independent of the timing of CS, but the SO distance shows a negative linear relationship with the cervical dilatation.
Nucleotide pools need to be constantly replenished in cancer cells to support cell proliferation. The synthesis of nucleotides requires glutamine and 5-phosphoribosyl-1-pyrophosphate produced from ribose-5-phosphate via the oxidative branch of the pentose phosphate pathway (ox-PPP). Both PPP and glutamine also play a key role in maintaining the redox status of cancer cells. Enhanced glutamine metabolism and increased glucose 6-phosphate dehydrogenase (G6PD) expression have been related to a malignant phenotype in tumors. However, the association between G6PD overexpression and glutamine consumption in cancer cell proliferation is still incompletely understood. In this study, we demonstrated that both inhibition of G6PD and glutamine deprivation decrease the proliferation of colon cancer cells and induce cell cycle arrest and apoptosis. Moreover, we unveiled that glutamine deprivation induce an increase of G6PD expression that is mediated through the activation of the nuclear factor (erythroid-derived 2)-like 2 (NRF2). This crosstalk between G6PD and glutamine points out the potential of combined therapies targeting oxidative PPP enzymes and glutamine catabolism to combat colon cancer.
Treatment response to neoadjuvant chemoradiotherapy (nCRT) varies considerably among individual patients in advanced rectal cancer indicating a clinical need for markers to predict treatment efficacy and to stratify patients for future personalized treatment. In recent years, there is a tremendous evidence on a pivotal impact of immune components on the development/pathogenesis of cancer and on mediating response to radiation and chemotherapy. Moreover, liquid biopsy biomarkers have become increasingly attractive to predict treatment response because they are easy to collect, reflect information on different aspects of tumor biology and can be accurately measured by standardized methods.
This study aimed to investigate the peripheral blood and tumor tissue immune cell contexture in patients with rectal adenocarcinoma treated with nCRT and chemotherapy (CT) within a prospective randomized phase II CAO-ARO-AIO-12 trial, conducted in the context of DKTK (Deutsches Konsortium für translationale Krebsforschung) and FCI (Frankfurt Cancer Institute), to address the questions whether peripheral blood and/or primary tumor immune contexture predict for treatment response, were modulated by nCRT/CT and correlated with each other. By this, immune cell components were assayed by flow cytometry from peripheral blood mononuclear cells (PBMCs) at baseline, day 43, and pre-surgery of 22 patients treated with nCRT/CT and subsequently correlated with pathologic treatment response. Immunophenotyping was performed applying different staining panels covering myeloid immune cells and human leukocyte antigen (HLA) molecules, T lymphocyte subpopulations and programmed cell death (PD)-1 protein expression and regulatory T cells (Tregs). In addition, tumor tissue samples from pre-therapeutic biopsies and surgical specimens were analyzed by immunohistochemistry and multiparametric immunofluorescence.
The present prospective study raised the following issues. First, peripheral lymphocytes seem to play a crucial role in the nCRT/CT mediated systemic anticancer immunological response. Second, among the various lymphocyte subsets, peripheral blood, but not tissue resident T lymphocytes seem to play a central role in predicting treatment response. By this, baseline blood phenotyping revealed a lymphocyte distribution with high numbers of (CD3+CD4+) T helper cells and low numbers of (CD3+CD8+) cytotoxic T cells expressing PD1, activation markers GranzymeB, perforin and HLA-DR to be associated with an improved response (ypT0ypN0) to nCRT/CT in the patient’s cohort investigated. Further, a decrease in B lymphocyte (CD3+CD19+) count correlated with intermediate and impaired response while an elevated monocyte (CD14+CD33+) levels predicted a complete and intermediate (ypT1-4ypN0) response to nCRT/CT. On a tissue level, patients with a complete response displayed a decrease in the amount of infiltrating neutrophils as the immunoscore of CD15+ cells was significantly higher in patients’ biopsies compared to post-nCRT/CT surgical specimen, while in both, patients with complete and intermediate response an increase of natural killer (CD56+) cell density and GranzymeB expression was observed. Finally, no significant correlation was observed between peripheral blood and tissue immune marker expression.
To validate and expand these findings, a continuation of the analysis in an extended patient cohort is necessary. In addition, a detailed insight on the role of peripheral blood T cells and monocytes and their activation status is desirable. Further, in a follow-up trial, soluble activation markers/cytokines should be assayed, further distinguishing activated from resting or exhausted lymphocytes.
Objectives: To test the effect of race/ethnicity on cancer-specific mortality after radical prostatectomy or external beam radiotherapy in localized prostate cancer patients. Methods: In the Surveillance, Epidemiology and End Results database 2004–2016, we identified intermediate-risk and high-risk white (n = 151 632), Asian (n = 11 189), Hispanic/Latino (n = 20 077) and African American (n = 32 550) localized prostate cancer patients, treated with external beam radiotherapy or radical prostatectomy. Race/ethnicity-stratified cancer-specific mortality analyses relied on competing risks regression, after propensity score matching for patient and cancer characteristics. Results: Compared with white patients, Asian intermediate- and high-risk external beam radiotherapy patients showed lower cancer-specific mortality (hazard ratio 0.58 and 0.70, respectively, both P ≤ 0.02). Additionally, Asian high-risk radical prostatectomy patients also showed lower cancer-specific mortality than white patients (hazard ratio 0.72, P = 0.04), but not Asian intermediate-risk radical prostatectomy patients (P = 0.08). Conversely, compared with white patients, African American intermediate-risk radical prostatectomy patients showed higher cancer-specific mortality (hazard ratio 1.36, P = 0.01), but not African American high-risk radical prostatectomy or intermediate- and high-risk external beam radiotherapy patients (all P ≥ 0.2). Finally, compared with white people, no cancer-specific mortality differences were recorded for Hispanic/Latino patients after external beam radiotherapy or radical prostatectomy, in both risk levels (P ≥ 0.2). Conclusions: Relative to white patients, an important cancer-specific mortality advantage applies to intermediate-risk and high-risk Asian prostate cancer patients treated with external beam radiotherapy, and to high-risk Asian patients treated with radical prostatectomy. These observations should be considered in pretreatment risk stratification and decision-making.
Correction to: Clinical Rheumatology. DOI: https://doi.org/10.1007/s10067-021-05891-5
In the original published version of this article, the Figure 4 contained error. The line “ACR50 plus PASI100” has been presented incorrectly. The Figure 4 is now presented correctly. The original article has been corrected.
Objective: Evaluation of survival of teeth with class III furcation involvement (FI) ≥5 years after active periodontal treatment (APT) and identification of prognostic factors. Methods: All charts of patients who completed APT at the Department of Periodontology of Goethe-University Frankfurt, Germany, beginning October 2004 were screened for teeth with class III FI. APT had to be accomplished for ≥5 years. Charts were analysed for data of class III FI teeth at baseline (T0), at accomplishment of APT (T1), and at the last supportive periodontal care (T2). Baseline radiographic bone loss (RBL) and treatment were assessed. Results: One-hundred and sixty patients (age: 54.4 ± 9.8 years; 82 females; 39 active smokers; 9 diabetics, 85 stage III, 75 stage IV, 59 grade B, 101 grade C) presented 265 teeth with class III FI. Ninety-eight teeth (37%) were lost during 110, 78/137 (median, lower/upper quartile) months. Logistic mixed-model regression and mixed Cox proportional hazard model associated adjunctive systemic antibiotics with fewer tooth loss (26% vs. 42%; p = .019/.004) and RBL (p = .014/.024) and mean probing pocket depth (PPD) at T1 (p < .001) with more tooth loss. Conclusions: Subgingival instrumentation with adjunctive systemic antibiotics favours retention of class III furcation-involved teeth. Baseline RBL and PPD at T1 deteriorate long-term prognosis.
Objective: This study was undertaken to evaluate the long-term efficacy, retention, and tolerability of add-on brivaracetam (BRV) in clinical practice. Methods: A multicenter, retrospective cohort study recruited all patients who initiated BRV between February and November 2016, with observation until February 2021. Results: Long-term data for 262 patients (mean age = 40 years, range = 5–81 years, 129 men) were analyzed, including 227 (87%) diagnosed with focal epilepsy, 19 (7%) with genetic generalized epilepsy, and 16 (6%) with other or unclassified epilepsy syndromes. Only 26 (10%) patients had never received levetiracetam (LEV), whereas 133 (50.8%) were switched from LEV. The length of BRV exposure ranged from 1 day to 5 years, with a median retention time of 1.6 years, resulting in a total BRV exposure time of 6829 months (569 years). The retention rate was 61.1% at 12 months, with a reported efficacy of 33.1% (79/239; 50% responder rate, 23 patients lost-to-follow-up), including 10.9% reported as seizure-free. The retention rate for the entire study period was 50.8%, and at last follow-up, 133 patients were receiving BRV at a mean dose of 222 ± 104 mg (median = 200, range = 25–400), including 52 (39.1%) who exceeded the recommended upper dose of 200 mg. Fewer concomitant antiseizure medications and switching from LEV to BRV correlated with better short-term responses, but no investigated parameters correlated with positive long-term outcomes. BRV was discontinued in 63 (24%) patients due to insufficient efficacy, in 29 (11%) for psychobehavioral adverse events, in 25 (10%) for other adverse events, and in 24 (9%) for other reasons. Significance: BRV showed a clinically useful 50% responder rate of 33% at 12 months and overall retention of >50%, despite 90% of included patients having previous LEV exposure. BRV was well tolerated; however, psychobehavioral adverse events occurred in one out of 10 patients. Although we identified short-term response and retention predictors, we could not identify significant predictors for long-term outcomes. Key Points Long-term postmarketing data for brivaracetam in 262 patients showed an overall retention rate of 50.8%; At 12 months, the 50% responder rate for brivaracetam was 33.1%, with 10.9% reporting seizure freedom; Previous treatment with levetiracetam (90%) did not impact brivaracetam retention or efficacy; Levetiracetam treatment failure should not preclude brivaracetam introduction; No long-term efficacy predictors could be identified.
Purpose: To compare Cancer-specific mortality (CSM) in patients with Squamous cell carcinoma (SCC) vs. non-SCC penile cancer, since survival outcomes may differ between histological subtypes. Methods: Within the Surveillance, Epidemiology and End Results database (2004–2016), penile cancer patients of all stages were identified. Temporal trend analyses, cumulative incidence and Kaplan–Meier plots, multivariable Cox regression and Fine and Gray competing-risks regression analyses tested for CSM differences between non-SCC vs. SCC penile cancer patients. Results: Of 4,120 eligible penile cancer patients, 123 (3%) harbored non-SCC vs. 4,027 (97%) SCC. Of all non-SCC patients, 51 (41%) harbored melanomas, 42 (34%) basal cell carcinomas, 10 (8%) adenocarcinomas, eight (6.5%) skin appendage malignancies, six (5%) epithelial cell neoplasms, two (1.5%) neuroendocrine tumors, two (1.5%) lymphomas, two (1.5%) sarcomas. Stage at presentation differed between non-SCC vs. SCC. In temporal trend analyses, non-SCC diagnoses neither decreased nor increased over time (p > 0.05). After stratification according to localized, locally advanced, and metastatic stage, no CSM differences were observed between non-SCC vs. SCC, with 5-year survival rates of 11 vs 11% (p = 0.9) for localized, 33 vs. 37% (p = 0.4) for locally advanced, and 1-year survival rates of 37 vs. 53% (p = 0.9) for metastatic penile cancer, respectively. After propensity score matching for patient and tumor characteristics and additional multivariable adjustment, no CSM differences between non-SCC vs. SCC were observed. Conclusion: Non-SCC penile cancer is rare. Although exceptions exist, on average, non-SCC penile cancer has comparable CSM as SCC penile cancer patients, after stratification for localized, locally invasive, and metastatic disease.
Background: Patients with colorectal carcinoma and high-grade microsatellite instability (MSI-H) or deficiency in mismatch repair (dMMR) exceptionally respond to immune checkpoint inhibitors (ICIs). ICIs are more active in treatment-naïve patients than in patients with refractory MSI-H/dMMR metastatic colorectal cancer and even more active in patients with locally advanced tumors. Material and Methods: A 33-year-old male patient with Lynch syndrome was diagnosed with a locally advanced rectal cancer and refused standard neoadjuvant chemoradiation because of the potential harm of sexual dysfunction. MMR and microsatellite instability status were analyzed by immunohistochemistry and fragment length polymerase chain reaction followed by capillary electrophoresis. Results: After MSI-H/dMMR was confirmed, the patient was treated with ICIs (1 mg/kg ipilimumab at day 1 and 3 mg/kg nivolumab at day 1 and 15). A complete clinical response was documented at day 21 after start of treatment. The patient underwent a total mesorectal excision at day 30. In the extirpated tissue, a complete pathological response was confirmed. Conclusion: In MSI-H/dMMR locally advanced rectal cancer short-course ICI treatment is highly effective and may be discussed in patients with dMMR locally advanced rectal cancer.
Background: Treatment options for poorly differentiated (PDTC) and anaplastic (ATC) thyroid carcinoma are unsatisfactory and prognosis is generally poor. Lenvatinib (LEN), a multi-tyrosine kinase inhibitor targeting fibroblast growth factor receptors (FGFR) 1-4 is approved for advanced radioiodine refractory thyroid carcinoma, but response to single agent is poor in ATC. Recent reports of combining LEN with PD-1 inhibitor pembrolizumab (PEM) are promising. Materials and Methods: Primary ATC (n=93) and PDTC (n=47) tissue samples diagnosed 1997-2019 at five German tertiary care centers were assessed for PD-L1 expression by immunohistochemistry using Tumor Proportion Score (TPS). FGFR 1-4 mRNA was quantified in 31 ATC and 14 PDTC with RNAscope in-situ hybridization. Normal thyroid tissue (NT) and papillary thyroid carcinoma (PTC) served as controls. Disease specific survival (DSS) was the primary outcome variable. Results: PD-L1 TPS≥50% was observed in 42% of ATC and 26% of PDTC specimens. Mean PD-L1 expression was significantly higher in ATC (TPS 30%) than in PDTC (5%; p<0.01) and NT (0%, p<0.001). 53% of PDTC samples had PD-L1 expression ≤5%. FGFR mRNA expression was generally low in all samples but combined FGFR1-4 expression was significantly higher in PDTC and ATC compared to NT (each p<0.001). No impact of PD-L1 and FGFR 1-4 expression was observed on DSS. Conclusion: High tumoral expression of PD-L1 in a large proportion of ATCs and a subgroup of PDTCs provides a rationale for immune checkpoint inhibition. FGFR expression is low thyroid tumor cells. The clinically observed synergism of PEM with LEN may be caused by immune modulation.
Aims: We investigated N471D WASH complex subunit strumpellin (Washc5) knock-in and Washc5 knock-out mice as models for hereditary spastic paraplegia type 8 (SPG8). Methods: We generated heterozygous and homozygous N471D Washc5 knock-in mice and subjected them to a comprehensive clinical, morphological and laboratory parameter screen, and gait analyses. Brain tissue was used for proteomic analysis. Furthermore, we generated heterozygous Washc5 knock-out mice. WASH complex subunit strumpellin expression was determined by qPCR and immunoblotting. Results: Homozygous N471D Washc5 knock-in mice showed mild dilated cardiomyopathy, decreased acoustic startle reactivity, thinner eye lenses, increased alkaline phosphatase and potassium levels and increased white blood cell counts. Gait analyses revealed multiple aberrations indicative of locomotor instability. Similarly, the clinical chemistry, haematology and gait parameters of heterozygous mice also deviated from the values expected for healthy animals, albeit to a lesser extent. Proteomic analysis of brain tissue depicted consistent upregulation of BPTF and downregulation of KLHL11 in heterozygous and homozygous knock-in mice. WASHC5-related protein interaction partners and complexes showed no change in abundancies. Heterozygous Washc5 knock-out mice showing normal WASHC5 levels could not be bred to homozygosity. Conclusions: While biallelic ablation of Washc5 was prenatally lethal, expression of N471D mutated WASHC5 led to several mild clinical and laboratory parameter abnormalities, but not to a typical SPG8 phenotype. The consistent upregulation of BPTF and downregulation of KLHL11 suggest mechanistic links between the expression of N471D mutated WASHC5 and the roles of both proteins in neurodegeneration and protein quality control, respectively.
Diabetes results from a decline in functional pancreatic β-cells, but the molecular mechanisms underlying the pathological β-cell failure are poorly understood. Here we report that large-tumor suppressor 2 (LATS2), a core component of the Hippo signaling pathway, is activated under diabetic conditions and induces β-cell apoptosis and impaired function. LATS2 deficiency in β-cells and primary isolated human islets as well as β-cell specific LATS2 ablation in mice improves β-cell viability, insulin secretion and β-cell mass and ameliorates diabetes development. LATS2 activates mechanistic target of rapamycin complex 1 (mTORC1), a physiological suppressor of autophagy, in β-cells and genetic and pharmacological inhibition of mTORC1 counteracts the pro-apoptotic action of activated LATS2. We further show a direct interplay between Hippo and autophagy, in which LATS2 is an autophagy substrate. On the other hand, LATS2 regulates β-cell apoptosis triggered by impaired autophagy suggesting an existence of a stress-sensitive multicomponent cellular loop coordinating β-cell compensation and survival. Our data reveal an important role for LATS2 in pancreatic β-cell turnover and suggest LATS2 as a potential therapeutic target to improve pancreatic β-cell survival and function in diabetes.
The article “Integrity of dural closure after autologous platelet rich fibrin augmentation: an in vitro study”, written by Vasilikos, I., Beck, J., Ghanaati, S., Grauvogel, J., Nisyrios, T., Grapatsas, K., and Hubbe, U., was originally published Online First without Open Access. After publication in volume 162, issue 4, page 737–743 the author decided to opt for Open Choice and to make the article an Open Access publication. Therefore, the copyright of the article has been changed to © The Author(s) 2020 and the article is forthwith distributed under the terms of the Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0. Open access funding enabled and organized by Projekt DEAL.
Background and purpose: During acute coronavirus disease 2019 (COVID-19) infection, neurological signs, symptoms and complications occur. We aimed to assess their clinical relevance by evaluating real-world data from a multinational registry. Methods: We analyzed COVID-19 patients from 127 centers, diagnosed between January 2020 and February 2021, and registered in the European multinational LEOSS (Lean European Open Survey on SARS-Infected Patients) registry. The effects of prior neurological diseases and the effect of neurological symptoms on outcome were studied using multivariate logistic regression. Results: A total of 6537 COVID-19 patients (97.7% PCR-confirmed) were analyzed, of whom 92.1% were hospitalized and 14.7% died. Commonly, excessive tiredness (28.0%), headache (18.5%), nausea/emesis (16.6%), muscular weakness (17.0%), impaired sense of smell (9.0%) and taste (12.8%), and delirium (6.7%) were reported. In patients with a complicated or critical disease course (53%) the most frequent neurological complications were ischemic stroke (1.0%) and intracerebral bleeding (ICB; 2.2%). ICB peaked in the critical disease phase (5%) and was associated with the administration of anticoagulation and extracorporeal membrane oxygenation (ECMO). Excessive tiredness (odds ratio [OR] 1.42, 95% confidence interval [CI] 1.20–1.68) and prior neurodegenerative diseases (OR 1.32, 95% CI 1.07–1.63) were associated with an increased risk of an unfavorable outcome. Prior cerebrovascular and neuroimmunological diseases were not associated with an unfavorable short-term outcome of COVID-19. Conclusion: Our data on mostly hospitalized COVID-19 patients show that excessive tiredness or prior neurodegenerative disease at first presentation increase the risk of an unfavorable short-term outcome. ICB in critical COVID-19 was associated with therapeutic interventions, such as anticoagulation and ECMO, and thus may be an indirect complication of a life-threatening systemic viral infection.
Purpose: The prospective, randomized ERGO2 trial investigated the effect of calorie-restricted ketogenic diet and intermittent fasting (KD-IF) on re-irradiation for recurrent brain tumors. The study did not meet its primary endpoint of improved progression-free survival in comparison to standard diet (SD). We here report the results of the quality of life/neurocognition and a detailed analysis of the diet diaries. Methods: 50 patients were randomized 1:1 to re-irradiation combined with either SD or KD-IF. The KD-IF schedule included 3 days of ketogenic diet (KD: 21–23 kcal/kg/d, carbohydrate intake limited to 50 g/d), followed by 3 days of fasting and again 3 days of KD. Follow-up included examination of cognition, quality of life and serum samples. Results: The 20 patients who completed KD-IF met the prespecified goals for calorie and carbohydrate restriction. Substantial decreases in leptin and insulin and an increase in uric acid were observed. The SD group, of note, had a lower calorie intake than expected (21 kcal/kg/d instead of 30 kcal/kg/d). Neither quality of life nor cognition were affected by the diet. Low glucose emerged as a significant prognostic parameter in a best responder analysis. Conclusion: The strict caloric goals of the ERGO2 trial were tolerated well by patients with recurrent brain cancer. The short diet schedule led to significant metabolic changes with low glucose emerging as a candidate marker of better prognosis. The unexpected lower calorie intake of the control group complicates the interpretation of the results. Clinicaltrials.gov number: NCT01754350; Registration: 21.12.2012.
Aims: To compare the effects of Ayurvedic and conventional nutritional therapy in patients with irritable bowel syndrome (IBS). Methods: Sixty-nine patients with IBS were randomized to Ayurvedic (n = 35) or conventional nutritional therapy according to the recommendations of the German Nutrition Society including the low-FODMAP diet (n = 34). Study visits took place at baseline and after 1, 3, and 6 months. The primary outcome was IBS symptom severity (IBS-SSS) after 3 months; secondary outcomes included stress (CPSS), anxiety and depression (HADS), well-being (WHO-5) and IBS-specific quality of life (IBS-QOL). A repeated measures general linear model (GLM) for intent-to-treat-analyses was applied in this explorative study. Results: After 3 months, estimated marginal means for IBS-SSS reductions were 123.8 [95% confidence interval (95% CI) = 92.8–154.9; p < 0.001] in the Ayurvedic and 72.7 (95% CI = 38.8–106.7; p < 0.001) in the conventional group. The IBS-SSS reduction was significantly higher in the Ayurveda group compared to the conventional therapy group (estimated marginal mean = 51.1; 95% CI = 3.8–98.5; p = 0.035) and clinically meaningful. Sixty-eight percentage of the variance in IBS-SSS reduction after 3 months can be explained by treatment, 6.5% by patients' expectations for their therapies and 23.4% by IBS-SSS at pre-intervention. Both therapies are equivalent in their contribution to the outcome variance. The higher the IBS-SSS score at pre-intervention and the larger the patients' expectations, the greater the IBS-SSS reduction. There were no significant group differences in any secondary outcome measures. No serious adverse events occurred in either group. Conclusion: Patients with IBS seem to benefit significantly from Ayurvedic or conventional nutritional therapy. The results warrant further studies with longer-term follow-ups and larger sample sizes. Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT03019861, identifier: NCT03019861.
In psychiatry, there has been a growing focus on identifying at-risk populations. For schizophrenia, these efforts have led to the development of early recognition and intervention measures. Despite a similar disease burden, the populations at risk of bipolar disorder have not been sufficiently characterized. Within the BipoLife consortium, we used magnetic resonance imaging (MRI) data from a multicenter study to assess structural gray matter alterations in N = 263 help-seeking individuals from seven study sites. We defined the risk using the EPIbipolar assessment tool as no-risk, low-risk, and high-risk and used a region-of-interest approach (ROI) based on the results of two large-scale multicenter studies of bipolar disorder by the ENIGMA working group. We detected significant differences in the thickness of the left pars opercularis (Cohen’s d = 0.47, p = 0.024) between groups. The cortex was significantly thinner in high-risk individuals compared to those in the no-risk group (p = 0.011). We detected no differences in the hippocampal volume. Exploratory analyses revealed no significant differences in other cortical or subcortical regions. The thinner cortex in help-seeking individuals at risk of bipolar disorder is in line with previous findings in patients with the established disorder and corresponds to the region of the highest effect size in the ENIGMA study of cortical alterations. Structural alterations in prefrontal cortex might be a trait marker of bipolar risk. This is the largest structural MRI study of help-seeking individuals at increased risk of bipolar disorder.
Periodontal furcation lesions: a survey of diagnosis and management by general dental practitioners
(2021)
Aim: The aim of this study was to explore general dental practitioners' (GDPs) attitude to periodontal furcation involvement (FI). Materials and methods: An online survey focused on diagnosis and management of periodontal FI was circulated to GDPs in seven different countries. Results: A total of 400 responses were collected. Nearly a fifth of participants reported rarely or never taking 6-point pocket charts; 65.8% of participants had access to a Nabers probe in their practice. When shown clinical pictures and radiographs of FI-involved molars, the majority of participants correctly diagnosed it. Although 47.1% of participants were very/extremely confident in detecting FI, only 8.9% felt very/extremely confident at treating it. Differences in responses were detected according to country and year of qualification, with a trend towards less interest in periodontal diagnosis and treatment in younger generations. Lack of knowledge of management/referral pathways (reported by 22.8%) and lack of correct equipment were considered the biggest barriers to FI management. Most participants (80.9%) were interested in learning more about FI, ideally face to face followed by online tutorials. Conclusions: Plans should be put in place to improve general dentists' knowledge and ability to manage FI, as this can have a significant impact on public health.
Cytochrome P450 (CYP) signalling pathway has been shown to play a vital role in the vasoreactivity of wild type mouse ophthalmic artery. In this study, we determined the expression, vascular responses and potential mechanisms of the CYP-derived arachidonic acid metabolites. The expression of murine CYP (Cyp2c44) and soluble epoxide hydrolase (sEH) in the wild type ophthalmic artery was determined with immunofluorescence, which showed predominant expression of Cyp2c44 in the vascular smooth muscle cells (VSMC), while sEH was found mainly in the endothelium of the wild type ophthalmic artery. Artery of Cyp2c44−/− and sEH−/− mice were used as negative controls. Targeted mass spectrometry-based lipidomics analysis of endogenous epoxide and diols of the wild type artery detected only 14, 15-EET. Vasorelaxant responses of isolated vessels in response to selective pharmacological blockers and agonist were analysed ex vivo. Direct antagonism of epoxyeicosatrienoic acids (EETs) with a selective inhibitor caused partial vasodilation, suggesting that EETs may behave as vasoconstrictors. Exogenous administration of synthetic EET regioisomers significantly constricted the vessels in a concentration-dependent manner, with the strongest responses elicited by 11, 12- and 14, 15-EETs. Our results provide the first experimental evidence that Cyp2c44-derived EETs in the VSMC mediate vasoconstriction of the ophthalmic artery.
Objectives: To test the effect of race/ethnicity on cancer-specific mortality after radical prostatectomy or external beam radiotherapy in localized prostate cancer patients. Methods: In the Surveillance, Epidemiology and End Results database 2004–2016, we identified intermediate-risk and high-risk white (n = 151 632), Asian (n = 11 189), Hispanic/Latino (n = 20 077) and African American (n = 32 550) localized prostate cancer patients, treated with external beam radiotherapy or radical prostatectomy. Race/ethnicity-stratified cancer-specific mortality analyses relied on competing risks regression, after propensity score matching for patient and cancer characteristics. Results: Compared with white patients, Asian intermediate- and high-risk external beam radiotherapy patients showed lower cancer-specific mortality (hazard ratio 0.58 and 0.70, respectively, both P ≤ 0.02). Additionally, Asian high-risk radical prostatectomy patients also showed lower cancer-specific mortality than white patients (hazard ratio 0.72, P = 0.04), but not Asian intermediate-risk radical prostatectomy patients (P = 0.08). Conversely, compared with white patients, African American intermediate-risk radical prostatectomy patients showed higher cancer-specific mortality (hazard ratio 1.36, P = 0.01), but not African American high-risk radical prostatectomy or intermediate- and high-risk external beam radiotherapy patients (all P ≥ 0.2). Finally, compared with white people, no cancer-specific mortality differences were recorded for Hispanic/Latino patients after external beam radiotherapy or radical prostatectomy, in both risk levels (P ≥ 0.2). Conclusions: Relative to white patients, an important cancer-specific mortality advantage applies to intermediate-risk and high-risk Asian prostate cancer patients treated with external beam radiotherapy, and to high-risk Asian patients treated with radical prostatectomy. These observations should be considered in pretreatment risk stratification and decision-making.
Cardiac rehabilitation (CR) is a multidisciplinary intervention including patient assessment and medical actions to promote stabilization, management of cardiovascular risk factors, vocational support, psychosocial management, physical activity counselling, and prescription of exercise training. Millions of people with cardiac implantable electronic devices live in Europe and their numbers are progressively increasing, therefore, large subsets of patients admitted in CR facilities have a cardiac implantable electronic device. Patients who are cardiac implantable electronic devices recipients are considered eligible for a CR programme. This is not only related to the underlying heart disease but also to specific issues, such as psychological adaptation to living with an implanted device and, in implantable cardioverter-defibrillator patients, the risk of arrhythmia, syncope, and sudden cardiac death. Therefore, these patients should receive special attention, as their needs may differ from other patients participating in CR. As evidence from studies of CR in patients with cardiac implantable electronic devices is sparse, detailed clinical practice guidelines are lacking. Here, we aim to provide practical recommendations for CR in cardiac implantable electronic devices recipients in order to increase CR implementation, efficacy, and safety in this subset of patients.
(1) Background: The aim of our study was to identify specific risk factors for fatal outcome in critically ill COVID-19 patients. (2) Methods: Our data set consisted of 840 patients enclosed in the LEOSS registry. Using lasso regression for variable selection, a multifactorial logistic regression model was fitted to the response variable survival. Specific risk factors and their odds ratios were derived. A nomogram was developed as a graphical representation of the model. (3) Results: 14 variables were identified as independent factors contributing to the risk of death for critically ill COVID-19 patients: age (OR 1.08, CI 1.06–1.10), cardiovascular disease (OR 1.64, CI 1.06–2.55), pulmonary disease (OR 1.87, CI 1.16–3.03), baseline Statin treatment (0.54, CI 0.33–0.87), oxygen saturation (unit = 1%, OR 0.94, CI 0.92–0.96), leukocytes (unit 1000/μL, OR 1.04, CI 1.01–1.07), lymphocytes (unit 100/μL, OR 0.96, CI 0.94–0.99), platelets (unit 100,000/μL, OR 0.70, CI 0.62–0.80), procalcitonin (unit ng/mL, OR 1.11, CI 1.05–1.18), kidney failure (OR 1.68, CI 1.05–2.70), congestive heart failure (OR 2.62, CI 1.11–6.21), severe liver failure (OR 4.93, CI 1.94–12.52), and a quick SOFA score of 3 (OR 1.78, CI 1.14–2.78). The nomogram graphically displays the importance of these 14 factors for mortality. (4) Conclusions: There are risk factors that are specific to the subpopulation of critically ill COVID-19 patients.
Severe traumatic injury induces phenotypic and functional changes of neutrophils and monocytes
(2021)
Background: Severe traumatic injury has been associated with high susceptibility for the development of secondary complications caused by dysbalanced immune response. As the first line of the cellular immune response, neutrophils and monocytes recruited to the site of tissue damage and/or infection, are divided into three different subsets according to their CD16/CD62L and CD16/CD14 expression, respectively. Their differential functions have not yet been clearly understood. Thus, we evaluated the phenotypic changes of neutrophil and monocyte subsets among their functionality regarding oxidative burst and the phagocytic capacity in severely traumatized patients. Methods: Peripheral blood was withdrawn from severely injured trauma patients (TP; n = 15, ISS ≥ 16) within the first 12 h post-trauma and from healthy volunteers (HV; n = 15) and stimulated with fMLP and PMA. CD16dimCD62Lbright (immature), CD16brightCD62Lbright (mature) and CD16brightCD62Ldim (CD62Llow) neutrophil subsets and CD14brightCD16− (classical), CD14brightCD16+ (intermediate) and CD14dimCD16+ (non-classical) monocyte subsets of HV and TP were either directly analyzed by flow cytometry or the examined subsets of HV were sorted first by fluorescence-activated cell sorting and subsequently analyzed. Subset-specific generation of reactive oxygen species (ROS) and of E. coli bioparticle phagocytosis were evaluated. Results: In TP, the counts of immature neutrophils were significantly increased vs. HV. The numbers of mature and CD62Ldim neutrophils remained unchanged but the production of ROS was significantly enhanced in TP vs. HV and the stimulation with fMLP significantly increased the generation of ROS in the mature and CD62Ldim neutrophils of HV. The counts of phagocyting neutrophils did not change but the mean phagocytic capacity showed an increasing trend in TP. In TP, the monocytes shifted toward the intermediate phenotype, whereas the classical and non-classical monocytes became less abundant. ROS generation was significantly increased in all monocyte subsets in TP vs. HV and PMA stimulation significantly increased those level in both, HV and TP. However, the PMA-induced mean ROS generation was significantly lower in intermediate monocytes of TP vs. HV. Sorting of monocyte and neutrophil subsets revealed a significant increase of ROS and decrease of phagocytic capacity vs. whole blood analysis. Conclusions: Neutrophils and monocytes display a phenotypic shift following severe injury. The increased functional abnormalities of certain subsets may contribute to the dysbalanced immune response and attenuate the antimicrobial function and thus, may represent a potential therapeutic target. Further studies on isolated subsets are necessary for evaluation of their physiological role after severe traumatic injury.
Objectives Our study aimed to assess the frequency of potentially inappropriate medication (PIM) use (according to three PIM lists) and to examine the association between PIM use and cognitive function among participants in the MultiCare cohort. Design MultiCare is conducted as a longitudinal, multicentre, observational cohort study. Setting The MultiCare study is located in eight different study centres in Germany. Participants 3189 patients (59.3% female). Primary and secondary outcome measures The study had a cross-sectional design using baseline data from the German MultiCare study. Prescribed and over-the-counter drugs were classified using FORTA (Fit fOR The Aged), PRISCUS (Latin for ‘time-honoured’) and EU(7)-PIM lists. A mixed-effect multivariate linear regression was performed to calculate the association between PIM use patients’ cognitive function (measured with (LDST)). Results Patients (3189) used 2152 FORTA PIM (mean 0.9±1.03 per patient), 936 PRISCUS PIM (0.3±0.58) and 4311 EU(7)-PIM (1.4±1.29). The most common FORTA PIM was phenprocoumon (13.8%); the most prevalent PRISCUS PIM was amitriptyline (2.8%); the most common EU(7)-PIM was omeprazole (14.0%). The lists rate PIM differently, with an overall overlap of 6.6%. Increasing use of PIM is significantly associated with reduced cognitive function that was detected with a correlation coefficient of −0.60 for FORTA PIM (p=0.002), −0.72 for PRISCUS PIM (p=0.025) and −0.44 for EU(7)-PIM (p=0.005). Conclusion We identified PIM using FORTA, PRISCUS and EU(7)-PIM lists differently and found that PIM use is associated with cognitive impairment according to LDST, whereby the FORTA list best explained cognitive decline for the German population. These findings are consistent with a negative impact of PIM use on multimorbid elderly patient outcomes.
Background: SARS-CoV-2 is one of the most threatening pandemics in human history. As of the date of this analysis, it had claimed about 2 million lives worldwide, and the number is rising sharply. Governments, societies, and scientists are equally challenged under this burden. Objective: This study aimed to map global coronavirus research in 2020 according to various influencing factors to highlight incentives or necessities for further research. Methods: The application of established and advanced bibliometric methods combined with the visualization technique of density-equalizing mapping provided a global picture of incentives and efforts on coronavirus research in 2020. Countries’ funding patterns and their epidemiological and socioeconomic characteristics as well as their publication performance data were included. Results: Research output exploded in 2020 with momentum, including citation and networking parameters. China and the United States were the countries with the highest publication performance. Globally, however, publication output correlated significantly with COVID-19 cases. Research funding has also increased immensely. Conclusions: Nonetheless, the abrupt decline in publication efforts following previous coronavirus epidemics should demonstrate to global researchers that they should not lose interest even after containment, as the next epidemiological challenge is certain to come. Validated reporting worldwide and the inclusion of low-income countries are additionally important for a successful future research strategy.
Following publication of the original article, the authors noticed an incorrect affiliation for Christine Stürken and Udo Schumacher. The correct affiliations are as follows: Christine Stürken: Institute of Anatomy and Experimental Morphology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany. Udo Schumacher: Institute of Anatomy and Experimental Morphology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany. The affiliations have been correctly published in this correction and the original article has been updated.
Conduct disorder (CD), a psychiatric disorder characterized by a repetitive pattern of antisocial behaviors, results from a complex interplay between genetic and environmental factors. The clinical presentation of CD varies both according to the individual’s sex and level of callous-unemotional (CU) traits, but it remains unclear how genetic and environmental factors interact at the molecular level to produce these differences. Emerging evidence in males implicates methylation of genes associated with socio-affective processes. Here, we combined an epigenome-wide association study with structural neuroimaging in 51 females with CD and 59 typically developing (TD) females to examine DNA methylation in relation to CD, CU traits, and gray matter volume (GMV). We demonstrate an inverse pattern of correlation between CU traits and methylation of a chromosome 1 region in CD females (positive) as compared to TD females (negative). The identified region spans exon 1 of the SLC25A24 gene, central to energy metabolism due to its role in mitochondrial function. Increased SLC25A24 methylation was also related to lower GMV in multiple brain regions in the overall cohort. These included the superior frontal gyrus, dorsolateral prefrontal cortex, supramarginal gyrus, secondary visual cortex and ventral posterior cingulate cortex, which are regions that have previously been implicated in CD and CU traits. While our findings are preliminary and need to be replicated in larger samples, they provide novel evidence that CU traits in females are associated with methylation levels in a fundamentally different way in CD and TD individuals, which in turn may relate to observable variations in GMV across the brain.
Background: Glucagon-like peptide-1 receptor agonists may be a treatment option in patients with non-alcoholic fatty liver disease (NAFLD). Aims: To investigate the effects of semaglutide on liver stiffness and liver fat in subjects with NAFLD using non-invasive magnetic resonance imaging (MRI) methods. Methods: This randomised, double-blind, placebo-controlled trial enrolled subjects with liver stiffness 2.50-4.63 kPa by magnetic resonance elastography (MRE) and liver steatosis ≥10% by MRI proton density fat fraction (MRI-PDFF). The primary endpoint was change from baseline to week 48 in liver stiffness assessed by MRE. Results: Sixty-seven subjects were randomised to once-daily subcutaneous semaglutide 0.4 mg (n = 34) or placebo (n = 33). Change from baseline in liver stiffness was not significantly different between semaglutide and placebo at week 48 (estimated treatment ratio 0.96 (95% CI 0.89, 1.03; P = 0.2798); significant differences in liver stiffness were not observed at weeks 24 or 72. Reductions in liver steatosis were significantly greater with semaglutide (estimated treatment ratios: 0.70 [0.59, 0.84], P = 0.0002; 0.47 [0.36, 0.60], P < 0.0001; and 0.50 [0.39, 0.66], P < 0.0001) and more subjects achieved a ≥ 30% reduction in liver fat content with semaglutide at weeks 24, 48 and 72, (all P < 0.001). Decreases in liver enzymes, body weight and HbA1c were also observed with semaglutide. Conclusions: The change in liver stiffness in subjects with NAFLD was not significantly different between semaglutide and placebo. However, semaglutide significantly reduced liver steatosis compared with placebo which, together with improvements in liver enzymes and metabolic parameters, suggests a positive impact on disease activity and metabolic profile. ClinicalTrials.gov identifier: NCT03357380
Aim: Comparison of the clinical efficacy (digitally volumetric, aesthetic, patient-centred outcomes) of tunnel technique (TUN) with subepithelial connective tissue graft (CTG) versus coronally advanced flap (CAF) with enamel matrix derivate (EMD) 5 years after gingival recession therapy. Materials and methods: In 18 patients contributing 36 RT1 recessions, study models were collected at baseline and follow-ups. Optical scans assessed recessions computer-assisted [recession depth, recession reduction (RECred), complete root coverage (CRC), percentage of root coverage (RC), pointwise (pTHK) and mean areal (aTHK) marginal soft tissue thickness]. Root coverage aesthetic Score (RES) was used for aesthetic evaluation and visual analogue scales for patient-centred data collection applied. Results: Sixty months after surgery, 50.0% (TUN+CTG) and 0.0% (CAF+EMD) of sites showed CRC (p = 0.0118), 82.2% (TUN+CTG) and 32.0% (CAF+EMD) achieved RC, respectively (p = 0.0023). CTG achieved significantly better RECred (TUN+CTG: 1.75±0.74 mm; CAF+EMD: 0.50 ± 0.39 mm; p = 0.0009) and aTHK (TUN+CTG: 0.95 ± 0.41 mm; CAF+EMD: 0.26 ± 0.28 mm; p = 0.0013). RES showed superior outcomes (p = 0.0533) for TUN+CTG (6.86 ± 2.31) compared to CAF+EMD (4.63 ± 1.99). The study failed to find significant differences related to patient-centred outcomes (TUN+CTG: 8.30 ± 2.21; CAF+EMD: 7.50 ± 1.51; p = 0.1136). Conclusions: Five years after treatment, CTG resulted in better clinical and aesthetic outcomes than CAF+EMD. Increased THK was associated with improved outcomes for RECred and RC.
Background: To test for rates of other cause mortality (OCM) and cancer-specific mortality (CSM) in elderly prostate cancer (PCa) patients treated with the combination of radical prostatectomy (RP) and external beam radiation therapy (EBRT) versus RP alone, since elderly PCa patients may be over-treated. Methods: Within the Surveillance, Epidemiology and End Results database (2004–2016), cumulative incidence plots, after propensity score matching for cT-stage, cN-stage, prostate specific antigen, age and biopsy Gleason score, and multivariable competing risks regression models (socioeconomic status, pathological Gleason score) addressed OCM and CSM in patients (70–79, 70–74, and 75–79 years) treated with RP and EBRT versus RP alone. Results: Of 18,126 eligible patients aged 70–79 years, 2520 (13.9%) underwent RP and EBRT versus 15,606 (86.1%) RP alone. After propensity score matching, 10-year OCM rates were respectively 27.9 versus 20.3% for RP and EBRT versus RP alone (p < .001), which resulted in a multivariable HR of 1.4 (p < .001). Moreover, 10-year CSM rates were respectively 13.4 versus 5.5% for RP and EBRT versus RP alone. In subgroup analyses separately addressing 70–74 year old and 75–79 years old PCa patients, 10-year OCM rates were 22.8 versus 16.2% and 39.5 versus 24.0% for respectively RP and EBRT versus RP alone patients (all p < .001). Conclusion: Elderly patients treated with RP and EBRT exhibited worrisome rates of OCM. These higher than expected OCM rates question the need for combination therapy (RP and EBRT) in elderly PCa patients and indicate the need for better patient selection, when combination therapy is contemplated.
Aims: Parkinson's disease (PD) is frequently associated with a prodromal sensory neuropathy manifesting with sensory loss and chronic pain. We have recently shown that PD-associated sensory neuropathy in patients is associated with high levels of glucosylceramides. Here, we assessed the underlying pathology and mechanisms in Pink1−/−SNCAA53T double mutant mice. Methods: We studied nociceptive and olfactory behaviour and the neuropathology of dorsal root ganglia (DRGs), including ultrastructure, mitochondrial respiration, transcriptomes, outgrowth and calcium currents of primary neurons, and tissue ceramides and sphingolipids before the onset of a PD-like disease that spontaneously develops in Pink1−/−SNCAA53T double mutant mice beyond 15 months of age. Results: Similar to PD patients, Pink1−/−SNCAA53T mice developed a progressive prodromal sensory neuropathy with a loss of thermal sensitivity starting as early as 4 months of age. In analogy to human plasma, lipid analyses revealed an accumulation of glucosylceramides (GlcCer) in the DRGs and sciatic nerves, which was associated with pathological mitochondria, impairment of mitochondrial respiration, and deregulation of transient receptor potential channels (TRPV and TRPA) at mRNA, protein and functional levels in DRGs. Direct exposure of DRG neurons to GlcCer caused transient hyperexcitability, followed by a premature decline of the viability of sensory neurons cultures upon repeated GlcCer application. Conclusions: The results suggest that pathological GlcCer contribute to prodromal sensory disease in PD mice via mitochondrial damage and calcium channel hyperexcitability. GlcCer-associated sensory neuron pathology might be amenable to GlcCer lowering therapeutic strategies.
Amide proton transfer-chemical exchange saturation transfer (APT-CEST) imaging provides important information for the diagnosis and monitoring of tumors. For such analysis, complete coverage of the brain is advantageous, especially when registration is performed with other magnetic resonance (MR) modalities, such as MR spectroscopy (MRS). However, the acquisition of Z-spectra across several slices via multislice imaging may be time-consuming. Therefore, in this paper, we present a new approach for fast multislice imaging, allowing us to acquire 16 slices per frequency offset within 8 s. The proposed fast CEST-EPI sequence employs a presaturation module, which drives the magnetization into the steady-state equilibrium for the first frequency offset. A second module, consisting of a single CEST pulse (for maintaining the steady-state) followed by an EPI acquisition, passes through a loop to acquire multiple slices and adjacent frequency offsets. Thus, the whole Z-spectrum can be recorded much faster than the conventional saturation scheme, which employs a presaturation for each single frequency offset. The validation of the CEST sequence parameters was performed by using the conventional saturation scheme. Subsequently, the proposed and a modified version of the conventional CEST sequence were compared in vitro on a phantom with different T1 times and in vivo on a brain tumor patient. No significant differences between both sequences could be found in vitro. The in vivo data yielded almost identical MTRasym contrasts for the white and gray matter as well as for tumor tissue. Our results show that the proposed fast CEST-EPI sequence allows for rapid data acquisition and provides similar CEST contrasts as the modified conventional scheme while reducing the scanning time by approximately 50%.
Objective: To assess the effect of cesarean section (CS) timing, elective versus unplanned, on the residual myometrial thickness (RMT) and CS scars. Methods: This is a prospective single-blinded observational cohort study with 186 observations. Patients indicated to undergo first singleton CS were preoperatively recruited. Exclusion criteria were history of repeated CS, vertical hysterotomy, diabetes, and additional uterine surgeries. Sonographic examination was performed for assessing the RMT ratio, the presence of a niche, fibrosis, and the distance from the scar to the internal os (SO) 1 year after CS. Power analysis was performed with 0.05 α, 0.1 β, and all statistical analyses were conducted with Stata®. Results: Wilcoxon rank-sum test for the association between CS timing, RMT ratio and SO showed Z values of −0.59 and −4.94 (P = 0.553 and P < 0.001), respectively. There was no association between CS timing and niches and fibrosis (P > 0.99 and P = 0.268, respectively). Linear regression between SO and the extent of cervical dilatation showed a −0.45 β (95% confidence interval −0.68 to −0.21) and a 10.22-mm intercept (P < 0.001). Conclusion: RMT is independent of the timing of CS, but the SO distance shows a negative linear relationship with the cervical dilatation.
Aim: To evaluate preclinical education in Endodontology at Austrian, German and Swiss dental schools using an online survey. Methodology: An online survey divided into nine categories was sent using SurveyMonkey software to 37 dental schools, before the spread of the COVID-19 pandemic. The questionnaire included 50 questions to evaluate preclinical endodontic education, such as faculty-to-student ratios, topics taught and materials used, in preclinical phantom head courses. Seven and 14 days after the first e-mail contact, dental schools received a reminder e-mail. After four and six weeks, the dental schools were contacted by telephone and asked to participate in the online survey. The processing time was eight weeks in total. Results: The response rate was 89%. Preclinical endodontic education at the participating dental schools differs considerably. Theory classes ranged from 1 to 70 h (15 h mean), and practical classes ranged from 3 to 78 h (39 h mean). The faculty-to-student ratio varied between 1:4 and 1:38 (1:15 mean). Forty-five per cent of the dental schools had a specialist in endodontics teaching theory. Several dental microscopes were available for preclinical teaching purposes at 82% of the dental schools. The majority (82%) taught root canal preparation with rotary or reciprocating NiTi instruments. Overall, 85% of the dental schools taught lateral compaction, amongst other methods, for canal filling. Conclusion: A substantial divergence amongst the dental schools regarding the time dedicated to theory and practical instruction in Endodontology was reported. However, convergence in the use of root canal treatment techniques and materials was reported.
Background: Recently, an increase in the rates of high-risk prostate cancer (PCa) was reported. We tested whether the rates of and low, intermediate, high and very high-risk PCa changed over time. We also tested whether the number of prostate biopsy cores contributed to changes rates over time. Methods: Within the Surveillance, Epidemiology and End Results (SEER) database (2010–2015), annual rates of low, intermediate, high-risk according to traditional National Comprehensive Cancer Network (NCCN) and high versus very high-risk PCa according to Johns Hopkins classification were tabulated without and with adjustment for the number of prostate biopsy cores. Results: In 119,574 eligible prostate cancer patients, the rates of NCCN low, intermediate, and high-risk PCa were, respectively, 29.7%, 47.8%, and 22.5%. Of high-risk patients, 39.6% and 60.4% fulfilled high and very high-risk criteria. Without adjustment for number of prostate biopsy cores, the estimated annual percentage changes (EAPC) for low, intermediate, high and very high-risk were respectively −5.5% (32.4%–24.9%, p < .01), +0.5% (47.6%–48.4%, p = .09), +4.1% (8.2%–9.9%, p < .01), and +8.9% (11.8%–16.9%, p < .01), between 2010 and 2015. After adjustment for number of prostate biopsy cores, differences in rates over time disappeared and ranged from 29.8%–29.7% for low risk, 47.9%–47.9% for intermediate risk, 8.9%–9.0% for high-risk, and 13.6%–13.6% for very high-risk PCa (all p > .05). Conclusions: The rates of high and very high-risk PCa are strongly associated with the number of prostate biopsy cores, that in turn may be driven by broader use magnetic resonance imaging (MRI).
BAG3 is a negative regulator of ciliogenesis in glioblastoma and triple-negative breast cancer cells
(2021)
By regulating several hallmarks of cancer, BAG3 exerts oncogenic functions in a wide variety of malignant diseases including glioblastoma (GBM) and triple-negative breast cancer (TNBC). Here we performed global proteomic/phosphoproteomic analyses of CRISPR/Cas9-mediated isogenic BAG3 knockouts of the two GBM lines U343 and U251 in comparison to parental controls. Depletion of BAG3 evoked major effects on proteins involved in ciliogenesis/ciliary function and the activity of the related kinases aurora-kinase A and CDK1. Cilia formation was significantly enhanced in BAG3 KO cells, a finding that could be confirmed in BAG3-deficient versus -proficient BT-549 TNBC cells, thus identifying a completely novel function of BAG3 as a negative regulator of ciliogenesis. Furthermore, we demonstrate that enhanced ciliogenesis and reduced expression of SNAI1 and ZEB1, two key transcription factors regulating epithelial to mesenchymal transition (EMT) are correlated to decreased cell migration, both in the GBM and TNBC BAG3 knockout cells. Our data obtained in two different tumor entities identify suppression of EMT and ciliogenesis as putative synergizing mechanisms of BAG3-driven tumor aggressiveness in therapy-resistant cancers.
Rationale: Postinfectious bronchiolitis obliterans (PIBO) is a rare, chronic respiratory condition, which follows an acute insult due to a severe infection of the lower airways. Objectives: The objective of this study was to investigate the long-term course of bronchial inflammation and pulmonary function testing in children with PIBO. Methods: Medical charts of 21 children with PIBO were analyzed retrospectively at the Children's University Hospital Frankfurt/Main Germany. Pulmonary function tests (PFTs) with an interval of at least 1 month were studied between 2002 and 2019. A total of 382 PFTs were analyzed retrospectively and per year, the two best PFTs, in total 217, were evaluated. Additionally, 56 sputum analysis were assessed and the sputum neutrophils were evaluated. Results: The evaluation of the 217 PFTs showed a decrease in FEV1 with a loss of 1.07% and a loss in z score of −0.075 per year. FEV1/FVC decreased by 1.44 per year. FVC remained stable, showing a nonsignificant increase by 0.006 in z score per year. However, FEV1 and FVC in L increased significantly with FEV1 0.032 L per cm and FVC 0.048 L/cm in height. Sputum neutrophils showed a significant increase of 2.12% per year. Conclusion: Our results demonstrated that in patients with PIBO pulmonary function decreased significantly showing persistent obstruction over an average follow-up period of 8 years. However, persistent lung growth was revealed. In addition, pulmonary inflammation persisted clearly showing an increasing amount of neutrophils in induced sputum. Patients did not present with a general susceptibility to respiratory infections.
Objective: To assess tooth loss (TL) in initially periodontally healthy/gingivitis (PHG) and periodontally compromised (PC) individuals during a 15- to 25-year follow-up in a specialist practice and to identify the factors influencing TL. Materials and methods: Patients were re-examined 240 ± 60 months after active periodontal therapy (PC) or initial examination (PHG). PHG patients were periodontally healthy or had gingivitis, and PC patients exhibited at least stage II periodontitis. TL, patient-related outcomes, and risk factors for TL were assessed at the patient level (group-relation, gender, age, smoking, bleeding on probing, educational status, mean number of visits/year). Results: Fifty-six PC patients receiving regular supportive periodontal care (12 female, mean age 49.1 ± 10.9 years, stage II: 10, stage III/IV: 46) lost 38 teeth (0.03 ± 0.05 teeth/year). Fifty-one PHG patients (23 female, mean age 34.5 ± 12.4 years) following regular oral prevention lost 39 teeth (0.04 ± 0.05 teeth/year) (p = .631). Both PC and PHG groups did not show any significant differences regarding visual analogue scale measurements [aesthetics (p = .309), chewing function (p = .362), hygiene (p = .989)] and overall Oral Health Impact Profile (p = .484). Age at the start of follow-up was identified as a risk factor for TL (p < .0001). Conclusion: PC and PHG patients exhibited similarly small TL rates over 240 ± 60 months, which should, however, be interpreted with caution in view of the group heterogeneity. Clinical trial number: DRKS00018840 (URL: https://drks.de).
Degradation of the endoplasmic reticulum (ER) via selective autophagy (ER-phagy) is vital for cellular homeostasis. We identify FAM134A/RETREG2 and FAM134C/RETREG3 as ER-phagy receptors, which predominantly exist in an inactive state under basal conditions. Upon autophagy induction and ER stress signal, they can induce significant ER fragmentation and subsequent lysosomal degradation. FAM134A, FAM134B/RETREG1, and FAM134C are essential for maintaining ER morphology in a LC3-interacting region (LIR)-dependent manner. Overexpression of any FAM134 paralogue has the capacity to significantly augment the general ER-phagy flux upon starvation or ER-stress. Global proteomic analysis of FAM134 overexpressing and knockout cell lines reveals several protein clusters that are distinctly regulated by each of the FAM134 paralogues as well as a cluster of commonly regulated ER-resident proteins. Utilizing pro-Collagen I, as a shared ER-phagy substrate, we observe that FAM134A acts in a LIR-independent manner and compensates for the loss of FAM134B and FAM134C, respectively. FAM134C instead is unable to compensate for the loss of its paralogues. Taken together, our data show that FAM134 paralogues contribute to common and unique ER-phagy pathways.
Introduction: Adeno-associated virus (AAV)-based gene therapy for haemophilia presents a challenge to the existing structure of haemophilia centres and requires a rethink of current collaboration and information exchange with the aim of ensuring a system that is fit-for-purpose for advanced therapies to maximise benefits and minimise risks. In Europe, a certification process based on the number of patients and facilities is offered to the haemophilia centres by European Haemophilia Network (EUHANET). Aim and methods: This joint European Association for Haemophilia and Allied Disorders (EAHAD) and European Haemophilia Consortium (EHC) publication describes criteria for centres participating in gene therapy care that require a reassessment of the infrastructure of comprehensive care and provides an outlook on how these criteria can be implemented in the future work of haemophilia centres. Results: The core definition of a haemophilia treatment centre remains, but additional roles could be implemented. A modifiable ‘hub-and-spoke’ model addresses all aspects associated with gene therapy, including preparation and administration of the gene therapy product, determination of coagulation and immunological parameters, joint score and function, and liver health. This will also include the strategy on how to follow-up patients for a long-term safety and efficacy surveillance. Conclusion: We propose a modifiable, networked ‘hub and spoke’ model with a long term safety and efficacy surveillance system. This approach will be progressively developed with the goal of making haemophilia centres better qualified to deliver gene therapy and to make gene therapy accessible to all persons with haemophilia, irrespective of their country or centre of origin.
Aim: It can be challenging to distinguish COVID-19 in children from other common infections. We set out to determine the rate at which children consulting a primary care paediatrician with an acute infection are infected with SARS-CoV-2 and to compare distinct findings. Method: In seven out-patient clinics, children aged 0–13 years with any new respiratory or gastrointestinal symptoms and presumed infection were invited to be tested for SARS-CoV-2. Factors that were correlated with testing positive were determined. Samples were collected from 25 January 2021 to 01 April 2021. Results: Seven hundred and eighty-three children participated in the study (median age 3 years and 0 months, range 1 month to 12 years and 11 months). Three hundred and fifty-eight were female (45.7%). SARS-CoV-2 RNA was detected in 19 (2.4%). The most common symptoms in children with as well as without detectable SARS-CoV-2 RNA were rhinitis, fever and cough. Known recent exposure to a case of COVID-19 was significantly correlated with testing positive, but symptoms or clinical findings were not. Conclusion: COVID-19 among the children with symptoms of an acute infection was uncommon, and the clinical presentation did not differ significantly between children with and without evidence of an infection with SARS-CoV-2.
The majority of excitatory synapses terminating on cortical neurons are found on dendritic spines. The geometry of spines, in particular the size of the spine head, tightly correlates with the strength of the excitatory synapse formed with the spine. Under conditions of synaptic plasticity, spine geometry may change, reflecting functional adaptations. Since the cytokine tumor necrosis factor (TNF) has been shown to influence synaptic transmission as well as Hebbian and homeostatic forms of synaptic plasticity, we speculated that TNF-deficiency may cause concomitant structural changes at the level of dendritic spines. To address this question, we analyzed spine density and spine head area of Alexa568-filled granule cells in the dentate gyrus of adult C57BL/6J and TNF-deficient (TNF-KO) mice. Tissue sections were double-stained for the actin-modulating and plasticity-related protein synaptopodin (SP), a molecular marker for strong and stable spines. Dendritic segments of TNF-deficient granule cells exhibited ∼20% fewer spines in the outer molecular layer of the dentate gyrus compared to controls, indicating a reduced afferent innervation. Of note, these segments also had larger spines containing larger SP-clusters. This pattern of changes is strikingly similar to the one seen after denervation-associated spine loss following experimental entorhinal denervation of granule cells: Denervated granule cells increase the SP-content and strength of their remaining spines to homeostatically compensate for those that were lost. Our data suggest a similar compensatory mechanism in TNF-deficient granule cells in response to a reduction in their afferent innervation.
Correction to: Infection (2020) 48:723–733 https://doi.org/10.1007/s15010-020-01469-6. The original version of this article unfortunately contained a mistake. In this article the authors Dirk Schürmann at affiliation Charité, University Medicine, Berlin, Olaf Degen at affiliation University Clinic Hamburg Eppendorf, Hamburg and Heinz-August Horst at affiliation University Hospital Schleswig–Holstein, Kiel, Germany were missing from the author list. The original article has been corrected.
Objective: Prisoners constitute a high-risk group for suicide, with suicide rates about 5 to 8 times higher than in the general population. The first weeks of imprisonment are a particularly vulnerable time, but there is limited knowledge about the risk factors for either early or late suicide events. Methods: Based on a national total sample of prison suicides in Germany between 2005 and 2017, suicides within the first 2 (4 and 8) weeks after reception into prison were matched by age and penalty length with cases that occurred later. Factors that potentially influence the timing of suicide were investigated. Results: The study has shown that 16.7% (31.5%) of all 390 suicides in German prisons occurred within the first two weeks (two months) of imprisonment. Factors that facilitate adaptation to the prison environment (e.g. prior prison experience) were negatively associated with early suicide events. Factors that hindered the adaptation process (e.g. withdrawal from illicit drugs) were observed more frequently in early suicide events than in late ones. These factors are active at different times of imprisonment. Conclusion: At reception, particular attention should be paid to the following factors associated with early suicide events: widowed marital status, lack of prison experience, and drug dependency.
Objective. We investigated the health-related quality of life (HRQoL) of patients with gastrointestinal stromal tumours (GIST). Methods: In the multicentre PROSa study, the HRQoL of adult GIST patients was assessed between 2017 and 2019 using the European Organisation for Research and Treatment of Cancer HRQoL questionnaire (EORTC QLQ-C30). We performed group comparisons and multivariate linear regressions. Results: Among 130 patients from 13 centres, the mean global HRQoL was 63.3 out of 100 points. Higher sores indicate better HRQoL. The highest restrictions were in emotional, social, role functioning, insomnia, fatigue, and pain. In multivariate linear regression, we found no significant differences between patients receiving tyrosine kinase inhibitor (TKI) treatment and those without TKI treatment as well as between patients treated with curative or with palliative intent. Patients who received multiple lines of TKI treatment had the most restrictions, notably in physical (unstandardized regression coefficient [B] = −15.7), role (B = −25.7), social (B = −18.4), and cognitive functioning (B = −19.7); fatigue (B = 15.93); general health (B = −14.23); and EORTC-sum score (B = −13.82) compared to all other patients. Conclusion: The highest HRQoL restrictions were in GIST patients receiving multiple lines of TKI therapy. Underlying causes need further investigation.
Objective: Using multimodal imaging, we tested the hypothesis that patients after hemispherotomy recruit non-primary motor areas and non-pyramidal descending motor fibers to restore motor function of the impaired limb. Methods: Functional and structural MRI data were acquired in a group of 25 patients who had undergone hemispherotomy and in a matched group of healthy controls. Patients’ motor impairment was measured using the Fugl-Meyer Motor Assessment. Cortical areas governing upper extremity motor-control were identified by task-based functional MRI. The resulting areas were used as nodes for functional and structural connectivity analyses. Results: In hemispherotomy patients, movement of the impaired upper extremity was associated to widespread activation of non-primary premotor areas, whereas movement of the unimpaired one and of the control group related to activations prevalently located in the primary motor cortex (all p ≤ 0.05, FWE-corrected). Non-pyramidal tracts originating in premotor/supplementary motor areas and descending through the pontine tegmentum showed relatively higher structural connectivity in patients (p < 0.001, FWE-corrected). Significant correlations between structural connectivity and motor impairment were found for non-pyramidal (p = 0.023, FWE-corrected), but not for pyramidal connections. Interpretation: A premotor/supplementary motor network and non-pyramidal fibers seem to mediate motor function in patients after hemispherotomy. In case of hemispheric lesion, the homologous regions in the contralesional hemisphere may not compensate the resulting motor deficit, but the functionally redundant premotor network.
Ependymomas encompass a heterogeneous group of central nervous system (CNS) neoplasms that occur along the entire neuroaxis. In recent years, extensive (epi-)genomic profiling efforts have identified several molecular groups of ependymoma that are characterized by distinct molecular alterations and/or patterns. Based on unsupervised visualization of a large cohort of genome-wide DNA methylation data, we identified a highly distinct group of pediatric-type tumors (n = 40) forming a cluster separate from all established CNS tumor types, of which a high proportion were histopathologically diagnosed as ependymoma. RNA sequencing revealed recurrent fusions involving the pleomorphic adenoma gene-like 1 (PLAGL1) gene in 19 of 20 of the samples analyzed, with the most common fusion being EWSR1:PLAGL1 (n = 13). Five tumors showed a PLAGL1:FOXO1 fusion and one a PLAGL1:EP300 fusion. High transcript levels of PLAGL1 were noted in these tumors, with concurrent overexpression of the imprinted genes H19 and IGF2, which are regulated by PLAGL1. Histopathological review of cases with sufficient material (n = 16) demonstrated a broad morphological spectrum of tumors with predominant ependymoma-like features. Immunohistochemically, tumors were GFAP positive and OLIG2- and SOX10 negative. In 3/16 of the cases, a dot-like positivity for EMA was detected. All tumors in our series were located in the supratentorial compartment. Median age of the patients at the time of diagnosis was 6.2 years. Median progression-free survival was 35 months (for 11 patients with data available). In summary, our findings suggest the existence of a novel group of supratentorial neuroepithelial tumors that are characterized by recurrent PLAGL1 fusions and enriched for pediatric patients.
Background: Compound flaps offer the advantage of one stage defect reconstruction respecting all relevant tissues and early functional recovery by optimal vascularity of all components. Due to its specific vascular anatomy and the three-dimensional donor site, compound flaps with bone components may result in higher complication rates compared to soft tissue compound flaps. The meta-analysis summarizes the available evidence and evaluates whether bone components are a risk factor for periprocedural complications in upper extremity multidimensional defect reconstruction. Method: PubMed and Embase were searched for all publications addressing compound free flaps for upper extremity defect reconstruction with bone or soft tissue components published between January 1988 and May 2018. The methodological quality was assessed with the American Society of Plastic Surgeons Evidence Rating Scale for Therapeutic Studies. Flap loss, thrombosis rate, early infection, hematoma, seroma, as well as donor site complications were extracted and analyzed. Results: Twelve out of 1157 potentially eligible studies (evidence-III) comprising 159 patients were finally included with publication bias for all summarized complication rates. Complication rates for flaps with/ without bone components were: total flap loss 5%, 95% CI = 3%–10% (6%/5%); partial flap loss 8%, 95% CI = 5%–15%, (9%/8%); arterial/venous thrombosis 7%, 95% CI = 4%–12%, (8%/5%)/14%, 95% CI = 9%–21% (16%/6%, P < .05) with higher risk for flaps with bone components; infection 6%, 95% CI = 3%–12% (6%/6%); hematoma 6%, 95% CI = 3%–11% (6%/5%); seroma 5%, 95% CI = 3%–10% (5%/5%); dehiscence 10%, 95% CI = 6%–17% (11%/9%). Conclusion: Compound flaps for upper extremity defect reconstruction including bone components have a higher venous thrombosis rate compared to compound soft-tissue flaps.
Scores to identify patients at high risk of progression of coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), may become instrumental for clinical decision-making and patient management. We used patient data from the multicentre Lean European Open Survey on SARS-CoV-2-Infected Patients (LEOSS) and applied variable selection to develop a simplified scoring system to identify patients at increased risk of critical illness or death. A total of 1946 patients who tested positive for SARS-CoV-2 were included in the initial analysis and assigned to derivation and validation cohorts (n = 1297 and n = 649, respectively). Stability selection from over 100 baseline predictors for the combined endpoint of progression to the critical phase or COVID-19-related death enabled the development of a simplified score consisting of five predictors: C-reactive protein (CRP), age, clinical disease phase (uncomplicated vs. complicated), serum urea, and D-dimer (abbreviated as CAPS-D score). This score yielded an area under the curve (AUC) of 0.81 (95% confidence interval [CI]: 0.77–0.85) in the validation cohort for predicting the combined endpoint within 7 days of diagnosis and 0.81 (95% CI: 0.77–0.85) during full follow-up. We used an additional prospective cohort of 682 patients, diagnosed largely after the “first wave” of the pandemic to validate the predictive accuracy of the score and observed similar results (AUC for the event within 7 days: 0.83 [95% CI: 0.78–0.87]; for full follow-up: 0.82 [95% CI: 0.78–0.86]). An easily applicable score to calculate the risk of COVID-19 progression to critical illness or death was thus established and validated.
Background: Number of positive prostate biopsy cores represents a key determinant between high versus very high-risk prostate cancer (PCa). We performed a critical appraisal of the association between the number of positive prostate biopsy cores and CSM in high versus very high-risk PCa. Methods: Within Surveillance, Epidemiology, and End Results database (2010–2016), 13,836 high versus 20,359 very high-risk PCa patients were identified. Discrimination according to 11 different positive prostate biopsy core cut-offs (≥2–≥12) were tested in Kaplan–Meier, cumulative incidence, and multivariable Cox and competing risks regression models. Results: Among 11 tested positive prostate biopsy core cut-offs, more than or equal to 8 (high-risk vs. very high-risk: n = 18,986 vs. n = 15,209, median prostate-specific antigen [PSA]: 10.6 vs. 16.8 ng/ml, <.001) yielded optimal discrimination and was closely followed by the established more than or equal to 5 cut-off (high-risk vs. very high-risk: n = 13,836 vs. n = 20,359, median PSA: 16.5 vs. 11.1 ng/ml, p < .001). Stratification according to more than or equal to 8 positive prostate biopsy cores resulted in CSM rates of 4.1 versus 14.2% (delta: 10.1%, multivariable hazard ratio: 2.2, p < .001) and stratification according to more than or equal to 5 positive prostate biopsy cores with CSM rates of 3.7 versus 11.9% (delta: 8.2%, multivariable hazard ratio: 2.0, p < .001) in respectively high versus very high-risk PCa. Conclusions: The more than or equal to 8 positive prostate biopsy cores cutoff yielded optimal results. It was very closely followed by more than or equal to 5 positive prostate biopsy cores. In consequence, virtually the same endorsement may be made for either cutoff. However, more than or equal to 5 positive prostate biopsy cores cutoff, based on its existing wide implementation, might represent the optimal choice.
Ataxia-telangiectasia (A-T) is a hereditary immune system disorder with neurodegeneration. Its first neurologic symptoms include ataxic gait in early childhood, with slowly progressive cerebellar ataxia, oculomotor apraxia, oculocutaneous telangiectasia, and progressive muscle weakness. Neonatal screening for severe T-cell deficiency was recently found to diagnose A-T patients with a significantly reduced naïve T-cell pool. Our study includes 69 A-T patients between 8 January 2002 and 1 December 2019. Nineteen cases of cancer were diagnosed in 17 patients (25%), with a median overall survival [OS; 95% cumulative indcidence (CI)] of 26·9 years for the entire cohort. The 15-year OS of 82·5% (72–95%) was significantly decreased among A-T patients with malignancies, who had a median OS of 2·11 years, with a two-year-estimated OS of 50·7% (31–82%). Haematological malignancies were the major causes of death within the initial years of life with a 15 times increased risk for death [HR (95% CI): 6·9 (3·1–15.2), P < 0·001] upon malignancy diagnosis. Male patients with A-T are at a higher cancer risk than their female counterparts. This manuscript highlights the need for cancer surveillance and prevention, as well as optimal treatment in this cohort.
Autophagy is a highly conserved catabolic process cells use to maintain their homeostasis by degrading misfolded, damaged and excessive proteins, nonfunctional organelles, foreign pathogens and other cellular components. Hence, autophagy can be nonselective, where bulky portions of the cytoplasm are degraded upon stress, or a highly selective process, where preselected cellular components are degraded. To distinguish between different cellular components, autophagy employs selective autophagy receptors, which will link the cargo to the autophagy machinery, thereby sequestering it in the autophagosome for its subsequent degradation in the lysosome. Autophagy receptors undergo post-translational and structural modifications to fulfil their role in autophagy, or upon executing their role, for their own degradation. We highlight the four most prominent protein modifications – phosphorylation, ubiquitination, acetylation and oligomerisation – that are essential for autophagy receptor recruitment, function and turnover. Understanding the regulation of selective autophagy receptors will provide deeper insights into the pathway and open up potential therapeutic avenues.
Objectives: To compare radiation dose and image quality of single-energy (SECT) and dual-energy (DECT) head and neck CT examinations performed with second- and third-generation dual-source CT (DSCT) in matched patient cohorts. Methods: 200 patients (mean age 55.1 ± 16.9 years) who underwent venous phase head and neck CT with a vendor-preset protocol were retrospectively divided into four equal groups (n = 50) matched by gender and BMI: second (Group A, SECT, 100-kV; Group B, DECT, 80/Sn140-kV), and third-generation DSCT (Group C, SECT, 100-kV; Group D, DECT, 90/Sn150-kV). Assess- ment of radiation dose was performed for an average scan length of 27 cm. Contrast-to-noise ratio measure- ments and dose-independent figure-of-merit calcu- lations of the submandibular gland, thyroid, internal jugular vein, and common carotid artery were analyzed quantitatively. Qualitative image parameters were evalu- ated regarding overall image quality, artifacts and reader confidence using 5-point Likert scales. Results: Effective radiation dose (ED) was not signifi- cantly different between SECT and DECT acquisition for each scanner generation (p = 0.10). Significantly lower effective radiation dose (p < 0.01) values were observed for third-generation DSCT groups C (1.1 ± 0.2 mSv) and D (1.0 ± 0.3 mSv) compared to second-generation DSCT groups A (1.8 ± 0.1 mSv) and B (1.6 ± 0.2 mSv). Figure-of- merit/contrast-to-noise ratio analysis revealed superior results for third-generation DECT Group D compared to all other groups. Qualitative image parameters showed non-significant differences between all groups (p > 0.06). Conclusion: Contrast-enhanced head and neck DECT can be performed with second- and third-generation DSCT systems without radiation penalty or impaired image quality compared with SECT, while third-generation DSCT is the most dose efficient acquisition method. Advances in knowledge: Differences in radiation dose between SECT and DECT of the dose-vulnerable head and neck region using DSCT systems have not been evaluated so far. Therefore, this study directly compares radiation dose and image quality of standard SECT and DECT protocols of second- and third-generation DSCT platforms.
Endothelial tip cells are essential for VEGF-induced angiogenesis, but underlying mechanisms are elusive. The Ena/VASP protein family, consisting of EVL, VASP, and Mena, plays a pivotal role in axon guidance. Given that axonal growth cones and endothelial tip cells share many common features, from the morphological to the molecular level, we investigated the role of Ena/VASP proteins in angiogenesis. EVL and VASP, but not Mena, are expressed in endothelial cells of the postnatal mouse retina. Global deletion of EVL (but not VASP) compromises the radial sprouting of the vascular plexus in mice. Similarly, endothelial-specific EVL deletion compromises the radial sprouting of the vascular plexus and reduces the endothelial tip cell density and filopodia formation. Gene sets involved in blood vessel development and angiogenesis are down-regulated in EVL-deficient P5-retinal endothelial cells. Consistently, EVL deletion impairs VEGF-induced endothelial cell proliferation and sprouting, and reduces the internalization and phosphorylation of VEGF receptor 2 and its downstream signaling via the MAPK/ERK pathway. Together, we show that endothelial EVL regulates sprouting angiogenesis via VEGF receptor-2 internalization and signaling.
Objectives: The four-dimensional ultrasound (4D-US) enables imaging of the aortic segment and simultaneous determination of the wall expansion. The method shows a high spatial and temporal resolution, but its in vivo reliability is so far unknown for low-measure values. The present study determines the intraobserver repeatability and interobserver reproducibility of 4D-US in the atherosclerotic and non-atherosclerotic infrarenal aorta. Methods: In all, 22 patients with non-aneurysmal aorta were examined by an experienced examiner and a medical student. After registration of 4D images, both the examiners marked the aortic wall manually before the commercially implemented speckle tracking algorithm was applied. The cyclic changes of the aortic diameter and circumferential strain were determined with the help of custom-made software. The reliability of 4D-US was tested by the intraclass correlation coefficient (ICC). Results: The 4D-US measurements showed very good reliability for the maximum aortic diameter and the circumferential strain for all patients and for the non-atherosclerotic aortae (ICC >0.7), but low reliability for circumferential strain in calcified aortae (ICC = 0.29). The observer- and masking-related variances for both maximum diameter and circumferential strain were close to zero. Conclusions: Despite the low-measured values, the high spatial and temporal resolution of the 4D-US enables a reliable evaluation of cyclic diameter changes and circumferential strain in non-aneurysmal aortae independent from the observer experience but with some limitations for calcified aortae. The 4D-US opens up a new perspective with regard to noninvasive, in vivo assessment of kinematic properties of the vessel wall in the abdominal aorta.
Abstract: The Children's Communication Checklist-2 (CCC-2) is often applied to assess pragmatic language impairment which is highly prevalent in autism spectrum disorder (ASD) and several mental health conditions. We replicated previous findings on the limited applicability of the CCC-2 in clinical samples and the inconsistent findings concerning the factor structure. The aim of the present study was, thus, to develop a concise, simplified, and revised version of the CCC-2 in a large German-speaking sample. Four groups of children and adolescents aged 4 to 17 years were included: ASD (n = 195), intellectual disability (ID, n = 83), diverse mental health conditions (MHC, n = 144) and a typically developing control group (TD, n = 417). We reduced the original number of items from 70 to 39, based on item analysis, exploratory factor analysis and the exclusion of communication-unrelated items. The revised version, CCC-R (α = 0.96), consists of two empirically derived factors: a pragmatic-language (α = 0.96) and a grammatical-semantic-language factor (α = 0.93). All clinical groups (ASD, ID, and MHC) had significantly increased CCC-R total scores, with the highest scores being in the neurodevelopmental disorder groups (ASD and ID). In addition, we found group-specific patterns of elevated pragmatic-language scores in the ASD group and grammatical-semantic scores in the ID group. The CCC-R was comparable to the CCC-2 in distinguishing ASD from the other groups. The CCC-R is proposed as a simplified and easily applied, clinical questionnaire for caregivers, assessing pragmatic language impairments across neurodevelopmental disorders and mental health conditions. Lay Summary: The CCC-2 is a questionnaire designed to identify children who have problems in the social use of language, however, it is limited in its clinical application and exhibits inconsistent factors. We have created a shorter and simpler version of the CCC-2 that we have called the CCC-R which overcomes the previous limitations of the CCC-2. It consists of two subscales: pragmatic language and grammatical-semantic language. The CCC-R can be used as a short and clinically relevant caregiver questionnaire which assesses pragmatic language impairments in children and adolescents. Autism Res 2021, 14: 759–772. © 2021 The Authors. Autism Research published by International Society for Autism Research published by Wiley Periodicals LLC.
Background: The approval of everolimus (EVE) for the treatment of angiomyolipoma (2013), subependymal giant cell astrocytoma (2013) and drug-refractory epilepsy (2017) in patients with tuberous sclerosis complex (TSC) represents the first disease-modifying treatment option available for this rare and complex genetic disorder. Objective: The objective of this study was to analyse the use, efficacy, tolerability and treatment retention of EVE in patients with TSC in Germany from the patient’s perspective. Methods: A structured cross-age survey was conducted at 26 specialised TSC centres in Germany and by the German TSC patient advocacy group between February and July 2019, enrolling children, adolescents and adult patients with TSC. Results: Of 365 participants, 36.7% (n = 134) reported the current or past intake of EVE, including 31.5% (n = 115) who were taking EVE at study entry. The mean EVE dosage was 6.1 ± 2.9 mg/m2 (median: 5.6 mg/m2, range 2.0–15.1 mg/m2) in children and adolescents and 4 ± 2.1 mg/m2 (median: 3.7 mg/m2, range 0.8–10.1 mg/m2) in adult patients. An early diagnosis of TSC, the presence of angiomyolipoma, drug-refractory epilepsy, neuropsychiatric manifestations, subependymal giant cell astrocytoma, cardiac rhabdomyoma and overall multi-organ involvement were associated with the use of EVE as a disease-modifying treatment. The reported efficacy was 64.0% for angiomyolipoma (75% in adult patients), 66.2% for drug-refractory epilepsy, and 54.4% for subependymal giant cell astrocytoma. The overall retention rate for EVE was 85.8%. The retention rates after 12 months of EVE therapy were higher among adults (93.7%) than among children and adolescents (88.7%; 90.5% vs 77.4% after 24 months; 87.3% vs 77.4% after 36 months). Tolerability was acceptable, with 70.9% of patients overall reporting adverse events, including stomatitis (47.0%), acne-like rash (7.7%), increased susceptibility to common infections and lymphoedema (each 6.0%), which were the most frequently reported symptoms. With a total score of 41.7 compared with 36.8 among patients not taking EVE, patients currently being treated with EVE showed an increased Liverpool Adverse Event Profile. Noticeable deviations in the sub-items ‘tiredness’, ‘skin problems’ and ‘mouth/gum problems’, which are likely related to EVE-typical adverse effects, were more frequently reported among patients taking EVE. Conclusions: From the patients’ perspective, EVE is an effective and relatively well-tolerated disease-modifying treatment option for children, adolescents and adults with TSC, associated with a high long-term retention rate that can be individually considered for each patient. Everolimus therapy should ideally be supervised by a centre experienced in the use of mechanistic target of rapamycin inhibitors, and adverse effects should be monitored on a regular basis.
Our purpose was to analyze the robustness and reproducibility of magnetic resonance imaging (MRI) radiomic features. We constructed a multi-object fruit phantom to perform MRI acquisition as scan-rescan using a 3 Tesla MRI scanner. We applied T2-weighted (T2w) half-Fourier acquisition single-shot turbo spin-echo (HASTE), T2w turbo spin-echo (TSE), T2w fluid-attenuated inversion recovery (FLAIR), T2 map and T1-weighted (T1w) TSE. Images were resampled to isotropic voxels. Fruits were segmented. The workflow was repeated by a second reader and the first reader after a pause of one month. We applied PyRadiomics to extract 107 radiomic features per fruit and sequence from seven feature classes. We calculated concordance correlation coefficients (CCC) and dynamic range (DR) to obtain measurements of feature robustness. Intraclass correlation coefficient (ICC) was calculated to assess intra- and inter-observer reproducibility. We calculated Gini scores to test the pairwise discriminative power specific for the features and MRI sequences. We depict Bland Altmann plots of features with top discriminative power (Mann–Whitney U test). Shape features were the most robust feature class. T2 map was the most robust imaging technique (robust features (rf), n = 84). HASTE sequence led to the least amount of rf (n = 20). Intra-observer ICC was excellent (≥ 0.75) for nearly all features (max–min; 99.1–97.2%). Deterioration of ICC values was seen in the inter-observer analyses (max–min; 88.7–81.1%). Complete robustness across all sequences was found for 8 features. Shape features and T2 map yielded the highest pairwise discriminative performance. Radiomics validity depends on the MRI sequence and feature class. T2 map seems to be the most promising imaging technique with the highest feature robustness, high intra-/inter-observer reproducibility and most promising discriminative power.
Patients with ataxia-telangiectasia (A-T) suffer from progressive cerebellar ataxia, immunodeficiency, respiratory failure, and cancer susceptibility. From a clinical point of view, A-T patients with IgA deficiency show more symptoms and may have a poorer prognosis. In this study, we analyzed mortality and immunity data of 659 A-T patients with regard to IgA deficiency collected from the European Society for Immunodeficiencies (ESID) registry and from 66 patients with classical A-T who attended at the Frankfurt Goethe-University between 2012 and 2018. We studied peripheral B- and T-cell subsets and T-cell repertoire of the Frankfurt cohort and survival rates of all A-T patients in the ESID registry. Patients with A-T have significant alterations in their lymphocyte phenotypes. All subsets (CD3, CD4, CD8, CD19, CD4/CD45RA, and CD8/CD45RA) were significantly diminished compared to standard values. Patients with IgA deficiency (n = 35) had significantly lower lymphocyte counts compared to A-T patients without IgA deficiency (n = 31) due to a further decrease of naïve CD4 T-cells, central memory CD4 cells, and regulatory T-cells. Although both patient groups showed affected TCR-ß repertoires compared to controls, no differences could be detected between patients with and without IgA deficiency. Overall survival of patients with IgA deficiency was significantly diminished. For the first time, our data show that patients with IgA deficiency have significantly lower lymphocyte counts and subsets, which are accompanied with reduced survival, compared to A-T patients without IgA deficiency. IgA, a simple surrogate marker, is indicating the poorest prognosis for classical A-T patients. Both non-interventional clinical trials were registered at clinicaltrials.gov 2012 (Susceptibility to infections in ataxia-telangiectasia; NCT02345135) and 2017 (Susceptibility to Infections, tumor risk and liver disease in patients with ataxia-telangiectasia; NCT03357978)
Physical inactivity is discussed as one of the most detrimental influences for lifestyle-related medical complications such as obesity, heart disease, hypertension, diabetes and premature mortality in in- and outpatients with major depressive disorder (MDD). In contrast, intervention studies indicate that moderate-to-vigorous-intensity physical activity (MVPA) might reduce complications and depression symptoms itself. Self-reported data on depression [Beck-Depression-Inventory-II (BDI-II)], general habitual well-being (FAHW), self-esteem and physical self-perception (FAHW, MSWS) were administrated in a cross-sectional study with 76 in- and outpatients with MDD. MVPA was documented using ActiGraph wGT3X + ® accelerometers and fitness was measured using cardiopulmonary exercise testing (CPET). Subgroups were built according to activity level (low PA defined as MVPA < 30 min/day, moderate PA defined as MVPA 30–45 min/day, high PA defined as MVPA > 45 min/day). Statistical analysis was performed using a Mann–Whitney U and Kruskal–Wallis test, Spearman correlation and mediation analysis. BDI-II scores and MVPA values of in- and outpatients were comparable, but fitness differed between the two groups. Analysis of the outpatient group showed a negative correlation between BDI-II and MVPA. No association of inpatient MVPA and psychopathology was found. General habitual well-being and self-esteem mediated the relationship between outpatient MVPA and BDI-II. The level of depression determined by the BDI-II score was significantly higher in the outpatient low- and moderate PA subgroups compared to outpatients with high PA. Fitness showed no association to depression symptoms or well-being. To ameliorate depressive symptoms of MDD outpatients, intervention strategies should promote habitual MVPA and exercise exceeding the duration recommended for general health (≥ 30 min/day). Further studies need to investigate sufficient MVPA strategies to impact MDD symptoms in inpatient settings. Exercise effects seem to be driven by changes of well-being rather than increased physical fitness.
Autophagy is a highly conserved catabolic process cells use to maintain their homeostasis by degrading misfolded, damaged and excessive proteins, nonfunctional organelles, foreign pathogens and other cellular components. Hence, autophagy can be nonselective, where bulky portions of the cytoplasm are degraded upon stress, or a highly selective process, where preselected cellular components are degraded. To distinguish between different cellular components, autophagy employs selective autophagy receptors, which will link the cargo to the autophagy machinery, thereby sequestering it in the autophagosome for its subsequent degradation in the lysosome. Autophagy receptors undergo post-translational and structural modifications to fulfil their role in autophagy, or upon executing their role, for their own degradation. We highlight the four most prominent protein modifications – phosphorylation, ubiquitination, acetylation and oligomerisation – that are essential for autophagy receptor recruitment, function and turnover. Understanding the regulation of selective autophagy receptors will provide deeper insights into the pathway and open up potential therapeutic avenues.
Long-term effects on cirrhosis and portal hypertension of direct antiviral agent (DAA)-based eradication of hepatitis C virus (HCV) are still under debate. We analysed dynamics of liver and spleen elastography to assess potential regression of cirrhosis and portal hypertension 3 years post-treatment. Fifty-four patients with HCV-associated cirrhosis and DAA-induced SVR were included. Liver and spleen stiffness were measured at baseline (BL), end of treatment (EOT), 24 weeks after EOT (FU24) and 1, 2 and 3 (FU144) years post-treatment by transient liver elastography (L-TE) and point shear wave elastography (pSWE) using acoustic radiation force impulse (ARFI) of the liver (L-ARFI) and spleen (S-ARFI). Biochemical, virological and clinical data were also obtained. Liver stiffness assessed by L-TE decreased between BL [median (range), 32.5(9.1–75) kPa] and EOT [21.3(6.7–73.5) kPa; p < .0001] and EOT and FU144 [16(4.1–75) kPa; p = .006]. L-ARFI values improved between EOT [2.5(1.2–4.1) m/s] and FU144 [1.7(0.9–4.1) m/s; p = .001], while spleen stiffness remained unchanged. Overall, L-TE improved in 38 of 54 (70.4%) patients at EOT and 29 of 38 (76.3%) declined further until FU144, whereas L-ARFI values decreased in 30/54 (55.6%) patients at EOT and continued to decrease in 28/30 (93.3%) patients at FU144. Low bilirubin and high albumin levels at BL were associated with improved L-ARFI values (p = .048) at EOT or regression of cirrhosis (<12.5 kPa) by L-TE at FU144 (p = .005), respectively. Liver stiffness, but not spleen stiffness, continued to decline in a considerable proportion of patients with advanced liver disease after HCV eradication.
Beneficial acute effects of resistance exercise on cognitive functions may be modified by exercise intensity or by habitual physical activity. Twenty-six participants (9 female and 17 male; 25.5 ± 3.4 years) completed four resistance exercise interventions in a randomized order on separate days (≥48 h washout). The intensities were set at 60%, 75%, and 90% of the one repetition maximum (1RM). Three interventions had matched workloads (equal resistance*nrepetitions). One intervention applied 75% of the 1RM and a 50% reduced workload (resistance*nrepetitions = 50%). Cognitive attention (Trail Making Test A—TMTA), task switching (Trail Making Test B—TMTB), and working memory (Digit Reading Spans Backward) were assessed before and immediately after exercise. Habitual activity was assessed as MET hours per week using the International Physical Activity Questionnaire. TMTB time to completion was significantly shorter after exercise with an intensity of 60% 1RM and 75% 1RM and 100% workload. Friedman test indicated a significant effect of exercise intensity in favor of 60% 1RM. TMTA performance was significantly shorter after exercise with an intensity of 60% 1RM, 90% 1RM, and 75% 1RM (50% workload). Habitual activity with vigorous intensity correlated positively with the baseline TMTB and Digit Span Forward performance but not with pre- to post-intervention changes. Task switching, based on working memory, mental flexibility, and inhibition, was beneficially influenced by acute exercise with moderate intensity whereas attention performance was increased after exercise with moderate and vigorous intensity. The effect of regular activity had no impact on acute exercise effects.
Purpose: 10-year retrospective study to assess burden of illness in individuals with tuberous sclerosis complex (TSC) identified from German healthcare data. Methods: Patients with TSC were identified by International Classification of Diseases code Q85.1. Patients with epilepsy were identified by epilepsy diagnosis or antiseizure medication (ASM) prescription after TSC diagnosis. Results: Using data from 2016 (final study year), 100 patients with TSC were identified (mean [range] age: 38 [1–86] years; male: 40%); prevalence: 7.9 per 100,000 (TSC), 2.2 per 100,000 (TSC with epilepsy). During the 10-year study period (2007–2016), 256 patients with TSC were identified and followed up for 1,784 patient- years (epilepsy: 36%, 616 patient-years). TSC manifestations/comorbidities (apart from epilepsy) were identi- fied more frequently in patients with epilepsy than without. Mean annual healthcare costs for patients with TSC were €6,139 per patient-year (PPY), mostly attributable to medication (35%) and inpatient care (29%). Patients with epilepsy incurred costs more than double those without. Mean (standard deviation [SD]) annual hospi- talisation rate (AHR) and length of stay (LOS) PPY: 0.5 (1.0) and 5.9 (18.6) days for TSC. AHR and LOS were greater in patients with epilepsy than without. Mean (SD) number of ASMs prescribed (TSC with epilepsy): 3.0 (2.3) over the entire observable time per patient. Mortality rates (vs. control): 5.08% (vs. 1.69%, p<0.001) for TSC, 7.53% (vs. 0.98%, p<0.001) for TSC with epilepsy, 3.68% (vs. 2.03%, p = 0.003) for TSC without epilepsy. Conclusion: Healthcare costs, resource utilisation, and mortality were greater in patients with TSC and epilepsy than those without epilepsy.
Glioblastoma is the most common malignant primary brain tumor. To date, clinically relevant biomarkers are restricted to isocitrate dehydrogenase (IDH) gene 1 or 2 mutations and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation. Long non-coding RNAs (lncRNAs) have been shown to contribute to glioblastoma pathogenesis and could potentially serve as novel biomarkers. The clinical significance of HOXA Transcript Antisense RNA, Myeloid-Specific 1 (HOTAIRM1) was determined by analyzing HOTAIRM1 in multiple glioblastoma gene expression data sets for associations with prognosis, as well as, IDH mutation and MGMT promoter methylation status. Finally, the role of HOTAIRM1 in glioblastoma biology and radiotherapy resistance was characterized in vitro and in vivo. We identified HOTAIRM1 as a candidate lncRNA whose up-regulation is significantly associated with shorter survival of glioblastoma patients, independent from IDH mutation and MGMT promoter methylation. Glioblastoma cell line models uniformly showed reduced cell viability, decreased invasive growth and diminished colony formation capacity upon HOTAIRM1 down-regulation. Integrated proteogenomic analyses revealed impaired mitochondrial function and determination of reactive oxygen species (ROS) levels confirmed increased ROS levels upon HOTAIRM1 knock-down. HOTAIRM1 knock-down decreased expression of transglutaminase 2 (TGM2), a candidate protein implicated in mitochondrial function, and knock-down of TGM2 mimicked the phenotype of HOTAIRM1 down-regulation in glioblastoma cells. Moreover, HOTAIRM1 modulates radiosensitivity of glioblastoma cells both in vitro and in vivo. Our data support a role for HOTAIRM1 as a driver of biological aggressiveness, radioresistance and poor outcome in glioblastoma. Targeting HOTAIRM1 may be a promising new therapeutic approach.
Background: Breast cancer (BC) is the most frequent female cancer and preferentially metastasizes to bone. The transcription factor TGFB-induced factor homeobox 1 (TGIF) is involved in bone metabolism. However, it is not yet known whether TGIF is associated with BC bone metastasis or patient outcome and thus of potential interest. Methods: TGIF expression was analyzed by immunohistochemistry in 1197 formalin-fixed, paraffin-embedded tissue samples from BC patients treated in the GAIN (German Adjuvant Intergroup Node-Positive) study with two adjuvant dose-dense schedules of chemotherapy with or without bisphosphonate ibandronate. TGIF expression was categorized into negative/low and moderate/strong staining. Endpoints were disease-free survival (DFS), overall survival (OS) and time to primary bone metastasis as first site of relapse (TTPBM). Results: We found associations of higher TGIF protein expression with smaller tumor size (p= 0.015), well differentiated phenotype (p< 0.001) and estrogen receptor (ER)-positive BC (p< 0.001). Patients with higher TGIF expression levels showed a significantly longer disease-free (DFS: HR 0.75 [95%CI 0.59–0.95], log-rank p=0.019) and overall survival (OS: HR 0.69 [95%CI 0.50–0.94], log-rank p= 0.019), but no association with TTPBM (HR 0.77 [95%CI 0.51–1.16]; p= 0.213). Univariate analysis in molecular subgroups emphasized that elevated TGIF expression was prognostic for both DFS and OS in ER-positive BC patients (DFS: HR 0.68 [95%CI 0.51–0.91]; log-rank p= 0.009, interaction p= 0.130; OS: HR 0.60 [95%CI 0.41–0.88], log-rank p= 0.008, interaction p= 0.107) and in the HER2-negative subgroup (DFS:HR 0.67 [95%CI 0.50–0.88], log-rank p= 0.004, interaction p= 0.034; OS: HR 0.57 [95%CI 0.40–0.81], log-rank p= 0.002, interaction p= 0.015). Conclusions: Our results suggest that moderate to high TGIF expression is a common feature of breast cancer cells and that this is not associated with bone metastases as first site of relapse. However, a reduced expression is linked to tumor progression, especially in HER2-negative breast cancer.
High-resolution fMRI in the sub-millimeter regime allows researchers to resolve brain activity across cortical layers and columns non-invasively. While these high-resolution data make it possible to address novel questions of directional information flow within and across brain circuits, the corresponding data analyses are challenged by MRI artifacts, including image blurring, image distortions, low SNR, and restricted coverage. These challenges often result in insufficient spatial accuracy of conventional analysis pipelines. Here we introduce a new software suite that is specifically designed for layer-specific functional MRI: LayNii. This toolbox is a collection of command-line executable programs written in C/C++ and is distributed opensource and as pre-compiled binaries for Linux, Windows, and macOS. LayNii is designed for layer-fMRI data that suffer from SNR and coverage constraints and thus cannot be straightforwardly analyzed in alternative software packages. Some of the most popular programs of LayNii contain ‘layerification’ and columnarization in the native voxel space of functional data as well as many other layer-fMRI specific analysis tasks: layer-specific smoothing, model-based vein mitigation of GE-BOLD data, quality assessment of artifact dominated sub-millimeter fMRI, as well as analyses of VASO data.
Aims: Cardio-oncology is a growing interdisciplinary field which aims to improve cardiological care for cancer patients in order to reduce morbidity and mortality. The impact of cardiac biomarkers, echocardiographic parameters, and cardiological assessment regarding risk stratification is still unclear. We aimed to identify potential parameters that allow an early risk stratification of cancer patients. Methods and results: In this cohort study, we evaluated 930 patients that were admitted to the cardio-oncology outpatient clinic of the University Hospital Heidelberg from January 2016 to January 2019. We performed echocardiography, including Global Longitudinal Strain (GLS) analysis and measured cardiac biomarkers including N-terminal pro brain-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T levels (hs-cTnT). Most patients were suffering from breast cancer (n = 450, 48.4%), upper gastrointestinal carcinoma (n = 99, 10.6%) or multiple myeloma (n = 51, 5.5%). At the initial visit, we observed 86.7% of patients having a preserved left ventricular ejection fraction (LVEF >50%). At the second follow up, still 78.9% of patients showed a preserved LVEF. Echocardiographic parameters or elevation of NT-proBNP did not significantly correlate with all-cause mortality (ACM) (logistic regression LVEF <50%: P = 0.46, NT-proBNP: P = 0.16) and failed to identify high-risk patients. In contrast, hs-cTnT above the median (≥7 ng/L) was an independent marker to determine ACM (multivariant logistic regression, OR: 2.21, P = 0.0038) among all included patients. In particular, hs-cTnT levels before start of a chemotherapy were predictive for ACM. Conclusions: Based on our non-selected cohort of cardio-oncological patients, hs-cTnT was able to identify patients with high mortality by using a low cutoff of 7 ng/L. We conclude that measurement of hs-cTnT is an important tool to stratify the risk for mortality of cancer patients before starting chemotherapy.
We retrospectively investigated histopathological growth patterns in individuals with advanced nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) treated within the randomized HD18 study. In all, 35/60 patients (58%) presented with atypical growth patterns. Patients with atypical growth patterns more often had stage IV disease (P = 0·0354) and splenic involvement (P = 0·0048) than patients with typical growth patterns; a positive positron emission tomography after two cycles of chemotherapy (PET-2) tended to be more common (P = 0·1078). Five-year progression-free survival [hazard ratio (HR) = 0·86; 95% confidence interval (CI) = 0·49–1·47] and overall survival (HR = 0·85; 95% CI = 0·49–1·51) did not differ between the groups after study treatment with PET-2-guided escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone). Thus, advanced NLPHL is often associated with atypical growth patterns but their prognostic impact is compensated by PET-2-guided escalated BEACOPP.
Since the early 1970s several studies have reported distal splenic artery embolization, better known as partial spleen embolization (PSE), as an efficacious treatment of portal hypertensive variceal bleeding and hypersplenism in cirrhosis.(1, 2) However, the effect of PSE on portal pressure is secondary to the induction of splenic infarction. Depending on both the infarct volume and possible infection, PSE can induce serious complications including death.(2, 3) On the other hand, proximal splenic artery embolization (PSAE), which mimics surgical splenic artery ligation, prevents large infarction of the spleen, favoring collateral perfusion of its intact distal vasculature.(3) For this, PSAE has been extensively preferred over PSE for reducing portal hyperflow and treating refractory ascites (RA) after whole or partial liver transplantation (LT).(3, 4) We report here a case of PSAE used to treat RA in a patient with cirrhosis not eligible for transjugular intrahepatic portosystemic shunt (TIPS) and LT.
Inhibition of fatty acid synthesis (FAS) stimulates tumor cell death and reduces angiogenesis. When SH-SY5Y cells or primary neurons are exposed to hypoxia only, inhibition of FAS yields significantly enhanced cell injury. The pathophysiology of stroke, however, is not only restricted to hypoxia but also includes reoxygenation injury. Hence, an oxygen-glucose-deprivation (OGD) model with subsequent reoxygenation in both SH-SY5Y cells and primary neurons as well as a murine stroke model were used herein in order to study the role of FAS inhibition and its underlying mechanisms. SH-SY5Y cells and cortical neurons exposed to 10 h of OGD and 24 h of reoxygenation displayed prominent cell death when treated with the Acetyl-CoA carboxylase inhibitor TOFA or the fatty acid synthase inhibitor cerulenin. Such FAS inhibition reduced the reduction potential of these cells, as indicated by increased NADH2+/NAD+ ratios under both in vitro and in vivo stroke conditions. As observed in the OGD model, FAS inhibition also resulted in increased cell death in the stroke model. Stroke mice treated with cerulenin did not only display increased brain injury but also showed reduced neurological recovery during the observation period of 4 weeks. Interestingly, cerulenin treatment enhanced endothelial cell leakage, reduced transcellular electrical resistance (TER) of the endothelium and contributed to poststroke blood-brain barrier (BBB) breakdown. The latter was a consequence of the activated NF-κB pathway, stimulating MMP-9 and ABCB1 transporter activity on the luminal side of the endothelium. In conclusion, FAS inhibition aggravated poststroke brain injury as consequence of BBB breakdown and NF-κB-dependent inflammation.
Background: No simple staging system has emerged for basal cell carcinomas (BCCs), since they do not follow the TNM process, and practitioners failed to agree on simple clinical or pathological criteria as a basis for a classification. Operational classification of BCCs is required for decision-making, trials and guidelines. Unsupervised clustering of real cases of difficult-to-treat BCCs (DTT-BCCs; part 1) has demonstrated that experts could blindly agree on a five groups classification of DTT-BCCs based on five patterns of clinical situations. Objective: Using this five patterns to generate an operational and comprehensive classification of BCCs. Method: Testing practitioner's agreement, when using the five patterns classification to ensure that it is robust enough to be used in the practice. Generating the first version of a staging system of BCCs based on pattern recognition. Results: Sixty-two physicians, including 48 practitioners and the 14 experts who participated in the generation of the five different patterns of DTT-BCCs, agreed on 90% of cases when classifying 199 DTT-BCCs cases using the five patterns classification (part 1) attesting that this classification is understandable and usable in practice. In order to cover the whole field of BCCs, these five groups of DTT-BCCs were added a group representing the huge number of easy-to-treat BCCs, for which sub-classification has little interest, and a group of very rare metastatic cases, resulting in a four-stage and seven-substage staging system of BCCs. Conclusion: A practical classification adapted to the specificities of BCCs is proposed. It is the first tumour classification based on pattern recognition of clinical situations, which proves to be consistent and usable. This EADO staging system version 1 will be improved step by step and tested as a decision tool and a prognostic instrument.
BAG3 is a negative regulator of ciliogenesis in glioblastoma and triple-negative breast cancer cells
(2021)
By regulating several hallmarks of cancer, BAG3 exerts oncogenic functions in a wide variety of malignant diseases including glioblastoma (GBM) and triple-negative breast cancer (TNBC). Here we performed global proteomic/phosphoproteomic analyses of CRISPR/Cas9-mediated isogenic BAG3 knockouts of the two GBM lines U343 and U251 in comparison to parental controls. Depletion of BAG3 evoked major effects on proteins involved in ciliogenesis/ciliary function and the activity of the related kinases aurora-kinase A and CDK1. Cilia formation was significantly enhanced in BAG3 KO cells, a finding that could be confirmed in BAG3-deficient versus -proficient BT-549 TNBC cells, thus identifying a completely novel function of BAG3 as a negative regulator of ciliogenesis. Furthermore, we demonstrate that enhanced ciliogenesis and reduced expression of SNAI1 and ZEB1, two key transcription factors regulating epithelial to mesenchymal transition (EMT) are correlated to decreased cell migration, both in the GBM and TNBC BAG3 knockout cells. Our data obtained in two different tumor entities identify suppression of EMT and ciliogenesis as putative synergizing mechanisms of BAG3-driven tumor aggressiveness in therapy-resistant cancers.
Childbirth-related post-traumatic stress disorder (CB-PTSD) occurs in 3–7% of all pregnancies and about 35% of women after preterm birth (PTB) meet the criteria for acute stress reaction. Known risk factors are trait anxiety and pain intensity, whereas planned delivery mode, medical support, and positive childbirth experience are protective factors. It has not yet been investigated whether the effects of anxiety and delivery mode are mediated by other factors, and whether a PTB-risk alters these relationships. 284 women were investigated antepartum and six weeks postpartum (risk-group with preterm birth (RG-PB) N = 95, risk-group with term birth (RG-TB) N = 99, and control group (CG) N = 90). CB-PTSD symptoms and anxiety were measured using standardized psychological questionnaires. Pain intensity, medical support, and childbirth experience were assessed by single items. Delivery modes were subdivided into planned vs. unplanned delivery modes. Group differences were examined using MANOVA. To examine direct and indirect effects on CB-PTSD symptoms, a multi-sample path analysis was performed. Rates of PTS were highest in the RG-PB = 11.58% (RG-TB = 7.01%, CG = 1.1%). MANOVA revealed higher values of CB-PTSD symptoms and pain intensity in RG-PB compared to RG-TB and CG. Women with planned delivery mode reported a more positive birth experience. Path modeling revealed a good model fit. Explained variance was highest in RG-PB (R2 = 44.7%). Direct enhancing effects of trait anxiety and indirect reducing effects of planned delivery mode on CB-PTSD symptoms were observed in all groups. In both risk groups, CB-PTSD symptoms were indirectly reduced via support by medical staff and positive childbirth experience, while trait anxiety indirectly enhanced CB-PTSD symptoms via pain intensity in the CG. Especially in the RG-PB, a positive birth experience serves as protective factor against CB-PTSD symptoms. Therefore, our data highlights the importance of involving patients in the decision process even under stressful birth conditions and the need for psychological support antepartum, mainly in patients with PTB-risk and anxious traits.